{
 "disease": "melanoma",
 "label": "Melanoma",
 "url": "https://usebiotransfer.org/disease/melanoma/",
 "built": "2026-09-12",
 "facts_hash": {
  "answers": "37d7783103a3",
  "targets": "b9061aeb2036"
 },
 "sources": {
  "targets": "Open Targets Platform GraphQL API v4",
  "trials": "ClinicalTrials.gov API v2"
 },
 "retrieved": {
  "targets": "2026-09-12",
  "trials": "2026-09-12"
 },
 "query": {
  "endpoint": "https://clinicaltrials.gov/api/v2/studies",
  "shape": "query.cond=<disease>&query.intr=<term>&pageSize=200",
  "active_statuses": [
   "ACTIVE_NOT_RECRUITING",
   "ENROLLING_BY_INVITATION",
   "NOT_YET_RECRUITING",
   "RECRUITING"
  ],
  "dedup": "by NCT id across synonyms",
  "study_types": "interventional counted in headline; observational reported separately",
  "known_floor": "trials naming an antigen only by product code are not retrieved by an intervention-name search"
 },
 "targets": [
  {
   "symbol": "BRAF",
   "ensembl": "ENSG00000157764",
   "n_drug_entries": 18,
   "n_distinct_drugs": 16,
   "drugs": {
    "ARQ-736": "PHASE_1",
    "BELVARAFENIB": "PHASE_2",
    "CEP-32496": "PHASE_1_2",
    "DABRAFENIB": "APPROVAL",
    "ENCORAFENIB": "APPROVAL",
    "LIFIRAFENIB": "PHASE_1_2",
    "LY-3009120": "PHASE_1",
    "NAPORAFENIB": "PHASE_3",
    "PLIXORAFENIB": "PHASE_2",
    "RAF-265": "PHASE_2",
    "REGORAFENIB": "APPROVAL",
    "RG-7256": "PHASE_1",
    "SORAFENIB": "APPROVAL",
    "TOVORAFENIB": "APPROVAL",
    "VEMURAFENIB": "APPROVAL",
    "XL-281": "PHASE_1_2"
   },
   "approved": [
    "DABRAFENIB",
    "ENCORAFENIB",
    "REGORAFENIB",
    "SORAFENIB",
    "TOVORAFENIB",
    "VEMURAFENIB"
   ],
   "n_approved": 6,
   "approved_for": {
    "DABRAFENIB": [
     "metastatic melanoma",
     "melanoma",
     "low grade glioma",
     "glioma"
    ],
    "ENCORAFENIB": [
     "melanoma",
     "colorectal neoplasm",
     "metastatic melanoma"
    ],
    "REGORAFENIB": [
     "colorectal cancer",
     "metastatic colorectal cancer",
     "colorectal neoplasm"
    ],
    "SORAFENIB": [
     "renal cell carcinoma",
     "hepatocellular carcinoma",
     "thyroid gland carcinoma"
    ],
    "TOVORAFENIB": [
     "glioma",
     "low grade glioma"
    ],
    "VEMURAFENIB": [
     "melanoma",
     "metastatic melanoma"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Approved Drug"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "Human Protein Atlas loc"
    },
    {
     "modality": "PR",
     "bucket": "Literature"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "NRAS",
   "ensembl": "ENSG00000213281",
   "n_drug_entries": 1,
   "n_distinct_drugs": 1,
   "drugs": {
    "SALIRASIB": "PHASE_2"
   },
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Advanced Clinical"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "NF1",
   "ensembl": "ENSG00000196712",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Pocket"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "Human Protein Atlas loc"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    }
   ]
  },
  {
   "symbol": "KIT",
   "ensembl": "ENSG00000157404",
   "n_drug_entries": 38,
   "n_distinct_drugs": 33,
   "drugs": {
    "AMUVATINIB": "PHASE_2",
    "AVAPRITINIB": "APPROVAL",
    "BRIQUILIMAB": "PHASE_2",
    "CATEQUENTINIB": "PHASE_3",
    "CEDIRANIB": "APPROVAL",
    "CM-082": "PHASE_2",
    "DASATINIB": "APPROVAL",
    "DOVITINIB": "PHASE_3",
    "ENMD-2076": "PHASE_2",
    "FAMITINIB": "PHASE_3",
    "FORETINIB": "PHASE_2",
    "IMATINIB": "APPROVAL",
    "MASITINIB": "APPROVAL",
    "MIDOSTAURIN": "APPROVAL",
    "MOTESANIB": "PHASE_3",
    "OSI-930": "PHASE_1",
    "PAZOPANIB": "APPROVAL",
    "PEXIDARTINIB": "APPROVAL",
    "QUIZARTINIB": "APPROVAL",
    "REGORAFENIB": "APPROVAL",
    "RIPRETINIB": "APPROVAL",
    "SEMAXANIB": "PHASE_3",
    "SERALUTINIB": "PHASE_3",
    "SORAFENIB": "APPROVAL",
    "SU-014813": "PHASE_2",
    "SUNITINIB": "APPROVAL",
    "SUNITINIB MALATE": "APPROVAL",
    "TANDUTINIB": "PHASE_2",
    "TELATINIB": "PHASE_2",
    "TIVOZANIB": "APPROVAL",
    "VATALANIB": "PHASE_3",
    "XL-820": "PHASE_2",
    "XL-999": "PHASE_2"
   },
   "approved": [
    "AVAPRITINIB",
    "CEDIRANIB",
    "DASATINIB",
    "IMATINIB",
    "MASITINIB",
    "MIDOSTAURIN",
    "PAZOPANIB",
    "PEXIDARTINIB",
    "QUIZARTINIB",
    "REGORAFENIB",
    "RIPRETINIB",
    "SORAFENIB",
    "SUNITINIB",
    "SUNITINIB MALATE",
    "TIVOZANIB"
   ],
   "n_approved": 15,
   "approved_for": {
    "AVAPRITINIB": [
     "gastrointestinal stromal tumor"
    ],
    "CEDIRANIB": [],
    "DASATINIB": [
     "chronic myelogenous leukemia, BCR-ABL1 positive",
     "acute lymphoblastic leukemia",
     "blast phase chronic myelogenous leukemia, BCR-ABL1 positive",
     "lymphoid leukemia"
    ],
    "IMATINIB": [
     "chronic myelogenous leukemia, BCR-ABL1 positive",
     "myelodysplastic/myeloproliferative disease",
     "gastrointestinal stromal tumor",
     "dermatofibrosarcoma protuberans",
     "blast phase chronic myelogenous leukemia, BCR-ABL1 positive",
     "B-cell acute lymphoblastic leukemia",
     "hypereosinophilic syndrome"
    ],
    "MASITINIB": [],
    "MIDOSTAURIN": [
     "mast cell leukemia",
     "mastocytosis",
     "acute myeloid leukemia by FAB classification",
     "systemic mastocytosis",
     "acute myeloid leukemia"
    ],
    "PAZOPANIB": [
     "renal cell carcinoma",
     "soft tissue sarcoma",
     "sarcoma"
    ],
    "PEXIDARTINIB": [
     "tenosynovial giant cell tumor",
     "tenosynovial giant cell tumor, diffuse type"
    ],
    "QUIZARTINIB": [
     "acute myeloid leukemia by FAB classification"
    ],
    "REGORAFENIB": [
     "colorectal cancer",
     "metastatic colorectal cancer",
     "colorectal neoplasm"
    ],
    "RIPRETINIB": [
     "gastrointestinal stromal tumor"
    ],
    "SORAFENIB": [
     "renal cell carcinoma",
     "hepatocellular carcinoma",
     "thyroid gland carcinoma"
    ],
    "SUNITINIB": [
     "gastrointestinal stromal tumor",
     "renal cell carcinoma",
     "neuroendocrine neoplasm"
    ],
    "SUNITINIB MALATE": [
     "renal cell carcinoma",
     "gastrointestinal stromal tumor",
     "neuroendocrine neoplasm"
    ],
    "TIVOZANIB": [
     "renal cell carcinoma"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Approved Drug"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "Phase 1 Clinical"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc med conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "AB",
     "bucket": "Human Protein Atlas loc"
    },
    {
     "modality": "PR",
     "bucket": "Literature"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "MAP2K1",
   "ensembl": "ENSG00000169032",
   "n_drug_entries": 19,
   "n_distinct_drugs": 17,
   "drugs": {
    "AS-703988": "PHASE_1",
    "AVUTOMETINIB": "PHASE_3",
    "AZD-8330": "PHASE_1",
    "BINIMETINIB": "APPROVAL",
    "CI-1040": "PHASE_2",
    "COBIMETINIB": "APPROVAL",
    "E-6201": "PHASE_2",
    "MIRDAMETINIB": "APPROVAL",
    "PIMASERTIB": "PHASE_2",
    "REFAMETINIB": "PHASE_3",
    "RG-7167": "PHASE_1",
    "RO-4987655": "PHASE_1",
    "SELUMETINIB": "APPROVAL",
    "TAK-733": "PHASE_2",
    "TRAMETINIB": "APPROVAL",
    "TRAMETINIB DIMETHYL SULFOXIDE": "APPROVAL",
    "WX-554": "PHASE_1_2"
   },
   "approved": [
    "BINIMETINIB",
    "COBIMETINIB",
    "MIRDAMETINIB",
    "SELUMETINIB",
    "TRAMETINIB",
    "TRAMETINIB DIMETHYL SULFOXIDE"
   ],
   "n_approved": 6,
   "approved_for": {
    "BINIMETINIB": [
     "melanoma",
     "metastatic melanoma"
    ],
    "COBIMETINIB": [
     "melanoma",
     "metastatic melanoma"
    ],
    "MIRDAMETINIB": [
     "neurofibromatosis type 1",
     "plexiform neurofibroma"
    ],
    "SELUMETINIB": [
     "neurofibromatosis",
     "neurofibromatosis type 1",
     "neurofibroma",
     "plexiform neurofibroma"
    ],
    "TRAMETINIB": [
     "metastatic melanoma",
     "melanoma",
     "glioma"
    ],
    "TRAMETINIB DIMETHYL SULFOXIDE": [
     "melanoma",
     "low grade glioma",
     "metastatic melanoma"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Approved Drug"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "Human Protein Atlas loc"
    },
    {
     "modality": "PR",
     "bucket": "Literature"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "CDKN2A",
   "ensembl": "ENSG00000147889",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": []
  },
  {
   "symbol": "PTEN",
   "ensembl": "ENSG00000171862",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "TERT",
   "ensembl": "ENSG00000164362",
   "n_drug_entries": 2,
   "n_distinct_drugs": 1,
   "drugs": {
    "IMETELSTAT": "APPROVAL"
   },
   "approved": [
    "IMETELSTAT"
   ],
   "n_approved": 1,
   "approved_for": {
    "IMETELSTAT": [
     "anemia",
     "myelodysplastic syndrome"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "GO CC med conf"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    },
    {
     "modality": "OC",
     "bucket": "Advanced Clinical"
    }
   ]
  },
  {
   "symbol": "PDCD1",
   "ensembl": "ENSG00000188389",
   "n_drug_entries": 26,
   "n_distinct_drugs": 26,
   "drugs": {
    "APL-501": "PHASE_2",
    "BALSTILIMAB": "PHASE_3",
    "BUDIGALIMAB": "PHASE_2_3",
    "CADONILIMAB": "PHASE_3",
    "CAMRELIZUMAB": "PHASE_3",
    "CEMIPLIMAB": "APPROVAL",
    "CETRELIMAB": "PHASE_3",
    "CS-1003": "PHASE_3",
    "DOSTARLIMAB": "APPROVAL",
    "FINOTONLIMAB": "PHASE_3",
    "LOMVASTOMIG": "PHASE_2",
    "NIVOLUMAB": "APPROVAL",
    "PEMBROLIZUMAB": "APPROVAL",
    "PENPULIMAB": "PHASE_3",
    "PIDILIZUMAB": "PHASE_2",
    "PIMIVALIMAB": "PHASE_2",
    "PUCOTENLIMAB": "PHASE_3",
    "RETIFANLIMAB": "APPROVAL",
    "SASANLIMAB": "PHASE_3",
    "SERPLULIMAB": "APPROVAL",
    "SINTILIMAB": "APPROVAL",
    "SPARTALIZUMAB": "PHASE_3",
    "TEBOTELIMAB": "PHASE_2_3",
    "TISLELIZUMAB": "APPROVAL",
    "TORIPALIMAB": "APPROVAL",
    "ZIMBERELIMAB": "PHASE_3"
   },
   "approved": [
    "CEMIPLIMAB",
    "DOSTARLIMAB",
    "NIVOLUMAB",
    "PEMBROLIZUMAB",
    "RETIFANLIMAB",
    "SERPLULIMAB",
    "SINTILIMAB",
    "TISLELIZUMAB",
    "TORIPALIMAB"
   ],
   "n_approved": 9,
   "approved_for": {
    "CEMIPLIMAB": [
     "squamous cell carcinoma",
     "basal cell carcinoma",
     "cutaneous squamous cell carcinoma",
     "cervical cancer"
    ],
    "DOSTARLIMAB": [
     "endometrial cancer",
     "endometrial neoplasm"
    ],
    "NIVOLUMAB": [
     "head and neck cancer",
     "pleural mesothelioma",
     "gastric cancer",
     "melanoma",
     "non-small cell lung carcinoma",
     "renal cell carcinoma",
     "transitional cell carcinoma",
     "colorectal neoplasm",
     "Hodgkins lymphoma",
     "mesothelioma",
     "head and neck squamous cell carcinoma",
     "classic Hodgkin lymphoma",
     "metastatic melanoma"
    ],
    "PEMBROLIZUMAB": [
     "melanoma",
     "metastatic melanoma",
     "endometrium neoplasm",
     "head and neck squamous cell carcinoma",
     "transitional cell carcinoma",
     "renal cell carcinoma",
     "Hodgkins lymphoma",
     "non-small cell lung carcinoma"
    ],
    "RETIFANLIMAB": [
     "neuroendocrine carcinoma",
     "Merkel cell skin cancer",
     "squamous cell carcinoma"
    ],
    "SERPLULIMAB": [
     "esophageal squamous cell carcinoma",
     "non-small cell lung carcinoma",
     "small cell lung carcinoma"
    ],
    "SINTILIMAB": [
     "Hodgkins lymphoma"
    ],
    "TISLELIZUMAB": [
     "esophageal cancer",
     "Hodgkins lymphoma",
     "non-small cell lung carcinoma",
     "adenocarcinoma",
     "esophageal squamous cell carcinoma",
     "gastric neoplasm"
    ],
    "TORIPALIMAB": [
     "melanoma",
     "nasopharyngeal carcinoma",
     "urothelial carcinoma",
     "esophageal squamous cell carcinoma",
     "Niemann-Pick disease type B"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "AB",
     "bucket": "Approved Drug"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "PR",
     "bucket": "Literature"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    },
    {
     "modality": "OC",
     "bucket": "Advanced Clinical"
    }
   ]
  },
  {
   "symbol": "CTLA4",
   "ensembl": "ENSG00000163599",
   "n_drug_entries": 6,
   "n_distinct_drugs": 6,
   "drugs": {
    "CADONILIMAB": "PHASE_3",
    "ERFONRILIMAB": "PHASE_3",
    "IPILIMUMAB": "APPROVAL",
    "QUAVONLIMAB": "PHASE_3",
    "TREMELIMUMAB": "APPROVAL",
    "ZALIFRELIMAB": "PHASE_2"
   },
   "approved": [
    "IPILIMUMAB",
    "TREMELIMUMAB"
   ],
   "n_approved": 2,
   "approved_for": {
    "IPILIMUMAB": [
     "metastatic melanoma",
     "melanoma",
     "colorectal neoplasm",
     "non-small cell lung carcinoma",
     "malignant mesothelioma",
     "renal cell carcinoma"
    ],
    "TREMELIMUMAB": [
     "non-small cell lung carcinoma",
     "hepatocellular carcinoma"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "AB",
     "bucket": "Approved Drug"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    }
   ]
  },
  {
   "symbol": "LAG3",
   "ensembl": "ENSG00000089692",
   "n_drug_entries": 6,
   "n_distinct_drugs": 6,
   "drugs": {
    "EFTILAGIMOD ALFA": "PHASE_3",
    "FAVEZELIMAB": "PHASE_3",
    "FIANLIMAB": "PHASE_3",
    "IERAMILIMAB": "PHASE_2",
    "RELATLIMAB": "APPROVAL",
    "TEBOTELIMAB": "PHASE_2_3"
   },
   "approved": [
    "RELATLIMAB"
   ],
   "n_approved": 1,
   "approved_for": {
    "RELATLIMAB": [
     "melanoma"
    ]
   },
   "tractability": [
    {
     "modality": "AB",
     "bucket": "Approved Drug"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc med conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "OC",
     "bucket": "Advanced Clinical"
    }
   ]
  },
  {
   "symbol": "MITF",
   "ensembl": "ENSG00000187098",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "PMEL",
   "ensembl": "ENSG00000185664",
   "n_drug_entries": 2,
   "n_distinct_drugs": 2,
   "drugs": {
    "IMC-GP100": "EARLY_PHASE_1",
    "TEBENTAFUSP": "APPROVAL"
   },
   "approved": [
    "TEBENTAFUSP"
   ],
   "n_approved": 1,
   "approved_for": {
    "TEBENTAFUSP": [
     "gastric cancer",
     "uveal cancer",
     "melanoma"
    ]
   },
   "tractability": [
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "OC",
     "bucket": "Approved Drug"
    }
   ]
  }
 ],
 "trials": {
  "by_antigen": {
   "PD-1": {
    "n": 429,
    "n_observational": 34,
    "n_active": 171,
    "n_withdrawn": 15,
    "trials": [
     {
      "nct": "NCT03340129",
      "title": "Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)",
      "status": "RECRUITING",
      "last_update": "2026-02-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03563729",
      "title": "Melanoma Metastasized to the Brain and Steroids",
      "status": "RECRUITING",
      "last_update": "2023-07-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03685890",
      "title": "Evaluating the Effect of Nivolumab for Patients With In-transit Metastases Treated With Isolated Limb Perfusion",
      "status": "RECRUITING",
      "last_update": "2024-04-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03888950",
      "title": "Interim FDG PET-CT in Melanoma Metastatic Patient's Treated by Anti-PD1 Therapy",
      "status": "RECRUITING",
      "last_update": "2025-03-19",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04114136",
      "title": "Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-06-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04198766",
      "title": "Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda\u00ae) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)",
      "status": "RECRUITING",
      "last_update": "2026-07-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04318717",
      "title": "Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-08-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04370587",
      "title": "A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2025-10-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04511013",
      "title": "A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases",
      "status": "RECRUITING",
      "last_update": "2025-09-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04513028",
      "title": "Beta Glucan's Effect on Pembrolizumab Immunologic Response in Stage III-IV Melanoma",
      "status": "RECRUITING",
      "last_update": "2025-10-30",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04594187",
      "title": "Nodal Radiation Therapy for Sentinel Lymph Node Positive Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-08-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04605146",
      "title": "Impact of Telemonitoring for the Management of Side Effects in Patients with Melanoma, Lung or Renal Cancer, Treated with Immunotherapy Combination of Nivolumab and Ipilimumab or Adjuvant Nivolumab Monotherapy",
      "status": "RECRUITING",
      "last_update": "2024-10-16",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04697576",
      "title": "Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-07-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04741997",
      "title": "Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-03-02",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04787042",
      "title": "Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067",
      "status": "RECRUITING",
      "last_update": "2024-11-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04793737",
      "title": "Precision Radiation of Immune Checkpoint Therapy Resistant Melanoma Metastases",
      "status": "RECRUITING",
      "last_update": "2025-03-05",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04895709",
      "title": "A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-08-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05076760",
      "title": "MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-06-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05086692",
      "title": "A Beta-only IL-2 ImmunoTherapY Study",
      "status": "RECRUITING",
      "last_update": "2025-07-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05136196",
      "title": "BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study",
      "status": "RECRUITING",
      "last_update": "2026-09-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05155033",
      "title": "Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-09-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05267626",
      "title": "Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2R\u03b1 Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer",
      "status": "RECRUITING",
      "last_update": "2026-07-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05384496",
      "title": "Axitinib and Nivolumab for the Treatment of Mucosal Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-02-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05483400",
      "title": "Open Label Phase 2 Basket Trial With Atezolizumab and Tiragolumab in Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2025-03-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05492682",
      "title": "START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer",
      "status": "RECRUITING",
      "last_update": "2026-05-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05498792",
      "title": "Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-05-22",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05629546",
      "title": "Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors",
      "status": "RECRUITING",
      "last_update": "2026-07-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05669430",
      "title": "A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies",
      "status": "RECRUITING",
      "last_update": "2025-02-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05704647",
      "title": "Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases",
      "status": "RECRUITING",
      "last_update": "2026-07-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05746897",
      "title": "A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2024-01-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05824975",
      "title": "A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)",
      "status": "RECRUITING",
      "last_update": "2024-11-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05859074",
      "title": "A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer",
      "status": "RECRUITING",
      "last_update": "2026-08-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05968690",
      "title": "Naltrexone and Propranolol Combined With Immunotherapy",
      "status": "RECRUITING",
      "last_update": "2025-09-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06022029",
      "title": "A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.",
      "status": "RECRUITING",
      "last_update": "2025-12-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06047379",
      "title": "Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis",
      "status": "RECRUITING",
      "last_update": "2026-07-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06066138",
      "title": "A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing",
      "status": "RECRUITING",
      "last_update": "2026-09-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06090266",
      "title": "A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents",
      "status": "RECRUITING",
      "last_update": "2025-01-07",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06112314",
      "title": "IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)",
      "status": "RECRUITING",
      "last_update": "2026-02-25",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06121180",
      "title": "Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma",
      "status": "RECRUITING",
      "last_update": "2025-12-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06163820",
      "title": "Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain Metastases",
      "status": "RECRUITING",
      "last_update": "2025-05-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06240143",
      "title": "Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma",
      "status": "RECRUITING",
      "last_update": "2024-11-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06246916",
      "title": "A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)",
      "status": "RECRUITING",
      "last_update": "2026-08-19",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06264180",
      "title": "VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]",
      "status": "RECRUITING",
      "last_update": "2026-07-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06270706",
      "title": "A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-08-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06281678",
      "title": "A Study of IBI363 in Subjects with Advanced Solid Malignancies",
      "status": "RECRUITING",
      "last_update": "2024-12-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06284590",
      "title": "Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients",
      "status": "RECRUITING",
      "last_update": "2026-09-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06319196",
      "title": "Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-06-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06398418",
      "title": "R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-09-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06413680",
      "title": "A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body",
      "status": "RECRUITING",
      "last_update": "2026-04-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06488482",
      "title": "Assessment of Short Immunotherapy After Radical Surgery of High-risk Malignant Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-03-09",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06585410",
      "title": "Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-08-17",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06594991",
      "title": "A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-05-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06624644",
      "title": "A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-04-22",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06683755",
      "title": "Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)",
      "status": "RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06697301",
      "title": "Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.",
      "status": "RECRUITING",
      "last_update": "2026-05-08",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06703398",
      "title": "A Study of GC101 TIL in Advanced Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-08-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06743126",
      "title": "SUPRAME-ACTengine\u00ae IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-08-18",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06771544",
      "title": "Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-03-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06797297",
      "title": "A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic Therapy",
      "status": "RECRUITING",
      "last_update": "2025-04-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06880198",
      "title": "Study to Evaluate Impact\u00ae as Support to Anti PD1 or Anti PD1 Based Regimen Treatment in Patients With Inoperable Locally Advanced or Metastatic Melanoma",
      "status": "RECRUITING",
      "last_update": "2025-09-17",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06880549",
      "title": "A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-08-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06887088",
      "title": "Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain Metastases",
      "status": "RECRUITING",
      "last_update": "2025-10-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06906822",
      "title": "PLUG-IN: Pembrolizumab Combined With Enfortumab Vedotin for Advanced Melanoma Patients",
      "status": "RECRUITING",
      "last_update": "2025-09-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06961006",
      "title": "A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)",
      "status": "RECRUITING",
      "last_update": "2026-07-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06965231",
      "title": "Perioperative Toripalimab and Endostatin for Stage II Melanoma: A Phase II Trial",
      "status": "RECRUITING",
      "last_update": "2025-05-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07050940",
      "title": "Anti PD-1 Plus Postbiotic Versus Anti PD-1 Alone in Locally Advanced or Metastatic, Treatment na\u00efve, Cutaneous Melanoma Study",
      "status": "RECRUITING",
      "last_update": "2025-07-03",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07070232",
      "title": "A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors",
      "status": "RECRUITING",
      "last_update": "2026-09-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07115043",
      "title": "A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-08-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07130032",
      "title": "Efficacy And Safety Of Anti-PD-1/PD-L1 Antibodies In Combination With Bevacizumab And Metronomic Cyclophosphamide In Patients With Non-Small Cell Lung Cancer And Cutaneous Melanoma Previously Treated With Immune Checkpoint Blockade",
      "status": "RECRUITING",
      "last_update": "2025-08-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07221734",
      "title": "Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo\u00ae in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-01-21",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07223424",
      "title": "Patient Preference for Subcutaneous vs. Intravenous Immune Therapy",
      "status": "RECRUITING",
      "last_update": "2026-04-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07237594",
      "title": "IL-17 Blockade to Decrease irAEs (REPLAY)",
      "status": "RECRUITING",
      "last_update": "2026-06-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07349303",
      "title": "Neoadjuvant Pembrolizumab in Patients With Stage IIb/c Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-08-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07376707",
      "title": "A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-01-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07410676",
      "title": "EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 \u00b1 Pembrolizumab in Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-02-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07422779",
      "title": "Immunotherapy Efficacy and PD-L1 as a Predictive Biomarker in Metastatic Melanoma in Slovenia",
      "status": "RECRUITING",
      "last_update": "2026-02-20",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07492680",
      "title": "A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)",
      "status": "RECRUITING",
      "last_update": "2026-08-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07504796",
      "title": "ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab",
      "status": "RECRUITING",
      "last_update": "2026-08-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07518043",
      "title": "A Study of HLX18 vs. OPDIVO\u00ae in Multiple Resected Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-07-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07555210",
      "title": "Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy",
      "status": "RECRUITING",
      "last_update": "2026-05-06",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07562841",
      "title": "Au-TMP and Radiotherapy for Advanced Melanoma With Anti-PD-1 Therapy",
      "status": "RECRUITING",
      "last_update": "2026-05-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07564570",
      "title": "Physical Activity Directly Before Immunotherapy (Nivolumab and Ipilimumab) in Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-05-04",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07586891",
      "title": "Exploratory Study With Parallel Controls on the Safety and Efficacy of Neoadjuvant Low Branched-Chain Amino Acid Diet in Combination With Anti-PD-1 Monoclonal Antibody for Stage III Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-05-14",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07634380",
      "title": "Sitagliptin With Pembro in RCC and Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-07-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07718243",
      "title": "Investigating the Combination of Bexmarilimab and Nivolumab in Solid Tumours, Melanoma and NSCLC",
      "status": "RECRUITING",
      "last_update": "2026-09-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07750067",
      "title": "Tunlametinib in Combination With Pucotenlimab and Hydroxychloroquine in NRAS Mutant Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-08-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01176474",
      "title": "Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma",
      "status": "COMPLETED",
      "last_update": "2023-07-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01295827",
      "title": "Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001)",
      "status": "COMPLETED",
      "last_update": "2019-12-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01585194",
      "title": "Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma",
      "status": "COMPLETED",
      "last_update": "2024-07-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01704287",
      "title": "Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Participants With Advanced Melanoma (MK-3475-002/P08719/KEYNOTE-002)",
      "status": "COMPLETED",
      "last_update": "2020-05-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01721746",
      "title": "A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)",
      "status": "COMPLETED",
      "last_update": "2022-04-19",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02009449",
      "title": "A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2026-07-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02027961",
      "title": "Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone",
      "status": "COMPLETED",
      "last_update": "2019-05-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02054520",
      "title": "Immunotherapy Study for Patients With Stage IV Melanoma",
      "status": "TERMINATED",
      "last_update": "2023-04-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02073123",
      "title": "Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2026-05-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02085070",
      "title": "MK-3475 in Melanoma and NSCLC Patients With Brain Metastases",
      "status": "COMPLETED",
      "last_update": "2021-03-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02089685",
      "title": "Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29)",
      "status": "COMPLETED",
      "last_update": "2022-09-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02122861",
      "title": "Phase 1 Study of Intradermal LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1",
      "status": "COMPLETED",
      "last_update": "2019-03-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02180061",
      "title": "Study of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-041/KEYNOTE-041)",
      "status": "COMPLETED",
      "last_update": "2020-03-31",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02259231",
      "title": "RTA 408 Capsules in Patients With Melanoma - REVEAL",
      "status": "COMPLETED",
      "last_update": "2025-06-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02263508",
      "title": "Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma",
      "status": "TERMINATED",
      "last_update": "2022-11-14",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02298959",
      "title": "Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02304458",
      "title": "Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas",
      "status": "COMPLETED",
      "last_update": "2023-10-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02306850",
      "title": "Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma",
      "status": "COMPLETED",
      "last_update": "2019-06-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02320058",
      "title": "An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by Itself",
      "status": "COMPLETED",
      "last_update": "2021-10-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02346955",
      "title": "Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001)",
      "status": "TERMINATED",
      "last_update": "2020-08-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02359851",
      "title": "Pembrolizumab in Treating Patients With Advanced Uveal Melanoma",
      "status": "TERMINATED",
      "last_update": "2019-09-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02376699",
      "title": "Safety Study of SEA-CD40 in Cancer Patients",
      "status": "TERMINATED",
      "last_update": "2023-05-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02388906",
      "title": "Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma",
      "status": "COMPLETED",
      "last_update": "2025-04-24",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02407171",
      "title": "Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLC",
      "status": "COMPLETED",
      "last_update": "2023-10-31",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02423863",
      "title": "In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol\u00ae",
      "status": "COMPLETED",
      "last_update": "2020-12-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02434354",
      "title": "A Tissue Collection Study of Pembrolizumab (MK-3475) in Subjects With Resectable Advanced Melanoma",
      "status": "COMPLETED",
      "last_update": "2022-06-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02460068",
      "title": "A Study of Fotemustine(FTM) Vs FTM and Ipilimumab (IPI) or IPI and Nivolumab in Melanoma Brain Metastasis",
      "status": "UNKNOWN",
      "last_update": "2015-06-02",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02465060",
      "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02475213",
      "title": "Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer",
      "status": "COMPLETED",
      "last_update": "2025-08-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02500576",
      "title": "Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2025-01-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02519322",
      "title": "Neoadjuvant and Adjuvant Checkpoint Blockade",
      "status": "COMPLETED",
      "last_update": "2024-04-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02523313",
      "title": "Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab vs. Double Placebo for Stage IV Melanoma w. NED",
      "status": "COMPLETED",
      "last_update": "2025-04-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02535078",
      "title": "Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma",
      "status": "WITHDRAWN",
      "last_update": "2024-07-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02565992",
      "title": "Intratumoral CAVATAK (CVA21) and Pembrolizumab in Patients With Advanced Melanoma (VLA-011 CAPRA)",
      "status": "COMPLETED",
      "last_update": "2023-01-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02574533",
      "title": "Pilot Study of Vigil\u2122 + Pembrolizumab for Advanced Melanoma",
      "status": "COMPLETED",
      "last_update": "2017-09-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02575404",
      "title": "GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients",
      "status": "COMPLETED",
      "last_update": "2023-06-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02595866",
      "title": "Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer",
      "status": "COMPLETED",
      "last_update": "2024-08-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02607813",
      "title": "Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations",
      "status": "TERMINATED",
      "last_update": "2022-12-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02608268",
      "title": "Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies",
      "status": "TERMINATED",
      "last_update": "2023-12-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02621515",
      "title": "Nivo/Ipi Combination Therapy in Symptomatic Brain Metastases",
      "status": "TERMINATED",
      "last_update": "2024-05-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02626962",
      "title": "Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melanoma",
      "status": "COMPLETED",
      "last_update": "2022-03-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02631447",
      "title": "Sequential Combo Immuno and Target Therapy (SECOMBIT) Study",
      "status": "COMPLETED",
      "last_update": "2024-06-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02637531",
      "title": "A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549",
      "status": "UNKNOWN",
      "last_update": "2022-04-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02644967",
      "title": "A Phase 2 Study to Assess the Safety and Efficacy of IMO-2125 With 8 mg Ipilimumab in Patients With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2022-08-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02652455",
      "title": "Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2025-08-19",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02658890",
      "title": "An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread",
      "status": "COMPLETED",
      "last_update": "2023-08-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02659540",
      "title": "Pilot Study of the Safety/Efficacy of Combination Checkpoint Blockade + External Beam Radiotherapy in Stage IV Melanoma",
      "status": "COMPLETED",
      "last_update": "2022-10-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02680184",
      "title": "Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy",
      "status": "COMPLETED",
      "last_update": "2025-07-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02681549",
      "title": "Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC)",
      "status": "COMPLETED",
      "last_update": "2025-08-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02702492",
      "title": "PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)",
      "status": "TERMINATED",
      "last_update": "2024-11-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02718066",
      "title": "Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer",
      "status": "COMPLETED",
      "last_update": "2026-07-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02738489",
      "title": "A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 in Patients With Advanced Melanoma",
      "status": "COMPLETED",
      "last_update": "2023-02-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02740920",
      "title": "Response to Pembrolizumab in Metastatic Melanoma: Computed Tomography Texture Analysis as a Predictive Biomarker",
      "status": "TERMINATED",
      "last_update": "2023-08-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02760225",
      "title": "Pembrolizumab-PET Imaging",
      "status": "COMPLETED",
      "last_update": "2024-05-03",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02763761",
      "title": "An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo",
      "status": "WITHDRAWN",
      "last_update": "2018-10-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02771626",
      "title": "Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)",
      "status": "TERMINATED",
      "last_update": "2023-03-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02783300",
      "title": "An Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-03-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02791334",
      "title": "A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2024-09-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02796352",
      "title": "A Phase II Study of High Dose Bolus IL2 in Patients With Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy: Efficacy and Biomarker Study",
      "status": "TERMINATED",
      "last_update": "2018-04-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02799095",
      "title": "A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2025-05-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02799901",
      "title": "Nivolumab Plus Radiotherapy in Advanced Melanoma",
      "status": "COMPLETED",
      "last_update": "2023-11-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02812693",
      "title": "Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplification",
      "status": "WITHDRAWN",
      "last_update": "2018-04-05",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02816021",
      "title": "Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2026-04-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02818023",
      "title": "Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced Melanoma",
      "status": "TERMINATED",
      "last_update": "2022-01-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02821182",
      "title": "A Phase II Trial of Stereotactic Body Radiotherapy With Concurrent Anti-PD1 Treatment in Metastatic Melanoma.",
      "status": "COMPLETED",
      "last_update": "2022-12-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02823405",
      "title": "X4P-001 and Pembrolizumab in Patients With Advanced Melanoma",
      "status": "COMPLETED",
      "last_update": "2020-07-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02836795",
      "title": "Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal Antibody Toripalimab for Patients With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2025-06-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02857569",
      "title": "A Trial Evaluating the Safety & Efficacy of Intra-Tumoral Ipilimumab in Combination With Intra-venous Nivolumab in Patients With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2023-02-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02872259",
      "title": "BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2025-01-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02875132",
      "title": "Pembrolizumab in Advanced/Metastatic Acral Lentiginous Melanoma",
      "status": "COMPLETED",
      "last_update": "2025-04-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02897765",
      "title": "A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer",
      "status": "COMPLETED",
      "last_update": "2021-02-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02905266",
      "title": "A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Melanoma",
      "status": "COMPLETED",
      "last_update": "2020-12-17",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02910700",
      "title": "Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02913417",
      "title": "Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases",
      "status": "UNKNOWN",
      "last_update": "2021-04-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02941744",
      "title": "A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma Macrometastases",
      "status": "COMPLETED",
      "last_update": "2019-01-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02970981",
      "title": "Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma",
      "status": "COMPLETED",
      "last_update": "2024-04-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02977052",
      "title": "Optimal Neo-adjuvant Combination Scheme of Ipilimumab and Nivolumab",
      "status": "UNKNOWN",
      "last_update": "2023-11-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02978443",
      "title": "A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab",
      "status": "TERMINATED",
      "last_update": "2024-04-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02978625",
      "title": "Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02981303",
      "title": "Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer",
      "status": "COMPLETED",
      "last_update": "2024-07-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02983045",
      "title": "A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2023-03-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03002376",
      "title": "An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Melanoma Patients Receiving REGN2810 (Anti-PD-1)",
      "status": "COMPLETED",
      "last_update": "2020-04-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03003676",
      "title": "A Pilot Study of Sequential ONCOS-102, an Engineered Oncolytic Adenovirus Expressing GMCSF, and Pembrolizumab in Patients With Advanced or Unresectable Melanoma Progressing After Programmed Cell Death Protein 1 (PD1) Blockade",
      "status": "COMPLETED",
      "last_update": "2021-11-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03006887",
      "title": "Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2021-05-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03021460",
      "title": "Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery",
      "status": "COMPLETED",
      "last_update": "2026-09-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03025256",
      "title": "Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03047928",
      "title": "Combination Therapy With Nivolumab and PD-L1/IDO Peptide Vaccine to Patients With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2025-02-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03050060",
      "title": "Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer",
      "status": "TERMINATED",
      "last_update": "2022-06-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03068455",
      "title": "An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma",
      "status": "COMPLETED",
      "last_update": "2021-09-20",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03086174",
      "title": "Tolerability and Pharmacokinetics of Toripalimab in Combination With Axitinib in Patients With Kidney Cancer and Melanoma",
      "status": "UNKNOWN",
      "last_update": "2020-09-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03092453",
      "title": "Dendritic Cell Vaccination in Patients With Advanced Melanoma",
      "status": "COMPLETED",
      "last_update": "2024-12-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03122522",
      "title": "A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03131908",
      "title": "Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss",
      "status": "COMPLETED",
      "last_update": "2026-08-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03132675",
      "title": "Tavo and Pembrolizumab in Patients With Stage III/IV Melanoma Progressing on Either Pembrolizumab or Nivolumab Treatment",
      "status": "UNKNOWN",
      "last_update": "2023-03-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03158935",
      "title": "The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) Trial",
      "status": "COMPLETED",
      "last_update": "2020-08-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03161431",
      "title": "SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-12-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03161756",
      "title": "Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma",
      "status": "UNKNOWN",
      "last_update": "2022-04-07",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03166397",
      "title": "Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients",
      "status": "UNKNOWN",
      "last_update": "2023-01-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03190174",
      "title": "Nivolumab (Opdivo\u00ae) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers",
      "status": "COMPLETED",
      "last_update": "2025-02-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03212404",
      "title": "Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-02-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03225365",
      "title": "Nivolumab +/- Ipilimumab Immunomonitoring in Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2026-07-20",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03236935",
      "title": "Phase Ib of L-NMMA and Pembrolizumab",
      "status": "COMPLETED",
      "last_update": "2026-04-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03239145",
      "title": "Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor",
      "status": "COMPLETED",
      "last_update": "2026-07-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03241173",
      "title": "A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies",
      "status": "COMPLETED",
      "last_update": "2022-09-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03269565",
      "title": "International Trial of the Efficacy and Safety of BCD-100 in Patients With Melanoma",
      "status": "UNKNOWN",
      "last_update": "2020-09-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03273153",
      "title": "A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma",
      "status": "TERMINATED",
      "last_update": "2022-09-21",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03276832",
      "title": "Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma",
      "status": "COMPLETED",
      "last_update": "2026-03-19",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03291002",
      "title": "Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC",
      "status": "UNKNOWN",
      "last_update": "2021-11-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03301636",
      "title": "A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects With Unresectable or Metastatic Melanoma",
      "status": "TERMINATED",
      "last_update": "2022-09-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03301896",
      "title": "Study of the Safety and Efficacy of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies",
      "status": "TERMINATED",
      "last_update": "2024-06-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03329950",
      "title": "A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies",
      "status": "COMPLETED",
      "last_update": "2024-03-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03347123",
      "title": "A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)",
      "status": "TERMINATED",
      "last_update": "2022-02-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03400332",
      "title": "A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers",
      "status": "COMPLETED",
      "last_update": "2026-02-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03407170",
      "title": "Immunologic Determinants of Response to Pembrolizumab (MK-3475) in Advanced Melanoma (MK-3475-161/KEYNOTE-161)",
      "status": "TERMINATED",
      "last_update": "2020-07-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03412058",
      "title": "Identifying the Predictive Factors of Response to PD-1 or PD-L1 Antagonists",
      "status": "TERMINATED",
      "last_update": "2026-08-03",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03430297",
      "title": "A Randomized, Controlled, Multi-center, Phase III Clinical Study to Investigate Recombinant Humanized PD-1 Monoclonal Antibody Injection (JS001) Versus Dacarbazine as the 1st-line Therapy for Unresectable or Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2024-09-19",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03435640",
      "title": "REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies",
      "status": "TERMINATED",
      "last_update": "2023-03-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03448666",
      "title": "ECT-Pembrolizumab in Patients With Unresectable Melanoma With Superficial or Superficial and Visceral Metastases",
      "status": "WITHDRAWN",
      "last_update": "2024-09-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03474497",
      "title": "UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03475134",
      "title": "TIL-ACT After NMA Chemo with IL-2 and Nivo Rescue in Metastatic Melanoma (mMEL)",
      "status": "COMPLETED",
      "last_update": "2025-02-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03511391",
      "title": "CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2024-01-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03514901",
      "title": "To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib.",
      "status": "UNKNOWN",
      "last_update": "2021-12-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03520634",
      "title": "PD-L1 PET Imaging in Melanoma Patients",
      "status": "COMPLETED",
      "last_update": "2024-05-06",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03534635",
      "title": "Analysis of the Modulation of the Tumor Microenvironment by MK-3475 (Pembrolizumab) Using a Systems Biology Approach (PEMSYS)",
      "status": "UNKNOWN",
      "last_update": "2023-02-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03538314",
      "title": "UV1 Vaccine With Pembrolizumab for Patients With Unresectable or Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2024-08-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03543969",
      "title": "Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-05",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03544723",
      "title": "Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.",
      "status": "UNKNOWN",
      "last_update": "2020-06-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03597282",
      "title": "A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma",
      "status": "TERMINATED",
      "last_update": "2020-09-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03611868",
      "title": "A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-08-07",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03618641",
      "title": "CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease",
      "status": "COMPLETED",
      "last_update": "2025-05-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03620019",
      "title": "Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma",
      "status": "COMPLETED",
      "last_update": "2026-03-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03621982",
      "title": "Study of ADCT-301 in Patients With Selected Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2024-06-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03629756",
      "title": "A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies",
      "status": "COMPLETED",
      "last_update": "2024-05-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03633110",
      "title": "Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine",
      "status": "COMPLETED",
      "last_update": "2022-04-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03637803",
      "title": "Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2023-06-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03645928",
      "title": "Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2026-05-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03646617",
      "title": "Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03673332",
      "title": "Elderly Cancer PatIents, Safety and qualiTy of Life Under immunOtheraPies",
      "status": "TERMINATED",
      "last_update": "2026-01-22",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03679767",
      "title": "A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)",
      "status": "COMPLETED",
      "last_update": "2023-07-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03684785",
      "title": "Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2022-04-07",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03698019",
      "title": "A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03708328",
      "title": "A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2025-08-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03715205",
      "title": "Study to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non-small Cell Lung Cancer in India (MK-3475-593/KEYNOTE-593)",
      "status": "COMPLETED",
      "last_update": "2025-08-29",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03715985",
      "title": "Personalized Neo-antigen Vaccine in Advanced Solid Tumors (NeoPepVac)",
      "status": "UNKNOWN",
      "last_update": "2022-01-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03719131",
      "title": "Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-04-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03724968",
      "title": "Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression",
      "status": "TERMINATED",
      "last_update": "2021-04-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03728465",
      "title": "Evaluation of Safety and Efficacy of Patients With Four and More Symptomatic Brain Metastases of Melanoma",
      "status": "TERMINATED",
      "last_update": "2021-02-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03729596",
      "title": "MGC018 With or Without MGA012 in Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-07-31",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03743298",
      "title": "Safety of AV-MEL-1 With Anti-PD-1 Therapy in Metastatic Melanoma",
      "status": "UNKNOWN",
      "last_update": "2023-04-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03754179",
      "title": "Dabrafenib/Trametinib/Hydroxychloroquine for Advanced Pretreated BRAF V600 Mutant Melanoma",
      "status": "UNKNOWN",
      "last_update": "2021-04-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03765229",
      "title": "An Exploratory Study of Pembrolizumab Plus Entinostat in Non-Inflamed Stage III/IV Melanoma",
      "status": "COMPLETED",
      "last_update": "2024-01-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03769155",
      "title": "VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03773744",
      "title": "MG1-MAGEA3 With Ad-MAGEA3 and Pembrolizumab in Patients With Previously Treated Metastatic Melanoma or Cutaneous Squamous Cell Carcinoma",
      "status": "WITHDRAWN",
      "last_update": "2021-04-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03776136",
      "title": "Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants (MK-7902-004/E7080-G000-225/LEAP-004)",
      "status": "COMPLETED",
      "last_update": "2024-10-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03799003",
      "title": "A Study of ASP1951 in Subjects With Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2024-11-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03809624",
      "title": "Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer",
      "status": "TERMINATED",
      "last_update": "2024-10-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03815682",
      "title": "RPTR-147 in Patients With Selected Solid Tumors and Lymphomas",
      "status": "TERMINATED",
      "last_update": "2022-12-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03818893",
      "title": "Combination Therapy With GEN0101 and Pembrolizmub in Advanced Melanoma Patients PIb/PII",
      "status": "UNKNOWN",
      "last_update": "2019-01-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03820986",
      "title": "Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)",
      "status": "COMPLETED",
      "last_update": "2026-02-09",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03834623",
      "title": "Avadomide (CC-122) in Combination With Nivolumab in Advanced Melanoma",
      "status": "COMPLETED",
      "last_update": "2022-10-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03872947",
      "title": "A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03875079",
      "title": "A Study to Evaluate Safety and Therapeutic Activity of RO6874281 in Combination with Pembrolizumab, in Participants with Advanced or Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2024-10-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03897881",
      "title": "An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03903640",
      "title": "Optune Device - TT Field Plus Nivolumab and Ipilimumab for Melanoma With Brain Metastasis",
      "status": "TERMINATED",
      "last_update": "2022-06-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03913923",
      "title": "Study of Efficacy and Safety of BCD-217 (Anti-CTLA-4 and Anti-PD-1) Followed By BCD-100 (Anti-PD-1) Versus BCD-100 Monotherapy as First-Line Treatment in Patients With Unresectable or Metastatic Melanoma",
      "status": "UNKNOWN",
      "last_update": "2023-02-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03917069",
      "title": "Nab-PCE vs PC for MM After Failure of Anti-PD-1",
      "status": "UNKNOWN",
      "last_update": "2019-04-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03922880",
      "title": "Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma",
      "status": "COMPLETED",
      "last_update": "2025-05-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03949153",
      "title": "Cryotherapy With in Situ Immunotherapy in Melanoma Metastasis",
      "status": "COMPLETED",
      "last_update": "2026-06-05",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03957551",
      "title": "Cabozantinib and Pembrolizumab for Advanced Metastatic Melanoma",
      "status": "TERMINATED",
      "last_update": "2026-01-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03970382",
      "title": "A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors",
      "status": "SUSPENDED",
      "last_update": "2022-08-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03991975",
      "title": "Study of TQB2450 Combined With Anlotinib in Subjects With Advanced Acral Malignant Melanoma",
      "status": "UNKNOWN",
      "last_update": "2019-10-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04007588",
      "title": "A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma",
      "status": "WITHDRAWN",
      "last_update": "2020-02-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04007744",
      "title": "Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04017897",
      "title": "The Combination of Anti-PD-1 With Radiotherapy in Previously Untreated Metastatic Melanoma",
      "status": "UNKNOWN",
      "last_update": "2019-07-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04032704",
      "title": "A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-03-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04044859",
      "title": "ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04060407",
      "title": "CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI)",
      "status": "WITHDRAWN",
      "last_update": "2021-06-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04074096",
      "title": "Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04074967",
      "title": "Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-11-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04079166",
      "title": "SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-12-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04083599",
      "title": "GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04091750",
      "title": "Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04116320",
      "title": "Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-07-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04125719",
      "title": "PVSRIPO in Combination With Nivolumab in Melanoma",
      "status": "WITHDRAWN",
      "last_update": "2020-02-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04137900",
      "title": "Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies",
      "status": "UNKNOWN",
      "last_update": "2024-02-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04140526",
      "title": "Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-05-23",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04142931",
      "title": "Sequentional Immuno Apheresis Plasma Volume Escalation Cohort Study of Reduction of Soluble Tumor Necrosis Factor Receptors 1 and 2 (sTNFR1/2) With or Without Nivolumab in Patients With Inoperable or Metastatic Solid Tumors",
      "status": "UNKNOWN",
      "last_update": "2021-03-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04148937",
      "title": "A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer",
      "status": "COMPLETED",
      "last_update": "2024-04-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04152018",
      "title": "Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.",
      "status": "TERMINATED",
      "last_update": "2025-05-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04152863",
      "title": "Efficacy, Safety, and Tolerability of Gebasaxturev (V937) Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011)",
      "status": "TERMINATED",
      "last_update": "2024-08-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04157985",
      "title": "Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2025-12-11",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04187872",
      "title": "LITT and Pembrolizumab in Recurrent Brain Metastasis",
      "status": "TERMINATED",
      "last_update": "2023-12-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04197882",
      "title": "Clinical Study to Evaluate OrienX010 in Combination With Toripalimab as Neoadjuvant Treatment in Advanced Melanoma",
      "status": "UNKNOWN",
      "last_update": "2021-02-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04205227",
      "title": "ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-09-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04250246",
      "title": "A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1",
      "status": "UNKNOWN",
      "last_update": "2020-01-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04283890",
      "title": "PHP and Immunotherapy in Metastasized UM",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04291105",
      "title": "Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04309409",
      "title": "Adjuvant Nivolumab Treatment in Stage II (IIA, IIB, IIC) High-risk Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-05-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04357509",
      "title": "The Tolerance,Pharmacokinetic Characteristics,Safety and Efficacy of ScTIL210 in the Treatment of Melanoma",
      "status": "UNKNOWN",
      "last_update": "2020-04-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04382664",
      "title": "UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma",
      "status": "COMPLETED",
      "last_update": "2025-01-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04386967",
      "title": "OH2 Injection in Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2026-08-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04423029",
      "title": "A Study of DF6002 Alone and in Combination With Nivolumab",
      "status": "COMPLETED",
      "last_update": "2026-03-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04452214",
      "title": "A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2023-07-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04455503",
      "title": "Study of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1",
      "status": "TERMINATED",
      "last_update": "2024-02-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04464759",
      "title": "A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04483778",
      "title": "B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04485013",
      "title": "TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04493203",
      "title": "Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma",
      "status": "COMPLETED",
      "last_update": "2025-07-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04495010",
      "title": "Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants",
      "status": "WITHDRAWN",
      "last_update": "2021-03-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04521075",
      "title": "A Phase Ib Trial to Evaluate the Safety and Efficacy of FMT and Nivolumab in Subjects With Metastatic or Inoperable Melanoma, MSI-H, dMMR or NSCLC",
      "status": "UNKNOWN",
      "last_update": "2021-08-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04526899",
      "title": "A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of Treatment",
      "status": "COMPLETED",
      "last_update": "2026-01-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04541108",
      "title": "Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-22",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04544748",
      "title": "A Phase 1 Study of GNR-051 in Subjects With Advanced Malignancies",
      "status": "UNKNOWN",
      "last_update": "2024-03-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04546074",
      "title": "Imatinib Mesylate in Combination With Pembrolizumab in Patients With Melanoma",
      "status": "UNKNOWN",
      "last_update": "2023-10-03",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04562129",
      "title": "IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04581382",
      "title": "Radiation Therapy, Plasma Exchange, and Immunotherapy (Pembrolizumab or Nivolumab) for the Treatment of Melanoma",
      "status": "COMPLETED",
      "last_update": "2025-07-10",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04606472",
      "title": "A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04609566",
      "title": "Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2026-07-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04625205",
      "title": "A Clinical Study of the Safety and Activity of the Investigational Cell Therapy NEO-PTC-01 in Patients With Advanced Melanoma",
      "status": "TERMINATED",
      "last_update": "2025-04-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04633902",
      "title": "Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation",
      "status": "UNKNOWN",
      "last_update": "2022-12-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04663126",
      "title": "Feasibility of IV Tc-99m-tilmanocept for Imaging of M2-like TAMs in Metastatic Melanoma",
      "status": "TERMINATED",
      "last_update": "2023-12-13",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04695977",
      "title": "CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma",
      "status": "TERMINATED",
      "last_update": "2026-06-15",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04700072",
      "title": "Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02)",
      "status": "COMPLETED",
      "last_update": "2025-10-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04703426",
      "title": "Sargramostim (GM-CSF) + PD-1",
      "status": "WITHDRAWN",
      "last_update": "2023-05-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04708418",
      "title": "A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04725331",
      "title": "A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-11-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04734704",
      "title": "Defining the Role of the Skin Microbiome in Immune-related Adverse Events",
      "status": "TERMINATED",
      "last_update": "2026-06-23",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04749485",
      "title": "A Study of HX008 for the Treatment of Patients With Malignant Melanoma",
      "status": "UNKNOWN",
      "last_update": "2021-02-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04802876",
      "title": "Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-03-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04830124",
      "title": "Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6",
      "status": "TERMINATED",
      "last_update": "2025-06-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04866810",
      "title": "The Effect of Diet and Exercise on ImmuNotherapy and the Microbiome (EDEN)",
      "status": "SUSPENDED",
      "last_update": "2026-09-11",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04889118",
      "title": "Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advanced Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)-China Extension Study",
      "status": "COMPLETED",
      "last_update": "2025-12-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04891718",
      "title": "CIVO Intratumoural Microdosing of Anti-Cancer Therapies in Australia",
      "status": "WITHDRAWN",
      "last_update": "2022-07-08",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04899921",
      "title": "Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets",
      "status": "TERMINATED",
      "last_update": "2024-03-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04901988",
      "title": "Circulating Tumour DNA guidEd Therapy for Stage IIB/C mElanoma After surgiCal resecTION",
      "status": "TERMINATED",
      "last_update": "2025-02-27",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04902040",
      "title": "Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies",
      "status": "TERMINATED",
      "last_update": "2026-04-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04913025",
      "title": "REduced Frequency ImmuNE Checkpoint Inhibition in Cancers",
      "status": "UNKNOWN",
      "last_update": "2022-09-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04913220",
      "title": "A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201)",
      "status": "TERMINATED",
      "last_update": "2026-02-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04913337",
      "title": "Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies",
      "status": "UNKNOWN",
      "last_update": "2024-10-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04924413",
      "title": "L-TIL Plus Tislelizumab as First-line Treatment in Advanced Malignant Melanoma",
      "status": "TERMINATED",
      "last_update": "2024-07-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04930783",
      "title": "NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04940299",
      "title": "Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04951583",
      "title": "Fecal Microbial Transplantation Non-Small Cell Lung Cancer and Melanoma",
      "status": "UNKNOWN",
      "last_update": "2024-08-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04955262",
      "title": "A CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Using \u2078\u2079Zr Df-IAB22M2C in Patients With Metastatic Melanoma Receiving Bempegaldesleukin (NKTR-214) and Nivolumab",
      "status": "WITHDRAWN",
      "last_update": "2021-07-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04955743",
      "title": "Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2026-06-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04967196",
      "title": "Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma",
      "status": "TERMINATED",
      "last_update": "2024-12-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04971499",
      "title": "A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04988841",
      "title": "Assessing the Tolerance and Clinical Benefit of feCAl tranSplantation in patientS With melanOma",
      "status": "COMPLETED",
      "last_update": "2025-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05002569",
      "title": "A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma",
      "status": "TERMINATED",
      "last_update": "2026-01-08",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05004025",
      "title": "Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma",
      "status": "COMPLETED",
      "last_update": "2025-08-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05031494",
      "title": "A Study to Assess YH003 in Combination with Toripalimab(anti-PD-1 MAb) Injection in Patients with Cancers",
      "status": "COMPLETED",
      "last_update": "2025-01-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05034536",
      "title": "PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05060432",
      "title": "Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors",
      "status": "UNKNOWN",
      "last_update": "2024-06-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05061017",
      "title": "Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)",
      "status": "COMPLETED",
      "last_update": "2026-09-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05061537",
      "title": "Study of PF-07263689 in Participants With Selected Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2024-04-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05063058",
      "title": "Biomarker-driven Therapy for Melanoma",
      "status": "COMPLETED",
      "last_update": "2021-09-30",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05069935",
      "title": "FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2023-09-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05070221",
      "title": "Study of Oncolytic Virus in Combination With HX-008 and Axitinib in Melanoma Patients With Liver Metastasis",
      "status": "UNKNOWN",
      "last_update": "2021-10-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05077280",
      "title": "A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma",
      "status": "UNKNOWN",
      "last_update": "2022-12-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05081609",
      "title": "A Study to Investigate Safety and Tolerability of TransCon IL-2 \u03b2/\u03b3 Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05089370",
      "title": "Oral Decitabine/Cedazuridine (DEC-C) in Combination With Nivolumab for Patients With Mucosal Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05094804",
      "title": "A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents",
      "status": "UNKNOWN",
      "last_update": "2023-11-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05155254",
      "title": "IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-08-28",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05176470",
      "title": "Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05200143",
      "title": "Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma",
      "status": "TERMINATED",
      "last_update": "2024-09-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05215574",
      "title": "Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-10-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05229614",
      "title": "Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease",
      "status": "UNKNOWN",
      "last_update": "2024-08-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05259696",
      "title": "Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)",
      "status": "COMPLETED",
      "last_update": "2025-08-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05293496",
      "title": "A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2025-10-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05302921",
      "title": "Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2025-01-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05303493",
      "title": "Camu-Camu Prebiotic and Immune Checkpoint Inhibition in Patients With Non-small Cell Lung Cancer and Melanoma",
      "status": "COMPLETED",
      "last_update": "2025-07-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05304546",
      "title": "Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2025-07-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05308901",
      "title": "Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Na\u00efve Metastatic Uveal Melanoma",
      "status": "TERMINATED",
      "last_update": "2026-08-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05309421",
      "title": "A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05311618",
      "title": "Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors",
      "status": "UNKNOWN",
      "last_update": "2024-04-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05352672",
      "title": "Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05354102",
      "title": "A First-in-human (FIH) Combination Treatment Study With a Single Dose Level of BMC128",
      "status": "UNKNOWN",
      "last_update": "2024-05-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05358938",
      "title": "Exercise to Boost Response to Checkpoint Blockade Immunotherapy",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-06",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05406466",
      "title": "Cryoablation Combined With Tislelizumab Plus Lenvatinib in Patients With Melanoma Liver Metastasis",
      "status": "UNKNOWN",
      "last_update": "2022-11-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05418972",
      "title": "A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05420324",
      "title": "A Study to Assess YH003 in Combination with Pebolizumab and Albumin Paclitaxel Injection in Subjects with Unresectable/metastatic Mucosal Melanoma",
      "status": "COMPLETED",
      "last_update": "2025-01-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05429866",
      "title": "Immunological Variables Associated to ICI Toxicity in Cancer Patients",
      "status": "UNKNOWN",
      "last_update": "2023-03-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05479812",
      "title": "Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2026-08-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05496192",
      "title": "A Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma and Bladder Cancer",
      "status": "WITHDRAWN",
      "last_update": "2023-04-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05498805",
      "title": "PD-1 Inhibitors With or Without Radiation in Advanced Melanoma",
      "status": "UNKNOWN",
      "last_update": "2022-08-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05524935",
      "title": "Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05537740",
      "title": "A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05561491",
      "title": "A Study of ONCOS-102 in Combination With Other Novel Immune-therapies in Advanced Treatment-resistant Melanoma Patients",
      "status": "WITHDRAWN",
      "last_update": "2023-06-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05576077",
      "title": "A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-03-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05577182",
      "title": "Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced Malignancies",
      "status": "COMPLETED",
      "last_update": "2025-11-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05581004",
      "title": "A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05585034",
      "title": "Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb\u00ae808 in Combination With Pembrolizumab in Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2025-08-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05585320",
      "title": "A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05608291",
      "title": "A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-06",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05614102",
      "title": "A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05620134",
      "title": "Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-10-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05625399",
      "title": "A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-26",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05647954",
      "title": "A Study of HX008 Plus Transcatheter Arterial Chemoembolization (TACE) in the First-Line Treatment of Subjects With Stage IV (M1c) Melanoma That is Metastatic to the Liver",
      "status": "UNKNOWN",
      "last_update": "2022-12-13",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05695898",
      "title": "XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) in Treating Melanoma Prior Immune Checkpoint Inhibitor Therapy",
      "status": "TERMINATED",
      "last_update": "2025-03-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05708950",
      "title": "A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)",
      "status": "COMPLETED",
      "last_update": "2026-06-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05709821",
      "title": "IMM60 and Pembrolizumab in Melanoma and NSCLC",
      "status": "TERMINATED",
      "last_update": "2024-04-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05717140",
      "title": "Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung",
      "status": "WITHDRAWN",
      "last_update": "2025-08-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05723432",
      "title": "KD6001 in Combination With Anti-PD-1 Antibody in Patients With Advanced Melanoma",
      "status": "UNKNOWN",
      "last_update": "2023-04-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05732805",
      "title": "A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-02-27",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05798533",
      "title": "Neo-T in Treating Patients With Advanced Solid Tumors(GI-NeoT-03)",
      "status": "UNKNOWN",
      "last_update": "2023-07-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05858736",
      "title": "Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05864144",
      "title": "A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2026-09-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05878288",
      "title": "Deep sequencIng in Cutaneous Squamous CEll caRciNomas",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-11-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05926960",
      "title": "A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma",
      "status": "TERMINATED",
      "last_update": "2026-03-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05961111",
      "title": "A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Advanced Solid Tumors",
      "status": "UNKNOWN",
      "last_update": "2023-07-27",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05987332",
      "title": "IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-17",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06014086",
      "title": "Intratumoral PH-762 for Cutaneous Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06034860",
      "title": "Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types",
      "status": "TERMINATED",
      "last_update": "2024-11-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06052852",
      "title": "Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies",
      "status": "TERMINATED",
      "last_update": "2025-11-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06054555",
      "title": "A Study to Evaluate ABP 206 Compared With OPDIVO\u00ae (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-12",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06101134",
      "title": "A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06112808",
      "title": "A Clinical Study of the Pharmacokinetics and Safety of BCD-263 and Opdivo\u00ae as Monotherapy in Subjects With Advanced Melanoma of the Skin",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-07-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06171178",
      "title": "A Study of ASP1012 in Adults With Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2026-08-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06190951",
      "title": "A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06212388",
      "title": "Allogeneic Gammadelta T Cells Combined With Interferon-\u03b11b or PD-1 Monoclonal Antibody in Stage III-IV Amenable to Surgical Resection Melanoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2024-01-25",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06250335",
      "title": "Impact of a Prebiotic Food-enriched Diet (PreFED) in Combination With Ipilimumab/Nivolumab Combination Immune Checkpoint Blockade (ICB) in ICB-refractory Melanoma Patients",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06285097",
      "title": "A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-09-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06320353",
      "title": "Study \u0441omparing the Efficacy and Safety of RPH-075 and Keytruda\u00ae in Patients With Unresectable or Metastatic Skin Melanoma",
      "status": "COMPLETED",
      "last_update": "2026-07-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06377111",
      "title": "A Study to Test the Benefit of Vitamin B5 in Patients With Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06448364",
      "title": "A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination",
      "status": "TERMINATED",
      "last_update": "2024-11-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06540391",
      "title": "A Phase 1b Trial to Evaluate Safety of MB097 in Combination With Pembrolizumab in Melanoma Patients",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06546553",
      "title": "A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.",
      "status": "TERMINATED",
      "last_update": "2026-02-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06640530",
      "title": "Clinical Study of the Efficacy and Safety of BCD-263 and Opdivo\u00ae as Monotherapy in Subjects With Advanced Melanoma of the Skin",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-07-08",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06784648",
      "title": "Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-11-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06848088",
      "title": "A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment",
      "status": "ENROLLING_BY_INVITATION",
      "last_update": "2026-07-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06894771",
      "title": "A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001)",
      "status": "COMPLETED",
      "last_update": "2026-03-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07004335",
      "title": "Efficacy and Safety of Iparomlimab and Tuvonralimab Injection in Combination With Bevacizumab After Progression on Anti-PD-(L)1 Therapy in Advanced Melanoma: A Prospective, Single-Arm, Exploratory Clinical Study",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-06-04",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07040436",
      "title": "Assessment of Safety and Efficacy of OPM-101 Combined With Anti-PD-1 in Patients With Advanced Melanoma Showing Resistance to Anti-PD-1",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-06-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07376317",
      "title": "Optimization of Immunotherapy Treatment for Advanced Melanoma in the Context of the Public Brazilian Health System (OTIMAS)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07436390",
      "title": "IFN-Gamma Expression as a Predictor of Response to Immune Checkpoint Inhibitors in First-Line Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2026-03-02",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07459543",
      "title": "A Study to Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Unresectable or Metastatic Melanoma Participants In India",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-12",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07476326",
      "title": "Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo\u00ae as Adjuvant Monotherapy in Participants With Melanoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07511036",
      "title": "PROSECCO: A Phase 2, Single Arm, Neoadjuvant Study Evaluating Combination Cemiplimab, Fianlimab, And Ipilimumab In Patients With Surgically Resectable Melanoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-04-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07527325",
      "title": "Fianlimab&Cemiplimab as TotalNeoadj The (TNT) ForMelanoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07574047",
      "title": "MELCHRONO: A Prospective Randomized Study Investigating Chrono-immunotherapy for Advanced Melanoma.",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07576725",
      "title": "Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-05-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07581509",
      "title": "Pharmacokinetics, Safety, and Immunogenicity of Bmab1800 and Keytruda\u00ae as Adjuvant Monotherapy in Patients With Melanoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-05-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07808515",
      "title": "A Study Comparing Cemiplimab-based Treatments for Adult Participants With Locally Advanced Basal Cell Skin Cancer (laBCC)",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 16,
     "n_observational": 0,
     "n_active": 5,
     "n_withdrawn": 1,
     "trials": [
      {
       "nct": "NCT06398418",
       "title": "R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors",
       "status": "RECRUITING",
       "last_update": "2026-09-04",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07410676",
       "title": "EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 \u00b1 Pembrolizumab in Advanced Solid Tumors",
       "status": "RECRUITING",
       "last_update": "2026-02-18",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02500576",
       "title": "Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma",
       "status": "COMPLETED",
       "last_update": "2025-01-15",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02652455",
       "title": "Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma",
       "status": "COMPLETED",
       "last_update": "2025-08-19",
       "phase": "EARLY_PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02983045",
       "title": "A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors",
       "status": "COMPLETED",
       "last_update": "2023-03-13",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03158935",
       "title": "The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) Trial",
       "status": "COMPLETED",
       "last_update": "2020-08-14",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03166397",
       "title": "Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients",
       "status": "UNKNOWN",
       "last_update": "2023-01-26",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03435640",
       "title": "REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies",
       "status": "TERMINATED",
       "last_update": "2023-03-08",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03645928",
       "title": "Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors",
       "status": "TERMINATED",
       "last_update": "2026-05-15",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03970382",
       "title": "A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors",
       "status": "SUSPENDED",
       "last_update": "2022-08-18",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04137900",
       "title": "Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies",
       "status": "UNKNOWN",
       "last_update": "2024-02-05",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04483778",
       "title": "B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2026-04-28",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04625205",
       "title": "A Clinical Study of the Safety and Activity of the Investigational Cell Therapy NEO-PTC-01 in Patients With Advanced Melanoma",
       "status": "TERMINATED",
       "last_update": "2025-04-06",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04955262",
       "title": "A CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Using \u2078\u2079Zr Df-IAB22M2C in Patients With Metastatic Melanoma Receiving Bempegaldesleukin (NKTR-214) and Nivolumab",
       "status": "WITHDRAWN",
       "last_update": "2021-07-08",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05176470",
       "title": "Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2026-02-24",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06212388",
       "title": "Allogeneic Gammadelta T Cells Combined With Interferon-\u03b11b or PD-1 Monoclonal Antibody in Stage III-IV Amenable to Surgical Resection Melanoma",
       "status": "NOT_YET_RECRUITING",
       "last_update": "2024-01-25",
       "phase": "EARLY_PHASE1",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "PD-1",
     "pembrolizumab",
     "nivolumab",
     "cemiplimab"
    ]
   },
   "CTLA-4": {
    "n": 272,
    "n_observational": 35,
    "n_active": 72,
    "n_withdrawn": 10,
    "trials": [
     {
      "nct": "NCT03340129",
      "title": "Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)",
      "status": "RECRUITING",
      "last_update": "2026-02-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03563729",
      "title": "Melanoma Metastasized to the Brain and Steroids",
      "status": "RECRUITING",
      "last_update": "2023-07-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04511013",
      "title": "A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases",
      "status": "RECRUITING",
      "last_update": "2025-09-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04605146",
      "title": "Impact of Telemonitoring for the Management of Side Effects in Patients with Melanoma, Lung or Renal Cancer, Treated with Immunotherapy Combination of Nivolumab and Ipilimumab or Adjuvant Nivolumab Monotherapy",
      "status": "RECRUITING",
      "last_update": "2024-10-16",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04697576",
      "title": "Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-07-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05384496",
      "title": "Axitinib and Nivolumab for the Treatment of Mucosal Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-02-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05428007",
      "title": "Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-01-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05498792",
      "title": "Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-05-22",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05649683",
      "title": "Immunological Functionnal Test Validation to Predict Melanoma Metastatic Patient Response to Checkpoint Inhibitors",
      "status": "RECRUITING",
      "last_update": "2024-06-04",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05824975",
      "title": "A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)",
      "status": "RECRUITING",
      "last_update": "2024-11-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05896839",
      "title": "Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer",
      "status": "RECRUITING",
      "last_update": "2026-08-31",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05968690",
      "title": "Naltrexone and Propranolol Combined With Immunotherapy",
      "status": "RECRUITING",
      "last_update": "2025-09-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06047379",
      "title": "Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis",
      "status": "RECRUITING",
      "last_update": "2026-07-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06163820",
      "title": "Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain Metastases",
      "status": "RECRUITING",
      "last_update": "2025-05-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06240143",
      "title": "Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma",
      "status": "RECRUITING",
      "last_update": "2024-11-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06264180",
      "title": "VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]",
      "status": "RECRUITING",
      "last_update": "2026-07-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06295159",
      "title": "Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-04-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06581406",
      "title": "A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Na\u00efve Adult Patients With Metastatic Uveal Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-04-02",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06594991",
      "title": "A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-05-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06624644",
      "title": "A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-04-22",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06683755",
      "title": "Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)",
      "status": "RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06743126",
      "title": "SUPRAME-ACTengine\u00ae IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-08-18",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06794775",
      "title": "SWE-NEO: Swedish NeoAdjuvant Trial Comparing Monotherapy to Combined Immunotherapy in Resectable Stage III Melanoma",
      "status": "RECRUITING",
      "last_update": "2025-12-12",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06880198",
      "title": "Study to Evaluate Impact\u00ae as Support to Anti PD1 or Anti PD1 Based Regimen Treatment in Patients With Inoperable Locally Advanced or Metastatic Melanoma",
      "status": "RECRUITING",
      "last_update": "2025-09-17",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07155317",
      "title": "Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial",
      "status": "RECRUITING",
      "last_update": "2025-11-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07230613",
      "title": "Neo-adjuvant Immunotherapy in Patients With Localized Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-07-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07237594",
      "title": "IL-17 Blockade to Decrease irAEs (REPLAY)",
      "status": "RECRUITING",
      "last_update": "2026-06-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07407166",
      "title": "Efficacy of First-Line Immunotherapy in Metastatic Melanoma in Slovenia and Identification of Predictive Biomarkers",
      "status": "RECRUITING",
      "last_update": "2026-02-17",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07422779",
      "title": "Immunotherapy Efficacy and PD-L1 as a Predictive Biomarker in Metastatic Melanoma in Slovenia",
      "status": "RECRUITING",
      "last_update": "2026-02-20",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07504796",
      "title": "ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab",
      "status": "RECRUITING",
      "last_update": "2026-08-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07564570",
      "title": "Physical Activity Directly Before Immunotherapy (Nivolumab and Ipilimumab) in Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-05-04",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00025181",
      "title": "Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery",
      "status": "COMPLETED",
      "last_update": "2014-05-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00028431",
      "title": "Novel Adjuvants for Peptide-Based Melanoma Vaccines",
      "status": "COMPLETED",
      "last_update": "2014-05-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00032045",
      "title": "Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma",
      "status": "COMPLETED",
      "last_update": "2013-06-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00039091",
      "title": "Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer",
      "status": "TERMINATED",
      "last_update": "2018-09-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00050102",
      "title": "Comparison Study of MDX-010 (CTLA-4) Alone and Combined With DTIC in the Treatment of Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2011-01-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00058279",
      "title": "Monoclonal Antibody Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2013-06-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00084656",
      "title": "Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma",
      "status": "COMPLETED",
      "last_update": "2022-04-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00090896",
      "title": "CP-675,206 (CTLA4-Blocking Monoclonal Antibody) Combined With Dendritic Cell Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery",
      "status": "COMPLETED",
      "last_update": "2020-08-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00094653",
      "title": "MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2011-07-11",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00135408",
      "title": "A Study of MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral Budesonide",
      "status": "COMPLETED",
      "last_update": "2016-09-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00162123",
      "title": "A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies",
      "status": "COMPLETED",
      "last_update": "2016-07-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00257205",
      "title": "CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy",
      "status": "COMPLETED",
      "last_update": "2012-07-02",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00261365",
      "title": "Phase II Study to Determine Predictive Markers of Response to BMS-734016 (MDX-010)",
      "status": "COMPLETED",
      "last_update": "2016-09-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00289640",
      "title": "Study of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma",
      "status": "COMPLETED",
      "last_update": "2010-03-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00324155",
      "title": "Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma",
      "status": "COMPLETED",
      "last_update": "2014-11-03",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00378482",
      "title": "A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.",
      "status": "COMPLETED",
      "last_update": "2024-08-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00431275",
      "title": "Study to Compare Two Formulations of CP-675,206 Monoclonal Antibody",
      "status": "COMPLETED",
      "last_update": "2012-06-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00610857",
      "title": "Safety and Efficacy of Combination HDI and Anti-CTLA4 for Recurrent Inoperable Stage III or Stage IV Melanoma",
      "status": "COMPLETED",
      "last_update": "2017-06-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00623766",
      "title": "Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases",
      "status": "COMPLETED",
      "last_update": "2014-06-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00636168",
      "title": "Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma",
      "status": "COMPLETED",
      "last_update": "2019-12-17",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00685750",
      "title": "Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma",
      "status": "TERMINATED",
      "last_update": "2019-06-20",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00729950",
      "title": "Study of MDX-010 in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma",
      "status": "COMPLETED",
      "last_update": "2010-04-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00790010",
      "title": "Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma",
      "status": "COMPLETED",
      "last_update": "2023-05-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00803374",
      "title": "Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma",
      "status": "WITHDRAWN",
      "last_update": "2011-11-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00871481",
      "title": "Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2017-04-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00972933",
      "title": "Immunogenicity and Biomarker Analysis of Neoadjuvant Ipilimumab for Melanoma",
      "status": "COMPLETED",
      "last_update": "2017-12-07",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01024231",
      "title": "Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma",
      "status": "COMPLETED",
      "last_update": "2026-08-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01103635",
      "title": "Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2020-04-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01119508",
      "title": "Ipilimumab + Temozolomide in Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2024-06-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01134614",
      "title": "Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01176474",
      "title": "Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma",
      "status": "COMPLETED",
      "last_update": "2023-07-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01216436",
      "title": "Local Modulation of Immune Receptors to Enhance the Response to Dendritic Cell Vaccination in Metastatic Melanoma",
      "status": "TERMINATED",
      "last_update": "2015-05-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01216696",
      "title": "Ipilimumab in Patients With Advanced Melanoma and Spontaneous Preexisting Immune Response to NY-ESO-1",
      "status": "COMPLETED",
      "last_update": "2016-08-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01245556",
      "title": "Safety and Efficacy Study of BMS-908662 in Combination With Ipilimumab in Subjects With Advanced Melanoma",
      "status": "COMPLETED",
      "last_update": "2013-06-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01274338",
      "title": "Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-08",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01302496",
      "title": "Autologous TriMix-DC Therapeutic Vaccine in Combination With Ipilimumab in Patients With Previously Treated Unresectable Stage III or IV Melanoma",
      "status": "COMPLETED",
      "last_update": "2021-03-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01323517",
      "title": "Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity",
      "status": "COMPLETED",
      "last_update": "2018-05-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01363206",
      "title": "Granulocyte Macrophage-Colony Stimulating Factor and Ipilimumab as Therapy in Melanoma",
      "status": "COMPLETED",
      "last_update": "2020-03-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01449279",
      "title": "Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation Therapy",
      "status": "COMPLETED",
      "last_update": "2020-03-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01480323",
      "title": "A Phase II Study to Evaluate Safety and Efficacy of Combined Treatment With Ipilimumab and Intratumoral Interleukin-2",
      "status": "COMPLETED",
      "last_update": "2015-07-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01496807",
      "title": "Yervoy With Sylatron Unresectable Stage 3 or 4 Melanoma",
      "status": "COMPLETED",
      "last_update": "2017-04-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01515189",
      "title": "Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab",
      "status": "COMPLETED",
      "last_update": "2019-07-31",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01557114",
      "title": "Study of Radiotherapy Administered in Combination With Ipilimumab in Patients With Unresectable Stage III or Stage IV Advanced Malignant Melanoma",
      "status": "TERMINATED",
      "last_update": "2016-06-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01565837",
      "title": "Concurrent Ipilimumab and Stereotactic Ablative Radiation Therapy (SART) for Oligometastatic But Unresectable Melanoma",
      "status": "UNKNOWN",
      "last_update": "2016-02-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01585194",
      "title": "Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma",
      "status": "COMPLETED",
      "last_update": "2024-07-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01590082",
      "title": "Doxycycline, Temozolomide and Ipilimumab in Melanoma",
      "status": "TERMINATED",
      "last_update": "2020-09-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01604889",
      "title": "A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma",
      "status": "TERMINATED",
      "last_update": "2026-04-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01608594",
      "title": "Neoadjuvant Combination Therapy With Ipilimumab and HighDose IFN-\u03b12b for Melanoma",
      "status": "COMPLETED",
      "last_update": "2018-08-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01673854",
      "title": "Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma",
      "status": "COMPLETED",
      "last_update": "2018-07-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01676649",
      "title": "Ipilimumab With Carboplatin and Paclitaxel in Patients With Unresectable Stage III and Stage IV Melanoma",
      "status": "UNKNOWN",
      "last_update": "2021-02-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01681212",
      "title": "Phase 2 Study of Ipilimumab Plus Dacarbazine in Japanese Patients With Advanced Melanoma",
      "status": "COMPLETED",
      "last_update": "2015-06-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01696045",
      "title": "Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma",
      "status": "TERMINATED",
      "last_update": "2017-08-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01701674",
      "title": "Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts",
      "status": "COMPLETED",
      "last_update": "2025-12-19",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01703507",
      "title": "Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma",
      "status": "COMPLETED",
      "last_update": "2025-05-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01708941",
      "title": "Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery",
      "status": "COMPLETED",
      "last_update": "2026-07-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01709162",
      "title": "Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma",
      "status": "TERMINATED",
      "last_update": "2015-11-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01715077",
      "title": "Study of Ipilimumab in the Immune System",
      "status": "COMPLETED",
      "last_update": "2018-08-13",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01721746",
      "title": "A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)",
      "status": "COMPLETED",
      "last_update": "2022-04-19",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01730157",
      "title": "Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases",
      "status": "TERMINATED",
      "last_update": "2016-03-10",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01738139",
      "title": "Ipilimumab and Imatinib Mesylate in Advanced Cancer",
      "status": "COMPLETED",
      "last_update": "2024-03-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01740297",
      "title": "Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma",
      "status": "COMPLETED",
      "last_update": "2024-05-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01740401",
      "title": "CTLA-4 Blockade and Low Dose Cyclophosphamide in Patients With Advanced Malignant Melanoma",
      "status": "TERMINATED",
      "last_update": "2017-12-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01767454",
      "title": "Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma",
      "status": "COMPLETED",
      "last_update": "2017-11-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01769222",
      "title": "Ipilimumab and Local Radiation for Selected Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2024-01-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01789827",
      "title": "Aldesleukin Imaging in Viewing Tumor Growth in Patients With Stage IV Melanoma Receiving Ipilimumab or Pembrolizumab Therapy",
      "status": "COMPLETED",
      "last_update": "2019-08-05",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01810016",
      "title": "NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma",
      "status": "TERMINATED",
      "last_update": "2022-10-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01827111",
      "title": "Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2022-02-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01856023",
      "title": "HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma",
      "status": "TERMINATED",
      "last_update": "2023-12-05",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01927419",
      "title": "Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2022-03-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01940809",
      "title": "Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery",
      "status": "TERMINATED",
      "last_update": "2022-03-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01950390",
      "title": "Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery",
      "status": "COMPLETED",
      "last_update": "2025-12-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01970527",
      "title": "Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma",
      "status": "TERMINATED",
      "last_update": "2020-02-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01973608",
      "title": "MSB0010445 and Stereotactic Body Radiation Therapy in Advanced Melanoma",
      "status": "TERMINATED",
      "last_update": "2016-10-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01984255",
      "title": "A Two-arm, Single Center Phase 1b Trial of Bavituximab Plus Ipilimumab in Advanced Melanoma Patients",
      "status": "TERMINATED",
      "last_update": "2016-12-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01988077",
      "title": "Clinical Evaluation of Yervoy in Combination With Adoptive T Cell Transfer for Metastatic Melanoma Patients",
      "status": "TERMINATED",
      "last_update": "2019-04-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01990859",
      "title": "Phase 2 Study of Ipilimumab in Japanese Advanced Melanoma Patients",
      "status": "COMPLETED",
      "last_update": "2016-03-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02009384",
      "title": "Ipilimumab Administered to Stage IIIC Stage IV Melanoma After Reg. T Cell Depletion With Denileukin Diftitox",
      "status": "TERMINATED",
      "last_update": "2021-10-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02027935",
      "title": "CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2024-10-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02032810",
      "title": "Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma",
      "status": "COMPLETED",
      "last_update": "2023-01-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02054520",
      "title": "Immunotherapy Study for Patients With Stage IV Melanoma",
      "status": "TERMINATED",
      "last_update": "2023-04-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02068196",
      "title": "A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma.",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2023-03-24",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02073123",
      "title": "Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2026-05-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02077114",
      "title": "Vaccination With Peptides in Combination With Either Ipilimumab or Vemurafenib for the Treatment of Unresectable Stage III or IV Malignant Melanoma",
      "status": "COMPLETED",
      "last_update": "2014-09-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02089685",
      "title": "Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29)",
      "status": "COMPLETED",
      "last_update": "2022-09-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02107755",
      "title": "Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2024-05-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02115139",
      "title": "GEM STUDY: Radiation And Yervoy in Patients With Melanoma and Brain Metastases",
      "status": "COMPLETED",
      "last_update": "2022-11-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02115243",
      "title": "Trial of Neoadjuvant Ipilimumab Followed by Melphalan Via Isolated Limb Infusion for Patients With Unresectable In-transit Extremity Melanoma",
      "status": "COMPLETED",
      "last_update": "2018-10-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02117362",
      "title": "Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2019-03-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02156804",
      "title": "A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172)",
      "status": "COMPLETED",
      "last_update": "2020-09-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02158520",
      "title": "Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery",
      "status": "COMPLETED",
      "last_update": "2020-01-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02200562",
      "title": "Ipilimumab and Dabrafenib in the 1st Line Tx of Unresectable Stage III/IV Melanoma",
      "status": "TERMINATED",
      "last_update": "2017-03-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02203604",
      "title": "High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery",
      "status": "TERMINATED",
      "last_update": "2023-07-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02210104",
      "title": "Adoptive Therapy Using Antigen-Specific CD4 T-Cells",
      "status": "WITHDRAWN",
      "last_update": "2017-07-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02224781",
      "title": "Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02259231",
      "title": "RTA 408 Capsules in Patients With Melanoma - REVEAL",
      "status": "COMPLETED",
      "last_update": "2025-06-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02304458",
      "title": "Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas",
      "status": "COMPLETED",
      "last_update": "2023-10-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02307149",
      "title": "Intratumoral CAVATAK (CVA21) and Ipilimumab in Patients With Advanced Melanoma (VLA-013 MITCI)",
      "status": "COMPLETED",
      "last_update": "2023-01-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02320058",
      "title": "An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by Itself",
      "status": "COMPLETED",
      "last_update": "2021-10-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02339571",
      "title": "A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02374242",
      "title": "Anti-PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-12-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02381314",
      "title": "Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer",
      "status": "COMPLETED",
      "last_update": "2022-02-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02385669",
      "title": "A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma",
      "status": "TERMINATED",
      "last_update": "2020-05-05",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02388906",
      "title": "Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma",
      "status": "COMPLETED",
      "last_update": "2025-04-24",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02403778",
      "title": "Ipilimumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma",
      "status": "COMPLETED",
      "last_update": "2023-09-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02406183",
      "title": "Trial of SBRT With Concurrent Ipilimumab in Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2017-01-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02419495",
      "title": "Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies",
      "status": "TERMINATED",
      "last_update": "2025-06-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02460068",
      "title": "A Study of Fotemustine(FTM) Vs FTM and Ipilimumab (IPI) or IPI and Nivolumab in Melanoma Brain Metastasis",
      "status": "UNKNOWN",
      "last_update": "2015-06-02",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02506153",
      "title": "Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02516527",
      "title": "A Phase 1 Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Ipilimumab in Chinese Subjects With Select Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2020-05-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02519322",
      "title": "Neoadjuvant and Adjuvant Checkpoint Blockade",
      "status": "COMPLETED",
      "last_update": "2024-04-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02523313",
      "title": "Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab vs. Double Placebo for Stage IV Melanoma w. NED",
      "status": "COMPLETED",
      "last_update": "2025-04-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02535078",
      "title": "Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma",
      "status": "WITHDRAWN",
      "last_update": "2024-07-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02545075",
      "title": "A Comparative Study in Chinese Subjects With Chemotherapy Na\u00efve Stage IV Melanoma Receiving Ipilimumab (3 mg/kg) vs. Dacarbazine",
      "status": "COMPLETED",
      "last_update": "2020-05-19",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02608437",
      "title": "A Study Investigating SGI-110 in Combination With Ipilimumab in Unresectable or Metastatic Melanoma Patients",
      "status": "UNKNOWN",
      "last_update": "2015-11-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02621515",
      "title": "Nivo/Ipi Combination Therapy in Symptomatic Brain Metastases",
      "status": "TERMINATED",
      "last_update": "2024-05-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02626962",
      "title": "Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melanoma",
      "status": "COMPLETED",
      "last_update": "2022-03-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02631447",
      "title": "Sequential Combo Immuno and Target Therapy (SECOMBIT) Study",
      "status": "COMPLETED",
      "last_update": "2024-06-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02643303",
      "title": "A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers",
      "status": "COMPLETED",
      "last_update": "2022-12-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02644967",
      "title": "A Phase 2 Study to Assess the Safety and Efficacy of IMO-2125 With 8 mg Ipilimumab in Patients With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2022-08-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02658890",
      "title": "An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread",
      "status": "COMPLETED",
      "last_update": "2023-08-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02659540",
      "title": "Pilot Study of the Safety/Efficacy of Combination Checkpoint Blockade + External Beam Radiotherapy in Stage IV Melanoma",
      "status": "COMPLETED",
      "last_update": "2022-10-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02700971",
      "title": "RATIO: Rational Approach To Immuno-Oncology",
      "status": "COMPLETED",
      "last_update": "2024-06-14",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02763761",
      "title": "An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo",
      "status": "WITHDRAWN",
      "last_update": "2018-10-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02771626",
      "title": "Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)",
      "status": "TERMINATED",
      "last_update": "2023-03-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02857569",
      "title": "A Trial Evaluating the Safety & Efficacy of Intra-Tumoral Ipilimumab in Combination With Intra-venous Nivolumab in Patients With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2023-02-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02905266",
      "title": "A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Melanoma",
      "status": "COMPLETED",
      "last_update": "2020-12-17",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02913417",
      "title": "Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases",
      "status": "UNKNOWN",
      "last_update": "2021-04-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02941744",
      "title": "A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma Macrometastases",
      "status": "COMPLETED",
      "last_update": "2019-01-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02970981",
      "title": "Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma",
      "status": "COMPLETED",
      "last_update": "2024-04-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02977052",
      "title": "Optimal Neo-adjuvant Combination Scheme of Ipilimumab and Nivolumab",
      "status": "UNKNOWN",
      "last_update": "2023-11-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02978443",
      "title": "A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab",
      "status": "TERMINATED",
      "last_update": "2024-04-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02983045",
      "title": "A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2023-03-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03009058",
      "title": "Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer",
      "status": "TERMINATED",
      "last_update": "2024-11-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03033576",
      "title": "Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma",
      "status": "COMPLETED",
      "last_update": "2025-01-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03068455",
      "title": "An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma",
      "status": "COMPLETED",
      "last_update": "2021-09-20",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03068624",
      "title": "Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma",
      "status": "UNKNOWN",
      "last_update": "2024-01-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03122522",
      "title": "A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03153085",
      "title": "A Study of Combination with TBI-1401(HF10) and Ipilimumab in Japanese Patients with Unresectable or Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2024-12-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03161756",
      "title": "Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma",
      "status": "UNKNOWN",
      "last_update": "2022-04-07",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03166397",
      "title": "Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients",
      "status": "UNKNOWN",
      "last_update": "2023-01-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03220009",
      "title": "Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma",
      "status": "WITHDRAWN",
      "last_update": "2018-10-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03225365",
      "title": "Nivolumab +/- Ipilimumab Immunomonitoring in Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2026-07-20",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03241173",
      "title": "A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies",
      "status": "COMPLETED",
      "last_update": "2022-09-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03293784",
      "title": "TNF-Inhibitor as Immune Checkpoint Inhibitor for Advanced MELanoma",
      "status": "COMPLETED",
      "last_update": "2026-03-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03297463",
      "title": "Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma",
      "status": "WITHDRAWN",
      "last_update": "2018-08-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03326258",
      "title": "Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery",
      "status": "WITHDRAWN",
      "last_update": "2018-07-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03347123",
      "title": "A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)",
      "status": "TERMINATED",
      "last_update": "2022-02-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03348891",
      "title": "TNF in Melanoma Patients Treated With Immunotherapy",
      "status": "COMPLETED",
      "last_update": "2026-04-14",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03354962",
      "title": "Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors (BOOSTER MELANOMA)",
      "status": "TERMINATED",
      "last_update": "2020-12-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03396952",
      "title": "Prostaglandin Inhibition and Immune Checkpoint Blockade in Melanoma",
      "status": "COMPLETED",
      "last_update": "2022-10-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03400332",
      "title": "A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers",
      "status": "COMPLETED",
      "last_update": "2026-02-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03408587",
      "title": "CAVATAK\u00ae and Ipilimumab in Uveal Melanoma Metastatic to the Liver (VLA-024 CLEVER)",
      "status": "COMPLETED",
      "last_update": "2023-05-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03425461",
      "title": "Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma",
      "status": "TERMINATED",
      "last_update": "2021-04-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03445533",
      "title": "A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma",
      "status": "TERMINATED",
      "last_update": "2022-11-08",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03472027",
      "title": "Phase I Study of BCD-145 (Anti-CTLA-4) in Patients With Unresectable/Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2019-05-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03472586",
      "title": "Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver",
      "status": "COMPLETED",
      "last_update": "2026-07-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03597282",
      "title": "A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma",
      "status": "TERMINATED",
      "last_update": "2020-09-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03618641",
      "title": "CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease",
      "status": "COMPLETED",
      "last_update": "2025-05-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03645928",
      "title": "Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2026-05-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03646617",
      "title": "Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03673332",
      "title": "Elderly Cancer PatIents, Safety and qualiTy of Life Under immunOtheraPies",
      "status": "TERMINATED",
      "last_update": "2026-01-22",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03674502",
      "title": "Safety of ADU-1604 in Adults With Metastatic Melanoma",
      "status": "TERMINATED",
      "last_update": "2020-05-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03693612",
      "title": "GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2024-08-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03719131",
      "title": "Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-04-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03724968",
      "title": "Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression",
      "status": "TERMINATED",
      "last_update": "2021-04-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03728465",
      "title": "Evaluation of Safety and Efficacy of Patients With Four and More Symptomatic Brain Metastases of Melanoma",
      "status": "TERMINATED",
      "last_update": "2021-02-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03761017",
      "title": "MGD019 DART\u00ae Protein in Unresectable/Metastatic Cancer",
      "status": "COMPLETED",
      "last_update": "2025-03-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03769155",
      "title": "VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03816332",
      "title": "Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-31",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03849469",
      "title": "A Study of XmAb\u00ae22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2023-03-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03873818",
      "title": "Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain",
      "status": "COMPLETED",
      "last_update": "2026-01-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03903640",
      "title": "Optune Device - TT Field Plus Nivolumab and Ipilimumab for Melanoma With Brain Metastasis",
      "status": "TERMINATED",
      "last_update": "2022-06-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03913923",
      "title": "Study of Efficacy and Safety of BCD-217 (Anti-CTLA-4 and Anti-PD-1) Followed By BCD-100 (Anti-PD-1) Versus BCD-100 Monotherapy as First-Line Treatment in Patients With Unresectable or Metastatic Melanoma",
      "status": "UNKNOWN",
      "last_update": "2023-02-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03922880",
      "title": "Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma",
      "status": "COMPLETED",
      "last_update": "2025-05-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03949153",
      "title": "Cryotherapy With in Situ Immunotherapy in Melanoma Metastasis",
      "status": "COMPLETED",
      "last_update": "2026-06-05",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03958383",
      "title": "IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma",
      "status": "TERMINATED",
      "last_update": "2026-06-03",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03978611",
      "title": "A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment",
      "status": "TERMINATED",
      "last_update": "2024-07-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03993379",
      "title": "PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-12-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04007588",
      "title": "A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma",
      "status": "WITHDRAWN",
      "last_update": "2020-02-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04021420",
      "title": "Safety and Efficacy of Sonocloud Device Combined With Nivolumab in Brain Metastases From Patients With Melanoma",
      "status": "UNKNOWN",
      "last_update": "2020-08-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04060407",
      "title": "CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI)",
      "status": "WITHDRAWN",
      "last_update": "2021-06-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04074967",
      "title": "Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-11-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04079166",
      "title": "SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-12-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04091750",
      "title": "Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04121676",
      "title": "Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer",
      "status": "COMPLETED",
      "last_update": "2025-01-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04140526",
      "title": "Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-05-23",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04157985",
      "title": "Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2025-12-11",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04172454",
      "title": "Safety and Efficacy of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Selected Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2022-10-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04225390",
      "title": "Preconditioning of Tumor, Tumor Microenvironment and the Immune System to Immunotherapy",
      "status": "COMPLETED",
      "last_update": "2026-02-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04250246",
      "title": "A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1",
      "status": "UNKNOWN",
      "last_update": "2020-01-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04253080",
      "title": "Expression of IL4 Induced Gene 1 in Patients With Cutaneous Melanoma: Value in Prognosis and/or in Predictive Response to Immune Checkpoint Inhibitors",
      "status": "COMPLETED",
      "last_update": "2026-05-20",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04274816",
      "title": "Intradermal Injection of Anti-CTLA-4 in Patients With Stage I/II Melanoma",
      "status": "COMPLETED",
      "last_update": "2020-02-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04283890",
      "title": "PHP and Immunotherapy in Metastasized UM",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04305054",
      "title": "Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)",
      "status": "COMPLETED",
      "last_update": "2026-05-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04382664",
      "title": "UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma",
      "status": "COMPLETED",
      "last_update": "2025-01-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04462406",
      "title": "Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04464759",
      "title": "A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04495010",
      "title": "Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants",
      "status": "WITHDRAWN",
      "last_update": "2021-03-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04562129",
      "title": "IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04606472",
      "title": "A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04625205",
      "title": "A Clinical Study of the Safety and Activity of the Investigational Cell Therapy NEO-PTC-01 in Patients With Advanced Melanoma",
      "status": "TERMINATED",
      "last_update": "2025-04-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04631731",
      "title": "Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity",
      "status": "UNKNOWN",
      "last_update": "2023-06-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04655157",
      "title": "Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimuma",
      "status": "TERMINATED",
      "last_update": "2024-05-23",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04866810",
      "title": "The Effect of Diet and Exercise on ImmuNotherapy and the Microbiome (EDEN)",
      "status": "SUSPENDED",
      "last_update": "2026-09-11",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04899921",
      "title": "Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets",
      "status": "TERMINATED",
      "last_update": "2024-03-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04940299",
      "title": "Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04949113",
      "title": "Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-03-08",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04951583",
      "title": "Fecal Microbial Transplantation Non-Small Cell Lung Cancer and Melanoma",
      "status": "UNKNOWN",
      "last_update": "2024-08-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04967196",
      "title": "Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma",
      "status": "TERMINATED",
      "last_update": "2024-12-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04988841",
      "title": "Assessing the Tolerance and Clinical Benefit of feCAl tranSplantation in patientS With melanOma",
      "status": "COMPLETED",
      "last_update": "2025-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05004025",
      "title": "Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma",
      "status": "COMPLETED",
      "last_update": "2025-08-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05031494",
      "title": "A Study to Assess YH003 in Combination with Toripalimab(anti-PD-1 MAb) Injection in Patients with Cancers",
      "status": "COMPLETED",
      "last_update": "2025-01-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05180799",
      "title": "A Phase 1/2 Study of BA3071 in Patients With Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-06-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05200143",
      "title": "Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma",
      "status": "TERMINATED",
      "last_update": "2024-09-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05293496",
      "title": "A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2025-10-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05302921",
      "title": "Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2025-01-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05303493",
      "title": "Camu-Camu Prebiotic and Immune Checkpoint Inhibition in Patients With Non-small Cell Lung Cancer and Melanoma",
      "status": "COMPLETED",
      "last_update": "2025-07-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05341349",
      "title": "Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases",
      "status": "TERMINATED",
      "last_update": "2026-04-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05529316",
      "title": "A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05578872",
      "title": "A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1).",
      "status": "COMPLETED",
      "last_update": "2025-08-26",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05598853",
      "title": "Intrathecal Double Checkpoint Inhibition",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-10-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05620134",
      "title": "Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-10-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05695898",
      "title": "XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) in Treating Melanoma Prior Immune Checkpoint Inhibitor Therapy",
      "status": "TERMINATED",
      "last_update": "2025-03-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05704933",
      "title": "Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases",
      "status": "COMPLETED",
      "last_update": "2026-04-06",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05732805",
      "title": "A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-02-27",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05751928",
      "title": "A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-07-08",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05858736",
      "title": "Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05909995",
      "title": "Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-02-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05926960",
      "title": "A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma",
      "status": "TERMINATED",
      "last_update": "2026-03-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05987332",
      "title": "IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-17",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06250335",
      "title": "Impact of a Prebiotic Food-enriched Diet (PreFED) in Combination With Ipilimumab/Nivolumab Combination Immune Checkpoint Blockade (ICB) in ICB-refractory Melanoma Patients",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06377111",
      "title": "A Study to Test the Benefit of Vitamin B5 in Patients With Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06784648",
      "title": "Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-11-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07004335",
      "title": "Efficacy and Safety of Iparomlimab and Tuvonralimab Injection in Combination With Bevacizumab After Progression on Anti-PD-(L)1 Therapy in Advanced Melanoma: A Prospective, Single-Arm, Exploratory Clinical Study",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-06-04",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07428252",
      "title": "Gastrointestinal Microbiome and Response to Immunotherapy in Metastatic Malignant Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-25",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07436390",
      "title": "IFN-Gamma Expression as a Predictor of Response to Immune Checkpoint Inhibitors in First-Line Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2026-03-02",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07476326",
      "title": "Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo\u00ae as Adjuvant Monotherapy in Participants With Melanoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07574047",
      "title": "MELCHRONO: A Prospective Randomized Study Investigating Chrono-immunotherapy for Advanced Melanoma.",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07615881",
      "title": "Comparing Intravenous or Intradermal Administration of Anti-CTLA-4 in Combination With Anti-PD1 Treatment in Patients With Melanoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-05-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07661966",
      "title": "Bright Light Therapy in Patients With Melanoma or Non-small Cell Lung Cancer (NSCLC) Who Are Receiving First-Line Immune Checkpoint Blockade",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-06-26",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07815574",
      "title": "iSCIB1+ in Combination With Ipilimumab and Nivolumab as First-Line Treatment for Advanced Unresectable Melanoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 10,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 1,
     "trials": [
      {
       "nct": "NCT00871481",
       "title": "Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma",
       "status": "COMPLETED",
       "last_update": "2017-04-19",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT01701674",
       "title": "Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts",
       "status": "COMPLETED",
       "last_update": "2025-12-19",
       "phase": "NA",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT01988077",
       "title": "Clinical Evaluation of Yervoy in Combination With Adoptive T Cell Transfer for Metastatic Melanoma Patients",
       "status": "TERMINATED",
       "last_update": "2019-04-05",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02027935",
       "title": "CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma",
       "status": "COMPLETED",
       "last_update": "2024-10-08",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02210104",
       "title": "Adoptive Therapy Using Antigen-Specific CD4 T-Cells",
       "status": "WITHDRAWN",
       "last_update": "2017-07-21",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02983045",
       "title": "A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors",
       "status": "COMPLETED",
       "last_update": "2023-03-13",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03068624",
       "title": "Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma",
       "status": "UNKNOWN",
       "last_update": "2024-01-25",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03166397",
       "title": "Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients",
       "status": "UNKNOWN",
       "last_update": "2023-01-26",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03645928",
       "title": "Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors",
       "status": "TERMINATED",
       "last_update": "2026-05-15",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04625205",
       "title": "A Clinical Study of the Safety and Activity of the Investigational Cell Therapy NEO-PTC-01 in Patients With Advanced Melanoma",
       "status": "TERMINATED",
       "last_update": "2025-04-06",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "CTLA-4",
     "ipilimumab"
    ]
   },
   "LAG-3": {
    "n": 55,
    "n_observational": 4,
    "n_active": 34,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT04697576",
      "title": "Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-07-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05428007",
      "title": "Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-01-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05629546",
      "title": "Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors",
      "status": "RECRUITING",
      "last_update": "2026-07-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05704647",
      "title": "Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases",
      "status": "RECRUITING",
      "last_update": "2026-07-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05970497",
      "title": "A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2025-05-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06112314",
      "title": "IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)",
      "status": "RECRUITING",
      "last_update": "2026-02-25",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06246916",
      "title": "A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)",
      "status": "RECRUITING",
      "last_update": "2026-08-19",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06264180",
      "title": "VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]",
      "status": "RECRUITING",
      "last_update": "2026-07-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06295159",
      "title": "Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-04-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06319196",
      "title": "Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-06-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06594991",
      "title": "A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-05-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06624644",
      "title": "A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-04-22",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06683755",
      "title": "Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)",
      "status": "RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06712927",
      "title": "Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases",
      "status": "RECRUITING",
      "last_update": "2026-05-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06743126",
      "title": "SUPRAME-ACTengine\u00ae IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-08-18",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06880198",
      "title": "Study to Evaluate Impact\u00ae as Support to Anti PD1 or Anti PD1 Based Regimen Treatment in Patients With Inoperable Locally Advanced or Metastatic Melanoma",
      "status": "RECRUITING",
      "last_update": "2025-09-17",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06999980",
      "title": "Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation)",
      "status": "RECRUITING",
      "last_update": "2026-02-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07237594",
      "title": "IL-17 Blockade to Decrease irAEs (REPLAY)",
      "status": "RECRUITING",
      "last_update": "2026-06-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07281924",
      "title": "Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis",
      "status": "RECRUITING",
      "last_update": "2026-09-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07492680",
      "title": "A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)",
      "status": "RECRUITING",
      "last_update": "2026-08-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07504796",
      "title": "ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab",
      "status": "RECRUITING",
      "last_update": "2026-08-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00365937",
      "title": "Immunization of Disease-Free Melanoma Patients With Different HLA-A2 Peptides",
      "status": "TERMINATED",
      "last_update": "2019-03-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01308294",
      "title": "Immunotherapy of HLA-A2 Positive Stage II-IV Melanoma Patients",
      "status": "TERMINATED",
      "last_update": "2020-06-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02465060",
      "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02519322",
      "title": "Neoadjuvant and Adjuvant Checkpoint Blockade",
      "status": "COMPLETED",
      "last_update": "2024-04-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02676869",
      "title": "Phase 1 Study of IMP321 (Eftilagimod Alpha) Adjuvant to Anti-PD-1 Therapy in Unresectable or Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2019-12-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03470922",
      "title": "A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-09",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03484923",
      "title": "Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2024-06-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03538028",
      "title": "A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies",
      "status": "COMPLETED",
      "last_update": "2020-10-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03645928",
      "title": "Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2026-05-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03724968",
      "title": "Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression",
      "status": "TERMINATED",
      "last_update": "2021-04-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03743766",
      "title": "Nivolumab, BMS-936558 in Combination With Relatlimab, BMS-986016 in Patients With Metastatic Melanoma Na\u00efve to Prior Immunotherapy in the Metastatic Setting",
      "status": "COMPLETED",
      "last_update": "2026-08-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03849469",
      "title": "A Study of XmAb\u00ae22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2023-03-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03978611",
      "title": "A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment",
      "status": "TERMINATED",
      "last_update": "2024-07-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04140500",
      "title": "Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04370704",
      "title": "Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies",
      "status": "COMPLETED",
      "last_update": "2026-08-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04552223",
      "title": "Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma",
      "status": "COMPLETED",
      "last_update": "2026-02-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04866810",
      "title": "The Effect of Diet and Exercise on ImmuNotherapy and the Microbiome (EDEN)",
      "status": "SUSPENDED",
      "last_update": "2026-09-11",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04935229",
      "title": "Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma",
      "status": "TERMINATED",
      "last_update": "2025-10-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05002569",
      "title": "A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma",
      "status": "TERMINATED",
      "last_update": "2026-01-08",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05034536",
      "title": "PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05077280",
      "title": "A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma",
      "status": "UNKNOWN",
      "last_update": "2022-12-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05352672",
      "title": "Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05358938",
      "title": "Exercise to Boost Response to Checkpoint Blockade Immunotherapy",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-06",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05418972",
      "title": "A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05572463",
      "title": "A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma",
      "status": "WITHDRAWN",
      "last_update": "2022-11-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05577182",
      "title": "Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced Malignancies",
      "status": "COMPLETED",
      "last_update": "2025-11-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05608291",
      "title": "A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-06",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05625399",
      "title": "A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-26",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05695898",
      "title": "XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) in Treating Melanoma Prior Immune Checkpoint Inhibitor Therapy",
      "status": "TERMINATED",
      "last_update": "2025-03-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05704933",
      "title": "Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases",
      "status": "COMPLETED",
      "last_update": "2026-04-06",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05912244",
      "title": "A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06101134",
      "title": "A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07459543",
      "title": "A Study to Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Unresectable or Metastatic Melanoma Participants In India",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-12",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07574047",
      "title": "MELCHRONO: A Prospective Randomized Study Investigating Chrono-immunotherapy for Advanced Melanoma.",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 1,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": [
      {
       "nct": "NCT03645928",
       "title": "Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors",
       "status": "TERMINATED",
       "last_update": "2026-05-15",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "LAG-3",
     "relatlimab",
     "Opdualag"
    ]
   },
   "gp100": {
    "n": 110,
    "n_observational": 1,
    "n_active": 14,
    "n_withdrawn": 2,
    "trials": [
     {
      "nct": "NCT05549297",
      "title": "Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)",
      "status": "RECRUITING",
      "last_update": "2026-02-25",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06070012",
      "title": "Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06246149",
      "title": "Adjuvant Tebentafusp in High Risk Ocular Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-06-30",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06414590",
      "title": "Neoadjuvant Tebentafusp for Uveal Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-06-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06626516",
      "title": "Tebentafusp-tebn With LDT in Metastatic UM",
      "status": "RECRUITING",
      "last_update": "2026-07-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06627244",
      "title": "Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-02-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07057596",
      "title": "Neoadjuvant Tebentafusp in Patients With Metastatic Uveal Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-03-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07063875",
      "title": "Adding IL-2 to Tebentafusp to Eradicate Cancer Progression",
      "status": "RECRUITING",
      "last_update": "2025-07-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07203391",
      "title": "Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell Homeostasis",
      "status": "RECRUITING",
      "last_update": "2026-04-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07276386",
      "title": "Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-03-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00001439",
      "title": "A Phase I Study of gp100 Human Melanoma Peptide Vaccine With Incomplete Freund's Adjuvant",
      "status": "COMPLETED",
      "last_update": "2008-03-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00001685",
      "title": "Immunization of HLA-A201 Patients With Metastatic Melanoma Using a Combination of Immunodominant Peptides From Three Melanoma Antigens, MART-1, GP100 and Tyrosinase",
      "status": "COMPLETED",
      "last_update": "2008-03-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00001705",
      "title": "Immunization of Patients With Metastatic Melanoma Using the GP100 Peptide Preceded by an Endoplasmic Reticulum Insertion Signal Sequence",
      "status": "COMPLETED",
      "last_update": "2008-03-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00001832",
      "title": "Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2012-12-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003222",
      "title": "Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma",
      "status": "COMPLETED",
      "last_update": "2014-12-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003224",
      "title": "Vaccine Therapy in Treating Patients With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2014-11-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003229",
      "title": "Vaccine Therapy in Treating Patients With Metastatic Melanoma Who Are Undergoing Surgery for Lymph Node and Tumor Removal",
      "status": "COMPLETED",
      "last_update": "2013-03-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003274",
      "title": "Vaccine Therapy in Treating Patients With Stage II Melanoma That Can Be Removed by Surgery",
      "status": "COMPLETED",
      "last_update": "2014-05-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003339",
      "title": "Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV Melanoma",
      "status": "COMPLETED",
      "last_update": "2014-05-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003362",
      "title": "Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma",
      "status": "COMPLETED",
      "last_update": "2013-06-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003568",
      "title": "Vaccine Therapy With High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2013-06-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003665",
      "title": "Vaccine Therapy in Treating Patients With Stage IV Melanoma",
      "status": "COMPLETED",
      "last_update": "2013-02-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003792",
      "title": "Vaccine Therapy in Treating Patients With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2013-06-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003895",
      "title": "Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma",
      "status": "COMPLETED",
      "last_update": "2017-02-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003897",
      "title": "Vaccine Therapy With gp100 and/or Sargramostim in Treating Patients With Malignant Melanoma",
      "status": "COMPLETED",
      "last_update": "2019-11-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00004025",
      "title": "Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma",
      "status": "UNKNOWN",
      "last_update": "2014-01-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00005633",
      "title": "Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma",
      "status": "COMPLETED",
      "last_update": "2013-06-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00005841",
      "title": "Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma",
      "status": "TERMINATED",
      "last_update": "2014-05-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00005949",
      "title": "Vaccine Plus Interleukin-2 in Treating Patients With Advanced Melanoma",
      "status": "COMPLETED",
      "last_update": "2013-01-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00006113",
      "title": "Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma",
      "status": "TERMINATED",
      "last_update": "2014-05-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00006243",
      "title": "Vaccine Therapy and Sargramostim in Treating Patients With Stage IV Malignant Melanoma",
      "status": "COMPLETED",
      "last_update": "2013-01-25",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00006385",
      "title": "Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2011-11-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00010309",
      "title": "Vaccine Therapy in Treating Patients Who Have Stage II, Stage III, or Stage IV Melanoma",
      "status": "UNKNOWN",
      "last_update": "2014-01-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00019175",
      "title": "Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Recurrent Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2015-04-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00019214",
      "title": "Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2013-06-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00019396",
      "title": "flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer",
      "status": "COMPLETED",
      "last_update": "2024-03-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00019448",
      "title": "Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2024-03-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00019669",
      "title": "Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2013-06-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00019682",
      "title": "Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2017-11-20",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00019721",
      "title": "Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2013-06-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00019890",
      "title": "Vaccine Therapy in Treating Patients With High-Risk Stage III or Completely Resected Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2024-03-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00019994",
      "title": "Vaccine Therapy in Treating Patients With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2013-06-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00020358",
      "title": "Vaccine Therapy in Treating Patients With Melanoma",
      "status": "COMPLETED",
      "last_update": "2013-06-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00020475",
      "title": "Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye",
      "status": "COMPLETED",
      "last_update": "2024-03-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00025181",
      "title": "Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery",
      "status": "COMPLETED",
      "last_update": "2014-05-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00028431",
      "title": "Novel Adjuvants for Peptide-Based Melanoma Vaccines",
      "status": "COMPLETED",
      "last_update": "2014-05-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00031733",
      "title": "Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma",
      "status": "COMPLETED",
      "last_update": "2014-05-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00032045",
      "title": "Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma",
      "status": "COMPLETED",
      "last_update": "2013-06-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00036816",
      "title": "Vaccine Therapy in Treating Patients With Melanoma of the Eye",
      "status": "TERMINATED",
      "last_update": "2012-09-24",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00059475",
      "title": "Peptide Vaccination for Patients at High Risk for Recurrent Melanoma",
      "status": "COMPLETED",
      "last_update": "2012-10-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00072085",
      "title": "Immunization With gp100 Protein Vaccine in Treating Patients With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2013-06-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00077532",
      "title": "Monoclonal Antibody With or Without gp100 Peptides Plus Montanide ISA-51 in Treating Patients With Stage IV Melanoma",
      "status": "COMPLETED",
      "last_update": "2012-06-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00080353",
      "title": "Vaccine Treatment in Combination With IL-2 and Treated Lymphocytes for Advanced Melanoma",
      "status": "COMPLETED",
      "last_update": "2012-06-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00084656",
      "title": "Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma",
      "status": "COMPLETED",
      "last_update": "2022-04-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00085189",
      "title": "Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma",
      "status": "COMPLETED",
      "last_update": "2014-05-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00085397",
      "title": "Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma",
      "status": "UNKNOWN",
      "last_update": "2009-02-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00085462",
      "title": "Gene-Modified White Blood Cells Followed By Interleukin-2 and Vaccine Therapy in Treating Patients With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2012-06-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00089063",
      "title": "Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma",
      "status": "COMPLETED",
      "last_update": "2015-04-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00091143",
      "title": "Fludarabine Followed by Vaccine Therapy and White Blood Cell Infusions in Treating Patients With Unresectable or Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2013-04-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00091338",
      "title": "Interleukin-7 and Vaccine Therapy in Treating Patients With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2015-04-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00094653",
      "title": "MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2011-07-11",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00104845",
      "title": "Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma",
      "status": "COMPLETED",
      "last_update": "2013-03-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00116597",
      "title": "Active Specific Intranodal Immunotherapy of Recombinant Vaccinia Virus in Locally Advanced to Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2009-12-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00184067",
      "title": "Continuation Booster Trial After a Vaccine Combining Tyrosinase/GP100/MART-1 Peptides Emulsified With Montanide ISA 51 With or Without GM-CSF for Patients With Melanoma",
      "status": "TERMINATED",
      "last_update": "2014-05-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00203879",
      "title": "Study of MAGE-3/Melan-A/gp 100/NA17 and rhIL-12 With/Out Low Dose IL-2 in Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2013-09-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00243529",
      "title": "Peptide-pulsed vs. RNA-transfected Dendritic Cell Vaccines in Melanoma Patients",
      "status": "COMPLETED",
      "last_update": "2009-09-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00254397",
      "title": "Melanoma Vaccine With Peptides and Leuprolide",
      "status": "COMPLETED",
      "last_update": "2019-10-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00273910",
      "title": "Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High-Risk Melanoma",
      "status": "COMPLETED",
      "last_update": "2012-10-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00295958",
      "title": "LMB-2 Immunotoxin and Vaccine Therapy in Treating Patients With Metastatic Melanoma That Cannot Be Removed By Surgery",
      "status": "COMPLETED",
      "last_update": "2012-06-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00303836",
      "title": "Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma",
      "status": "TERMINATED",
      "last_update": "2013-06-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00313508",
      "title": "Dendritic Cell Vaccination During Lymphoid Reconstruction",
      "status": "COMPLETED",
      "last_update": "2014-02-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00334776",
      "title": "Vaccine Therapy in Treating Patients With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2014-05-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00357461",
      "title": "Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV Melanoma",
      "status": "WITHDRAWN",
      "last_update": "2013-05-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00398073",
      "title": "Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma",
      "status": "COMPLETED",
      "last_update": "2017-03-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00470015",
      "title": "Vaccine Therapy and GM-CSF With or Without Low-Dose Aldesleukin in Treating Patients With Stage II, Stage III, or Stage IV Melanoma",
      "status": "COMPLETED",
      "last_update": "2019-02-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00471471",
      "title": "Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery",
      "status": "COMPLETED",
      "last_update": "2017-06-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00509496",
      "title": "Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Anti-gp100:154-162 TCR Gene Engineered Lymphocytes",
      "status": "TERMINATED",
      "last_update": "2013-01-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00515528",
      "title": "Vaccination Plus Ontak in Patients With Metastatic Melanoma",
      "status": "TERMINATED",
      "last_update": "2021-01-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00559026",
      "title": "Phase I/II Study of Chemo-Immunotherapy Combination in Melanoma Patients",
      "status": "COMPLETED",
      "last_update": "2007-11-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00580060",
      "title": "Injection Of AJCC Stage IIB, IIC, III And IV Melanoma Patients With A Multi-Epitope Peptide Vaccine Using GM-CSF DNA As An Adjuvant: A Pilot Trial To Assess Safety And Immunity",
      "status": "COMPLETED",
      "last_update": "2011-06-10",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00610311",
      "title": "Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced Melanoma",
      "status": "TERMINATED",
      "last_update": "2015-10-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00665470",
      "title": "Chemotherapy Followed by gp100 Lymphocytes and Aldesleukin to Treat Melanoma",
      "status": "COMPLETED",
      "last_update": "2015-10-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00672542",
      "title": "Immunotherapy of Melanoma With Tumor Antigen RNA and Small Inhibitory RNA Transfected Autologous Dendritic Cells",
      "status": "COMPLETED",
      "last_update": "2014-01-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00683670",
      "title": "Dendritic Cells (White Blood Cells) Vaccination for Advanced Melanoma",
      "status": "COMPLETED",
      "last_update": "2025-06-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00798629",
      "title": "Adenovirus CCL-21 Transduced MART-1/gp100/Tyrosinase/NY-ESO-1 Peptide-Pulsed Dendritic Cells Matured",
      "status": "COMPLETED",
      "last_update": "2012-09-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00861406",
      "title": "Adjuvant Therapy of Pegylated Interferon- 2b Plus Melanoma Peptide Vaccine",
      "status": "COMPLETED",
      "last_update": "2017-03-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00923195",
      "title": "Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2015-10-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00929019",
      "title": "Messenger Ribonucleic Acid (mRNA) Transfected Dendritic Cell Vaccination in High Risk Uveal Melanoma Patients",
      "status": "TERMINATED",
      "last_update": "2018-12-07",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00940004",
      "title": "Toll-like Receptor (TLR) Ligand Matured Dendritic Cell Vaccination in Melanoma Patients",
      "status": "COMPLETED",
      "last_update": "2017-04-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00960752",
      "title": "Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist",
      "status": "COMPLETED",
      "last_update": "2021-08-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01008527",
      "title": "Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100",
      "status": "COMPLETED",
      "last_update": "2015-09-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01082198",
      "title": "Melanoma Vaccine in Treating Patients With Stage III Melanoma After Surgery to Remove Lymph Nodes",
      "status": "UNKNOWN",
      "last_update": "2013-08-26",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01176461",
      "title": "Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558",
      "status": "COMPLETED",
      "last_update": "2023-01-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01176474",
      "title": "Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma",
      "status": "COMPLETED",
      "last_update": "2023-07-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01216436",
      "title": "Local Modulation of Immune Receptors to Enhance the Response to Dendritic Cell Vaccination in Metastatic Melanoma",
      "status": "TERMINATED",
      "last_update": "2015-05-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01307618",
      "title": "Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic Melanoma",
      "status": "TERMINATED",
      "last_update": "2016-10-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01530698",
      "title": "Single-step Antigen Loading and TLR Activation of Dendritic Cells in Melanoma Patients",
      "status": "COMPLETED",
      "last_update": "2017-04-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01744171",
      "title": "Vaccine Therapy in Treating Patients With Advanced Stage III-IV Melanoma",
      "status": "TERMINATED",
      "last_update": "2022-07-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01989559",
      "title": "Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By Surgery",
      "status": "COMPLETED",
      "last_update": "2015-01-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01989572",
      "title": "Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery",
      "status": "COMPLETED",
      "last_update": "2026-06-24",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02285413",
      "title": "Platin-based Chemotherapeutics to Enhance Dendritic Cell Vaccine Efficacy in Melanoma Patients",
      "status": "COMPLETED",
      "last_update": "2016-05-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02535078",
      "title": "Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma",
      "status": "WITHDRAWN",
      "last_update": "2024-07-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02570308",
      "title": "A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma",
      "status": "COMPLETED",
      "last_update": "2023-03-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02889861",
      "title": "IMCgp100-401 Rollover Study",
      "status": "TERMINATED",
      "last_update": "2020-07-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03070392",
      "title": "Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma",
      "status": "COMPLETED",
      "last_update": "2026-03-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03649529",
      "title": "Treatment of Malignant Melanoma With GPA-TriMAR-T Cell Therapy",
      "status": "UNKNOWN",
      "last_update": "2019-12-06",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05315258",
      "title": "Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-07-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05415072",
      "title": "A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07803562",
      "title": "Low Dose Dexamethasone for the Prevention of Cytokine Release Syndrome Associated With Tebentafusp",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-09-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07815574",
      "title": "iSCIB1+ in Combination With Ipilimumab and Nivolumab as First-Line Treatment for Advanced Unresectable Melanoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 5,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": [
      {
       "nct": "NCT00001832",
       "title": "Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma",
       "status": "COMPLETED",
       "last_update": "2012-12-21",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT00080353",
       "title": "Vaccine Treatment in Combination With IL-2 and Treated Lymphocytes for Advanced Melanoma",
       "status": "COMPLETED",
       "last_update": "2012-06-14",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT00509496",
       "title": "Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Anti-gp100:154-162 TCR Gene Engineered Lymphocytes",
       "status": "TERMINATED",
       "last_update": "2013-01-15",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT00665470",
       "title": "Chemotherapy Followed by gp100 Lymphocytes and Aldesleukin to Treat Melanoma",
       "status": "COMPLETED",
       "last_update": "2015-10-19",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03649529",
       "title": "Treatment of Malignant Melanoma With GPA-TriMAR-T Cell Therapy",
       "status": "UNKNOWN",
       "last_update": "2019-12-06",
       "phase": "EARLY_PHASE1",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "gp100",
     "PMEL",
     "tebentafusp",
     "Kimmtrak"
    ]
   },
   "MART-1": {
    "n": 74,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT00001685",
      "title": "Immunization of HLA-A201 Patients With Metastatic Melanoma Using a Combination of Immunodominant Peptides From Three Melanoma Antigens, MART-1, GP100 and Tyrosinase",
      "status": "COMPLETED",
      "last_update": "2008-03-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00001832",
      "title": "Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2012-12-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00002952",
      "title": "Vaccine Therapy and Interleukin-12 in Treating Patients With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2013-09-05",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003274",
      "title": "Vaccine Therapy in Treating Patients With Stage II Melanoma That Can Be Removed by Surgery",
      "status": "COMPLETED",
      "last_update": "2014-05-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003665",
      "title": "Vaccine Therapy in Treating Patients With Stage IV Melanoma",
      "status": "COMPLETED",
      "last_update": "2013-02-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003792",
      "title": "Vaccine Therapy in Treating Patients With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2013-06-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00004025",
      "title": "Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma",
      "status": "UNKNOWN",
      "last_update": "2014-01-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00005617",
      "title": "Vaccine Therapy in Treating Patients With Stage IV or Relapsed Malignant Melanoma",
      "status": "COMPLETED",
      "last_update": "2020-08-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00005841",
      "title": "Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma",
      "status": "TERMINATED",
      "last_update": "2014-05-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00006113",
      "title": "Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma",
      "status": "TERMINATED",
      "last_update": "2014-05-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00006243",
      "title": "Vaccine Therapy and Sargramostim in Treating Patients With Stage IV Malignant Melanoma",
      "status": "COMPLETED",
      "last_update": "2013-01-25",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00006385",
      "title": "Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2011-11-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00010309",
      "title": "Vaccine Therapy in Treating Patients Who Have Stage II, Stage III, or Stage IV Melanoma",
      "status": "UNKNOWN",
      "last_update": "2014-01-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00019214",
      "title": "Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2013-06-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00019396",
      "title": "flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer",
      "status": "COMPLETED",
      "last_update": "2024-03-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00019721",
      "title": "Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2013-06-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00019890",
      "title": "Vaccine Therapy in Treating Patients With High-Risk Stage III or Completely Resected Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2024-03-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00019994",
      "title": "Vaccine Therapy in Treating Patients With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2013-06-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00020475",
      "title": "Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye",
      "status": "COMPLETED",
      "last_update": "2024-03-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00025181",
      "title": "Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery",
      "status": "COMPLETED",
      "last_update": "2014-05-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00028431",
      "title": "Novel Adjuvants for Peptide-Based Melanoma Vaccines",
      "status": "COMPLETED",
      "last_update": "2014-05-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00031733",
      "title": "Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma",
      "status": "COMPLETED",
      "last_update": "2014-05-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00036816",
      "title": "Vaccine Therapy in Treating Patients With Melanoma of the Eye",
      "status": "TERMINATED",
      "last_update": "2012-09-24",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00037037",
      "title": "Vaccine Therapy With or Without Sargramostim in Treating Patients With High-Risk or Metastatic Melanoma",
      "status": "UNKNOWN",
      "last_update": "2013-12-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00039325",
      "title": "Vaccine Therapy in Treating Patients With Stage IV or Recurrent Malignant Melanoma",
      "status": "COMPLETED",
      "last_update": "2020-08-03",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00049010",
      "title": "Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma",
      "status": "COMPLETED",
      "last_update": "2016-07-01",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00059475",
      "title": "Peptide Vaccination for Patients at High Risk for Recurrent Melanoma",
      "status": "COMPLETED",
      "last_update": "2012-10-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00074230",
      "title": "Vaccine Therapy in Treating Patients With Stage IV Cutaneous Melanoma",
      "status": "COMPLETED",
      "last_update": "2015-05-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00084656",
      "title": "Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma",
      "status": "COMPLETED",
      "last_update": "2022-04-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00089063",
      "title": "Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma",
      "status": "COMPLETED",
      "last_update": "2015-04-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00090896",
      "title": "CP-675,206 (CTLA4-Blocking Monoclonal Antibody) Combined With Dendritic Cell Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery",
      "status": "COMPLETED",
      "last_update": "2020-08-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00091104",
      "title": "Cyclophosphamide and Fludarabine Followed by Vaccine Therapy, Gene-Modified White Blood Cell Infusions, and Aldesleukin in Treating Patients With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2012-03-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00091338",
      "title": "Interleukin-7 and Vaccine Therapy in Treating Patients With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2015-04-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00112216",
      "title": "Immunotherapy of Melanoma Patients",
      "status": "COMPLETED",
      "last_update": "2013-04-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00112229",
      "title": "Immunotherapy of HLA-A2 Positive Stage III/IV Melanoma Patients",
      "status": "COMPLETED",
      "last_update": "2013-04-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00112242",
      "title": "Immunotherapy of Stage III/IV Melanoma Patients",
      "status": "COMPLETED",
      "last_update": "2020-06-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00116597",
      "title": "Active Specific Intranodal Immunotherapy of Recombinant Vaccinia Virus in Locally Advanced to Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2009-12-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00160992",
      "title": "Adoptive Cell Transfer Combined With Peptide Vaccination in Transiently Immunosuppressed Melanoma Patients",
      "status": "SUSPENDED",
      "last_update": "2005-09-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00184067",
      "title": "Continuation Booster Trial After a Vaccine Combining Tyrosinase/GP100/MART-1 Peptides Emulsified With Montanide ISA 51 With or Without GM-CSF for Patients With Melanoma",
      "status": "TERMINATED",
      "last_update": "2014-05-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00203879",
      "title": "Study of MAGE-3/Melan-A/gp 100/NA17 and rhIL-12 With/Out Low Dose IL-2 in Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2013-09-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00295958",
      "title": "LMB-2 Immunotoxin and Vaccine Therapy in Treating Patients With Metastatic Melanoma That Cannot Be Removed By Surgery",
      "status": "COMPLETED",
      "last_update": "2012-06-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00303836",
      "title": "Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma",
      "status": "TERMINATED",
      "last_update": "2013-06-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00306514",
      "title": "Safety and Immunogenicity of a Melan-A VLP Vaccine in Advanced Stage Melanoma Patients",
      "status": "COMPLETED",
      "last_update": "2007-09-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00306553",
      "title": "Safety and Immunogenicity of a Melan-A VLP Vaccine in Advanced Stage Melanoma Patients",
      "status": "COMPLETED",
      "last_update": "2006-09-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00306566",
      "title": "Safety and Immunogenicity of a Melan-A VLP Vaccine in Early Stage Melanoma Patients",
      "status": "COMPLETED",
      "last_update": "2007-09-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00313508",
      "title": "Dendritic Cell Vaccination During Lymphoid Reconstruction",
      "status": "COMPLETED",
      "last_update": "2014-02-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00324623",
      "title": "Cyclophosphamide and Fludarabine Followed by Cellular Adoptive Immunotherapy and Vaccine Therapy in Patients With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2012-11-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00334776",
      "title": "Vaccine Therapy in Treating Patients With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2014-05-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00338377",
      "title": "Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00470015",
      "title": "Vaccine Therapy and GM-CSF With or Without Low-Dose Aldesleukin in Treating Patients With Stage II, Stage III, or Stage IV Melanoma",
      "status": "COMPLETED",
      "last_update": "2019-02-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00471471",
      "title": "Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery",
      "status": "COMPLETED",
      "last_update": "2017-06-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00509288",
      "title": "Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Infusion of Anti-MART-1 F5 TCR-Gene-Engineered Lymphocytes",
      "status": "COMPLETED",
      "last_update": "2012-12-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00512889",
      "title": "Adoptive Transfer of MART1/Melan-A CTL for Malignant Melanoma",
      "status": "COMPLETED",
      "last_update": "2013-03-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00515528",
      "title": "Vaccination Plus Ontak in Patients With Metastatic Melanoma",
      "status": "TERMINATED",
      "last_update": "2021-01-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00559026",
      "title": "Phase I/II Study of Chemo-Immunotherapy Combination in Melanoma Patients",
      "status": "COMPLETED",
      "last_update": "2007-11-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00612222",
      "title": "Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma",
      "status": "TERMINATED",
      "last_update": "2015-10-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00706992",
      "title": "Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma Patients",
      "status": "TERMINATED",
      "last_update": "2015-10-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00720031",
      "title": "Treatment of Metastatic Melanoma With Autologous Melan-A/MART-1 Specific CTL Clones",
      "status": "COMPLETED",
      "last_update": "2008-07-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00798629",
      "title": "Adenovirus CCL-21 Transduced MART-1/gp100/Tyrosinase/NY-ESO-1 Peptide-Pulsed Dendritic Cells Matured",
      "status": "COMPLETED",
      "last_update": "2012-09-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00910650",
      "title": "Study of Gene Modified Immune Cells in Patients With Advanced Melanoma",
      "status": "COMPLETED",
      "last_update": "2021-12-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00923195",
      "title": "Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2015-10-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01082198",
      "title": "Melanoma Vaccine in Treating Patients With Stage III Melanoma After Surgery to Remove Lymph Nodes",
      "status": "UNKNOWN",
      "last_update": "2013-08-26",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01106235",
      "title": "Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Metastatic Melanoma",
      "status": "TERMINATED",
      "last_update": "2011-12-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01176461",
      "title": "Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558",
      "status": "COMPLETED",
      "last_update": "2023-01-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01307618",
      "title": "Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic Melanoma",
      "status": "TERMINATED",
      "last_update": "2016-10-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01308294",
      "title": "Immunotherapy of HLA-A2 Positive Stage II-IV Melanoma Patients",
      "status": "TERMINATED",
      "last_update": "2020-06-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01495572",
      "title": "Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells",
      "status": "TERMINATED",
      "last_update": "2015-10-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01748747",
      "title": "Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery",
      "status": "COMPLETED",
      "last_update": "2018-10-09",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01944709",
      "title": "Phase I/II Study of Vaccination With Antigen Loaded Dendritic Cells (DCs) in Patients With Inoperable Stage III and Stage IV Melanoma",
      "status": "TERMINATED",
      "last_update": "2013-09-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01989572",
      "title": "Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery",
      "status": "COMPLETED",
      "last_update": "2026-06-24",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02306512",
      "title": "Mohs and Immunofluorescence for Malignant Melanoma In Situ",
      "status": "WITHDRAWN",
      "last_update": "2019-01-07",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02320305",
      "title": "MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery",
      "status": "COMPLETED",
      "last_update": "2020-01-14",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02334735",
      "title": "A Comparison of Matured Dendritic Cells and Montanide\u00ae in Study Subjects With High Risk of Melanoma Recurrence",
      "status": "COMPLETED",
      "last_update": "2022-09-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02424916",
      "title": "Adoptive Transfer of Specific Melanoma Antigens CD8+ T Cells in Metastatic Melanoma Patients: a Phase I/II Study",
      "status": "COMPLETED",
      "last_update": "2020-01-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 9,
     "n_observational": 0,
     "n_active": 1,
     "n_withdrawn": 0,
     "trials": [
      {
       "nct": "NCT00001832",
       "title": "Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma",
       "status": "COMPLETED",
       "last_update": "2012-12-21",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT00160992",
       "title": "Adoptive Cell Transfer Combined With Peptide Vaccination in Transiently Immunosuppressed Melanoma Patients",
       "status": "SUSPENDED",
       "last_update": "2005-09-12",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT00324623",
       "title": "Cyclophosphamide and Fludarabine Followed by Cellular Adoptive Immunotherapy and Vaccine Therapy in Patients With Metastatic Melanoma",
       "status": "COMPLETED",
       "last_update": "2012-11-20",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT00338377",
       "title": "Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2026-08-12",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT00509288",
       "title": "Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Infusion of Anti-MART-1 F5 TCR-Gene-Engineered Lymphocytes",
       "status": "COMPLETED",
       "last_update": "2012-12-28",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT00512889",
       "title": "Adoptive Transfer of MART1/Melan-A CTL for Malignant Melanoma",
       "status": "COMPLETED",
       "last_update": "2013-03-01",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT00706992",
       "title": "Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma Patients",
       "status": "TERMINATED",
       "last_update": "2015-10-28",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT01106235",
       "title": "Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Metastatic Melanoma",
       "status": "TERMINATED",
       "last_update": "2011-12-21",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02424916",
       "title": "Adoptive Transfer of Specific Melanoma Antigens CD8+ T Cells in Metastatic Melanoma Patients: a Phase I/II Study",
       "status": "COMPLETED",
       "last_update": "2020-01-18",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "MART-1",
     "Melan-A",
     "MLANA"
    ]
   },
   "NY-ESO-1": {
    "n": 46,
    "n_observational": 0,
    "n_active": 6,
    "n_withdrawn": 2,
    "trials": [
     {
      "nct": "NCT05296564",
      "title": "Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers",
      "status": "RECRUITING",
      "last_update": "2025-10-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05492682",
      "title": "START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer",
      "status": "RECRUITING",
      "last_update": "2026-05-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06889766",
      "title": "NY-ESO-1-redirected T Cells in Patients With Advanced Melanoma and Sarcoma",
      "status": "RECRUITING",
      "last_update": "2026-05-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06942143",
      "title": "An Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2025-09-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00020397",
      "title": "Vaccine Therapy in Treating Patients With Refractory Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2013-06-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00037037",
      "title": "Vaccine Therapy With or Without Sargramostim in Treating Patients With High-Risk or Metastatic Melanoma",
      "status": "UNKNOWN",
      "last_update": "2013-12-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00079144",
      "title": "Lymphocyte-Depleting Nonmyeloablative Preparative Chemotherapy Followed By Autologous Lymphocyte Infusion, Peptide Vaccine Plus Montanide ISA-51, and Interleukin-2 in Treating Patients With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2013-06-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00112242",
      "title": "Immunotherapy of Stage III/IV Melanoma Patients",
      "status": "COMPLETED",
      "last_update": "2020-06-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00142454",
      "title": "NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting)",
      "status": "COMPLETED",
      "last_update": "2022-10-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00145158",
      "title": "Immunization With 8 Peptides Mixed With CpG 7909 or Montanide ISA51 in Patients With Metastatic Cutaneous Melanoma",
      "status": "TERMINATED",
      "last_update": "2022-10-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00199901",
      "title": "Study of NY-ESO-1 ISCOMATRIX\u00ae in Patients With High-risk, Resected Melanoma",
      "status": "COMPLETED",
      "last_update": "2022-10-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00313508",
      "title": "Dendritic Cell Vaccination During Lymphoid Reconstruction",
      "status": "COMPLETED",
      "last_update": "2014-02-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00518206",
      "title": "Study of NY-ESO-1 ISCOMATRIX\u00ae in Patients With Measurable Stage III or IV Melanoma",
      "status": "COMPLETED",
      "last_update": "2022-10-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00623831",
      "title": "A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen",
      "status": "COMPLETED",
      "last_update": "2022-10-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00670748",
      "title": "Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer",
      "status": "TERMINATED",
      "last_update": "2019-11-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00798629",
      "title": "Adenovirus CCL-21 Transduced MART-1/gp100/Tyrosinase/NY-ESO-1 Peptide-Pulsed Dendritic Cells Matured",
      "status": "COMPLETED",
      "last_update": "2012-09-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00948961",
      "title": "A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1",
      "status": "COMPLETED",
      "last_update": "2016-06-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01008527",
      "title": "Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100",
      "status": "COMPLETED",
      "last_update": "2015-09-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01079741",
      "title": "Safety Study of Adjuvant Vaccine to Treat Melanoma Patients",
      "status": "COMPLETED",
      "last_update": "2018-02-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01176461",
      "title": "Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558",
      "status": "COMPLETED",
      "last_update": "2023-01-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01176474",
      "title": "Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma",
      "status": "COMPLETED",
      "last_update": "2023-07-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01213472",
      "title": "Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma",
      "status": "COMPLETED",
      "last_update": "2019-10-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01216696",
      "title": "Ipilimumab in Patients With Advanced Melanoma and Spontaneous Preexisting Immune Response to NY-ESO-1",
      "status": "COMPLETED",
      "last_update": "2016-08-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01234012",
      "title": "Study of IMF-001 in Patients With Malignancies Expressing NY-ESO-1",
      "status": "COMPLETED",
      "last_update": "2015-03-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01308294",
      "title": "Immunotherapy of HLA-A2 Positive Stage II-IV Melanoma Patients",
      "status": "TERMINATED",
      "last_update": "2020-06-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01350401",
      "title": "Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma",
      "status": "TERMINATED",
      "last_update": "2019-01-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01457131",
      "title": "Modified White Blood Cells That Secrete IL-2 and Express a Protein That Targets the ESO-1tumor Protein for Metastatic Cancer",
      "status": "TERMINATED",
      "last_update": "2019-01-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01522820",
      "title": "Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2016-10-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01584115",
      "title": "Clinical Trial of a Therapeutic Vaccine With NY-ESO-1 in Combination With the Adjuvant Monophosphoryl Lipid A (MPLA)",
      "status": "UNKNOWN",
      "last_update": "2012-04-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01810016",
      "title": "NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma",
      "status": "TERMINATED",
      "last_update": "2022-10-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01946373",
      "title": "T Cell Transfer With or Without Dendritic Cell Vaccination in Patients With Melanoma",
      "status": "UNKNOWN",
      "last_update": "2022-10-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01967823",
      "title": "T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer",
      "status": "COMPLETED",
      "last_update": "2021-03-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02015416",
      "title": "A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer",
      "status": "COMPLETED",
      "last_update": "2017-08-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02062359",
      "title": "T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma",
      "status": "TERMINATED",
      "last_update": "2016-06-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02122861",
      "title": "Phase 1 Study of Intradermal LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1",
      "status": "COMPLETED",
      "last_update": "2019-03-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02129075",
      "title": "A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma",
      "status": "COMPLETED",
      "last_update": "2021-11-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02210104",
      "title": "Adoptive Therapy Using Antigen-Specific CD4 T-Cells",
      "status": "WITHDRAWN",
      "last_update": "2017-07-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02334735",
      "title": "A Comparison of Matured Dendritic Cells and Montanide\u00ae in Study Subjects With High Risk of Melanoma Recurrence",
      "status": "COMPLETED",
      "last_update": "2022-09-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02366546",
      "title": "Investigator Initiated Phase 1 Study of TBI-1301",
      "status": "UNKNOWN",
      "last_update": "2018-10-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02387125",
      "title": "Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1",
      "status": "TERMINATED",
      "last_update": "2020-07-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02410733",
      "title": "Evaluation of the Safety and Tolerability of i.v. Administration of a Cancer Vaccine in Patients With Advanced Melanoma",
      "status": "COMPLETED",
      "last_update": "2026-03-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02457650",
      "title": "T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies",
      "status": "UNKNOWN",
      "last_update": "2016-08-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02650986",
      "title": "Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02661100",
      "title": "A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients",
      "status": "WITHDRAWN",
      "last_update": "2016-12-07",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02869217",
      "title": "Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-12-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03399448",
      "title": "NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)",
      "status": "TERMINATED",
      "last_update": "2023-06-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 11,
     "n_observational": 0,
     "n_active": 5,
     "n_withdrawn": 1,
     "trials": [
      {
       "nct": "NCT05296564",
       "title": "Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers",
       "status": "RECRUITING",
       "last_update": "2025-10-02",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06889766",
       "title": "NY-ESO-1-redirected T Cells in Patients With Advanced Melanoma and Sarcoma",
       "status": "RECRUITING",
       "last_update": "2026-05-15",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06942143",
       "title": "An Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid Tumors",
       "status": "RECRUITING",
       "last_update": "2025-09-03",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT00079144",
       "title": "Lymphocyte-Depleting Nonmyeloablative Preparative Chemotherapy Followed By Autologous Lymphocyte Infusion, Peptide Vaccine Plus Montanide ISA-51, and Interleukin-2 in Treating Patients With Metastatic Melanoma",
       "status": "COMPLETED",
       "last_update": "2013-06-19",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT00670748",
       "title": "Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer",
       "status": "TERMINATED",
       "last_update": "2019-11-19",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT01350401",
       "title": "Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma",
       "status": "TERMINATED",
       "last_update": "2019-01-10",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02210104",
       "title": "Adoptive Therapy Using Antigen-Specific CD4 T-Cells",
       "status": "WITHDRAWN",
       "last_update": "2017-07-21",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02457650",
       "title": "T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies",
       "status": "UNKNOWN",
       "last_update": "2016-08-03",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02650986",
       "title": "Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2026-07-08",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02869217",
       "title": "Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2025-12-03",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03399448",
       "title": "NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)",
       "status": "TERMINATED",
       "last_update": "2023-06-22",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "NY-ESO-1",
     "CTAG1B"
    ]
   },
   "GD2": {
    "n": 13,
    "n_observational": 0,
    "n_active": 3,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT07627698",
      "title": "Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-06-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003022",
      "title": "Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer",
      "status": "COMPLETED",
      "last_update": "2013-07-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003750",
      "title": "Biological Therapy in Treating Children With Refractory or Recurrent Neuroblastoma or Other Tumors",
      "status": "COMPLETED",
      "last_update": "2014-08-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00004184",
      "title": "Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Melanoma",
      "status": "COMPLETED",
      "last_update": "2013-04-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00445965",
      "title": "Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer",
      "status": "COMPLETED",
      "last_update": "2024-04-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00597272",
      "title": "Determine Toxicity and Antibody Responses With a KLH Conjugated Bivalent Vaccine Containing GD2 Lactone, GD3 Lactone With Immunological Adjuvant QS-DG or OPT-821 in Patients With Disease Free AJCC Stage III or IV Cutaneous Melanoma",
      "status": "COMPLETED",
      "last_update": "2016-09-20",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00743496",
      "title": "A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma",
      "status": "COMPLETED",
      "last_update": "2017-08-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01123304",
      "title": "Safety Study of Human IgM (MORAb-028) to Treat Metastatic Melanoma",
      "status": "TERMINATED",
      "last_update": "2014-07-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02107963",
      "title": "A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2024-05-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02482532",
      "title": "Vaccine Enriched, Autologous, Activated T-Cells Directed to Tumor in Patients With Relapsed/Refractory Melanoma",
      "status": "COMPLETED",
      "last_update": "2022-02-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03635632",
      "title": "C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05130255",
      "title": "GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2",
      "status": "TERMINATED",
      "last_update": "2026-06-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06739226",
      "title": "Combination Immunotherapy Targeting Melanoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 4,
     "n_observational": 0,
     "n_active": 2,
     "n_withdrawn": 0,
     "trials": [
      {
       "nct": "NCT07627698",
       "title": "Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma",
       "status": "RECRUITING",
       "last_update": "2026-06-04",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02107963",
       "title": "A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors",
       "status": "COMPLETED",
       "last_update": "2024-05-16",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02482532",
       "title": "Vaccine Enriched, Autologous, Activated T-Cells Directed to Tumor in Patients With Relapsed/Refractory Melanoma",
       "status": "COMPLETED",
       "last_update": "2022-02-04",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03635632",
       "title": "C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2026-07-06",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "GD2",
     "dinutuximab"
    ]
   },
   "GD3": {
    "n": 4,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00199342",
      "title": "A Study of a Monoclonal Antibody, KW-2871, in Patients With Advanced Melanoma",
      "status": "TERMINATED",
      "last_update": "2024-05-03",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00597272",
      "title": "Determine Toxicity and Antibody Responses With a KLH Conjugated Bivalent Vaccine Containing GD2 Lactone, GD3 Lactone With Immunological Adjuvant QS-DG or OPT-821 in Patients With Disease Free AJCC Stage III or IV Cutaneous Melanoma",
      "status": "COMPLETED",
      "last_update": "2016-09-20",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00679289",
      "title": "Phase II Study of KW2871 Combined With High Dose Interferon-\u03b12b in Patients With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2022-10-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03159117",
      "title": "Pfizer PF-06688992 in Patients With Stage III or Stage IV Melanoma",
      "status": "COMPLETED",
      "last_update": "2020-01-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "GD3"
    ]
   },
   "TIL": {
    "n": 109,
    "n_observational": 3,
    "n_active": 38,
    "n_withdrawn": 4,
    "trials": [
     {
      "nct": "NCT02621021",
      "title": "A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab",
      "status": "RECRUITING",
      "last_update": "2026-08-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04114136",
      "title": "Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-06-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05098184",
      "title": "A Study of GC101 TIL in Advanced Melanoma (10hospital)",
      "status": "RECRUITING",
      "last_update": "2025-12-11",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05361174",
      "title": "A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer",
      "status": "RECRUITING",
      "last_update": "2026-06-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05366478",
      "title": "A Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2022-08-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05607095",
      "title": "A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or Angiosarcoma",
      "status": "RECRUITING",
      "last_update": "2026-07-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05727904",
      "title": "Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.",
      "status": "RECRUITING",
      "last_update": "2026-06-26",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06060613",
      "title": "Safety and Efficacy of OBX-115 in Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-07-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06204991",
      "title": "To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic Melanoma",
      "status": "RECRUITING",
      "last_update": "2025-08-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06295159",
      "title": "Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-04-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06630611",
      "title": "Evaluation of a Pragmatic Approach to Adoptive Cell Therapy (ACT) Using an IL2 Analog (ANV419) vs High Dose IL2 After Tumor Infiltrating Lymphocytes (TIL) Therapy in Patients With Melanoma, NSCLC and Cervical Cancer (PragmaTIL)",
      "status": "RECRUITING",
      "last_update": "2025-01-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06703398",
      "title": "A Study of GC101 TIL in Advanced Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-08-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06743126",
      "title": "SUPRAME-ACTengine\u00ae IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-08-18",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06783270",
      "title": "T-cell Therapy with CRISPR PD1-edited Tumor Infiltrating Lymphocytes for Patients with Metastatic Melanoma",
      "status": "RECRUITING",
      "last_update": "2025-01-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06940739",
      "title": "A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel",
      "status": "RECRUITING",
      "last_update": "2026-06-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06961357",
      "title": "Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-06-26",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07310784",
      "title": "A Phase II Trial of LM103 in Advanced Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-08-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00001832",
      "title": "Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2012-12-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00002535",
      "title": "Indomethacin Plus Biological Therapy in Treating Patients With Advanced Melanoma",
      "status": "COMPLETED",
      "last_update": "2013-06-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00002733",
      "title": "Biological Therapy in Treating Patients With Metastatic Cancer",
      "status": "COMPLETED",
      "last_update": "2011-05-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00002786",
      "title": "Biological Therapy in Treating Patients With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2010-05-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003665",
      "title": "Vaccine Therapy in Treating Patients With Stage IV Melanoma",
      "status": "COMPLETED",
      "last_update": "2013-02-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00006113",
      "title": "Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma",
      "status": "TERMINATED",
      "last_update": "2014-05-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00045149",
      "title": "Biological Therapy in Treating Patients With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2010-05-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00062036",
      "title": "Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2017-07-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00085462",
      "title": "Gene-Modified White Blood Cells Followed By Interleukin-2 and Vaccine Therapy in Treating Patients With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2012-06-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00091104",
      "title": "Cyclophosphamide and Fludarabine Followed by Vaccine Therapy, Gene-Modified White Blood Cell Infusions, and Aldesleukin in Treating Patients With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2012-03-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00096382",
      "title": "Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2015-10-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00200577",
      "title": "Tumor Infiltrating Lymphocytes Adjuvant Therapy of Melanoma",
      "status": "COMPLETED",
      "last_update": "2017-06-01",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00314106",
      "title": "Chemotherapy, Irradiation, Cell Infusions, and Interleukin-2 to Treat Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2012-10-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00338377",
      "title": "Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00509288",
      "title": "Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Infusion of Anti-MART-1 F5 TCR-Gene-Engineered Lymphocytes",
      "status": "COMPLETED",
      "last_update": "2012-12-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00509496",
      "title": "Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Anti-gp100:154-162 TCR Gene Engineered Lymphocytes",
      "status": "TERMINATED",
      "last_update": "2013-01-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00513604",
      "title": "Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2013-06-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00604136",
      "title": "Treatment of Metastatic Melanoma With Tumor Infiltrating Lymphocytes and IL-2 Following Lympho-depleting Chemotherapy",
      "status": "UNKNOWN",
      "last_update": "2018-09-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00610389",
      "title": "Phase II Study With Immunotherapy With Dendritic Cells and Tumor Infiltrating Lymphocytes in Solid Tumors",
      "status": "UNKNOWN",
      "last_update": "2010-05-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00863330",
      "title": "Laboratory-Treated Autologous Lymphocytes and Aldesleukin After Cyclophosphamide and Fludarabine in Treating Patients With Metastatic Melanoma",
      "status": "TERMINATED",
      "last_update": "2024-10-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00937625",
      "title": "T-cell Based Immunotherapy for of Melanoma",
      "status": "COMPLETED",
      "last_update": "2015-08-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01005745",
      "title": "Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2025-12-19",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01082887",
      "title": "A Study of Immunotherapy With TIL (Tumor Infiltrating Lymphocytes) in Combination With Intra-tumoral Injections of Interferon Gamma-adenovirus (Ad-IFNg) in Patients With Stage IIIc or Stage IV Metastatic Melanoma (AJCC)(Protocol TIL-Ad-INFg)",
      "status": "TERMINATED",
      "last_update": "2016-08-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01118091",
      "title": "Prospective Randomized Comparative Study of Cell Transfer Therapy Using CD8+-Enriched Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Compared to High-Dose Aldesleukin in M...",
      "status": "COMPLETED",
      "last_update": "2015-10-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01236573",
      "title": "Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating Lymphocytes",
      "status": "TERMINATED",
      "last_update": "2015-11-26",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01319565",
      "title": "Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI...",
      "status": "COMPLETED",
      "last_update": "2025-12-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01369875",
      "title": "Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma",
      "status": "TERMINATED",
      "last_update": "2019-12-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01369888",
      "title": "Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic Melanoma",
      "status": "TERMINATED",
      "last_update": "2015-01-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01468818",
      "title": "Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma",
      "status": "TERMINATED",
      "last_update": "2016-06-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01585415",
      "title": "Vemurafenib and White Blood Cell Therapy for Advanced Melanoma",
      "status": "TERMINATED",
      "last_update": "2019-11-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01659151",
      "title": "Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2026-02-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01701674",
      "title": "Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts",
      "status": "COMPLETED",
      "last_update": "2025-12-19",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01715077",
      "title": "Study of Ipilimumab in the Immune System",
      "status": "COMPLETED",
      "last_update": "2018-08-13",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01740557",
      "title": "Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2024-10-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01807182",
      "title": "Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2022-11-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01814046",
      "title": "Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma",
      "status": "TERMINATED",
      "last_update": "2018-10-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01883323",
      "title": "Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy Following Cyclophosphamide And Fludarabine In Patients With Melanoma",
      "status": "COMPLETED",
      "last_update": "2019-11-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01946373",
      "title": "T Cell Transfer With or Without Dendritic Cell Vaccination in Patients With Melanoma",
      "status": "UNKNOWN",
      "last_update": "2022-10-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01955460",
      "title": "Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01993719",
      "title": "Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2023-01-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01995344",
      "title": "TIL Therapy in Metastatic Melanoma and IL2 Dose Assessment",
      "status": "TERMINATED",
      "last_update": "2023-04-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02111863",
      "title": "Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma",
      "status": "TERMINATED",
      "last_update": "2017-09-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02278887",
      "title": "Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2025-03-10",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02354690",
      "title": "Vemurafenib and TIL Therapy for Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2020-03-23",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02360579",
      "title": "Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2026-03-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02375984",
      "title": "A Study Using Tumor-Reactive Autologous Tumor Infiltrating Lymphocytes (TIL) in Metastatic Melanomas",
      "status": "TERMINATED",
      "last_update": "2021-09-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02489266",
      "title": "In Vivo Persistence of Adoptively-Transferred TIL Cultured With Akti in People With Metastatic Melanoma",
      "status": "WITHDRAWN",
      "last_update": "2017-07-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02493361",
      "title": "Trial of pIL-12/MK-3475 in Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2021-01-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02500576",
      "title": "Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2025-01-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02650986",
      "title": "Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02652455",
      "title": "Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2025-08-19",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03158935",
      "title": "The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) Trial",
      "status": "COMPLETED",
      "last_update": "2020-08-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03161756",
      "title": "Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma",
      "status": "UNKNOWN",
      "last_update": "2022-04-07",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03348891",
      "title": "TNF in Melanoma Patients Treated With Immunotherapy",
      "status": "COMPLETED",
      "last_update": "2026-04-14",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03374839",
      "title": "Combined Therapy of Nivolumab and Adoptive T Cell Therapy in Metastatic Melanoma Patients",
      "status": "UNKNOWN",
      "last_update": "2022-05-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03467516",
      "title": "Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03475134",
      "title": "TIL-ACT After NMA Chemo with IL-2 and Nivo Rescue in Metastatic Melanoma (mMEL)",
      "status": "COMPLETED",
      "last_update": "2025-02-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03526185",
      "title": "A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes",
      "status": "TERMINATED",
      "last_update": "2022-07-25",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03627026",
      "title": "Evaluation of Sphingolipids as Predictive Biomarkers of Immune Checkpoint Inhibitor Response in Melanoma Patients",
      "status": "COMPLETED",
      "last_update": "2024-06-10",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03638375",
      "title": "TIL and Anti-PD1 in Metastatic Melanoma",
      "status": "UNKNOWN",
      "last_update": "2023-12-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03645928",
      "title": "Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2026-05-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03991741",
      "title": "Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-07-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04165967",
      "title": "Adoptive Tumor-infiltrating Lymphocyte Transfer With Nivolumab for Melanoma",
      "status": "COMPLETED",
      "last_update": "2024-04-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04217473",
      "title": "TNFalpha and Interleukin 2 Coding Oncolytic Adenovirus TILT-123 During TIL Treatment of Advanced Melanoma",
      "status": "COMPLETED",
      "last_update": "2025-08-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04223648",
      "title": "Programmed Cell Death 1 + Selected Cell Therapy With Durvalumab (MEDI4736) and Tremelimumab in Metastatic Melanoma",
      "status": "WITHDRAWN",
      "last_update": "2021-11-22",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04357509",
      "title": "The Tolerance,Pharmacokinetic Characteristics,Safety and Efficacy of ScTIL210 in the Treatment of Melanoma",
      "status": "UNKNOWN",
      "last_update": "2020-04-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04812470",
      "title": "Hepatic Arterial Infusion of Autologous Tumor Infiltrating Lymphocytes in Patients With Melanoma and Liver Metastases",
      "status": "COMPLETED",
      "last_update": "2025-09-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05050006",
      "title": "ITIL-168 in Advanced Melanoma",
      "status": "TERMINATED",
      "last_update": "2024-04-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05176470",
      "title": "Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05418972",
      "title": "A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05470283",
      "title": "Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05573035",
      "title": "A Study to Investigate LYL845 in Adults With Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-07-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05576077",
      "title": "A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-03-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05628883",
      "title": "Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma",
      "status": "COMPLETED",
      "last_update": "2026-04-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05640193",
      "title": "A Study of LN-144 in People With Metastatic Melanoma to the Brain",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05869539",
      "title": "ACT-TIL and ANV419 for Advanced Melanoma.",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05902520",
      "title": "Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05903937",
      "title": "Locoregional Administration of TIL and Lymphodepletion in Patients With Melanoma and Liver Metastases",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06120712",
      "title": "A Study of GC101 TIL in Advanced Melanoma (BZ)",
      "status": "COMPLETED",
      "last_update": "2025-12-23",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06151847",
      "title": "Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2026-04-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06190249",
      "title": "Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable Melanoma",
      "status": "WITHDRAWN",
      "last_update": "2025-06-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06237881",
      "title": "A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06566092",
      "title": "Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06626256",
      "title": "STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma",
      "status": "WITHDRAWN",
      "last_update": "2025-12-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06961786",
      "title": "TNF\u03b1 and IL-2 Coding Oncolytic Adenovirus TILT-123 With Lymphocyte-depleting Chemotherapy and TILs in the Treatment of Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07028008",
      "title": "Evaluate the Safety and Efficacy of Autologous Tumor-infiltrating Lymphocyte in Patients With Refractory Melanoma Who Failed to Immune Checkpoint Inhibitors",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-06-26",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07183852",
      "title": "Locoregional or Systemic Administration of Autologous Tumor Infiltrating Lymphocytes in Patients With Metastatic Melanoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07288203",
      "title": "A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07406724",
      "title": "HS-IT101 Injection Versus Chemotherapy in the Treatment of Advanced Melanoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-02-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07628894",
      "title": "Circadian-Optimized Light Therapy for the Treatment of Patients With Advanced Melanoma Receiving Tumor-Infiltrating Lymphocyte Therapy",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-06-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07651618",
      "title": "A Phase II Trial of Tumour Infiltrating Lymphocyte Adoptive Cell Therapy in Patients With Immune Checkpoint Inhibitor Resistant Unresectable or Metastatic Melanoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-06-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07700121",
      "title": "PICSTAT Pilot Study for CD8 PET/CT-Guided Lifileucel Treatment in Advanced Melanoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-13",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 58,
     "n_observational": 1,
     "n_active": 18,
     "n_withdrawn": 2,
     "trials": [
      {
       "nct": "NCT02621021",
       "title": "A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab",
       "status": "RECRUITING",
       "last_update": "2026-08-20",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06630611",
       "title": "Evaluation of a Pragmatic Approach to Adoptive Cell Therapy (ACT) Using an IL2 Analog (ANV419) vs High Dose IL2 After Tumor Infiltrating Lymphocytes (TIL) Therapy in Patients With Melanoma, NSCLC and Cervical Cancer (PragmaTIL)",
       "status": "RECRUITING",
       "last_update": "2025-01-28",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06783270",
       "title": "T-cell Therapy with CRISPR PD1-edited Tumor Infiltrating Lymphocytes for Patients with Metastatic Melanoma",
       "status": "RECRUITING",
       "last_update": "2025-01-20",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT00001832",
       "title": "Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma",
       "status": "COMPLETED",
       "last_update": "2012-12-21",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT00062036",
       "title": "Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic Melanoma",
       "status": "COMPLETED",
       "last_update": "2017-07-02",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT00096382",
       "title": "Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma",
       "status": "COMPLETED",
       "last_update": "2015-10-28",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT00200577",
       "title": "Tumor Infiltrating Lymphocytes Adjuvant Therapy of Melanoma",
       "status": "COMPLETED",
       "last_update": "2017-06-01",
       "phase": "PHASE3",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT00338377",
       "title": "Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2026-08-12",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT00509288",
       "title": "Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Infusion of Anti-MART-1 F5 TCR-Gene-Engineered Lymphocytes",
       "status": "COMPLETED",
       "last_update": "2012-12-28",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT00509496",
       "title": "Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Anti-gp100:154-162 TCR Gene Engineered Lymphocytes",
       "status": "TERMINATED",
       "last_update": "2013-01-15",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT00513604",
       "title": "Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic Melanoma",
       "status": "COMPLETED",
       "last_update": "2013-06-03",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT00604136",
       "title": "Treatment of Metastatic Melanoma With Tumor Infiltrating Lymphocytes and IL-2 Following Lympho-depleting Chemotherapy",
       "status": "UNKNOWN",
       "last_update": "2018-09-18",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT00610389",
       "title": "Phase II Study With Immunotherapy With Dendritic Cells and Tumor Infiltrating Lymphocytes in Solid Tumors",
       "status": "UNKNOWN",
       "last_update": "2010-05-10",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT00863330",
       "title": "Laboratory-Treated Autologous Lymphocytes and Aldesleukin After Cyclophosphamide and Fludarabine in Treating Patients With Metastatic Melanoma",
       "status": "TERMINATED",
       "last_update": "2024-10-03",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT01005745",
       "title": "Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic Melanoma",
       "status": "COMPLETED",
       "last_update": "2025-12-19",
       "phase": "NA",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT01082887",
       "title": "A Study of Immunotherapy With TIL (Tumor Infiltrating Lymphocytes) in Combination With Intra-tumoral Injections of Interferon Gamma-adenovirus (Ad-IFNg) in Patients With Stage IIIc or Stage IV Metastatic Melanoma (AJCC)(Protocol TIL-Ad-INFg)",
       "status": "TERMINATED",
       "last_update": "2016-08-08",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT01118091",
       "title": "Prospective Randomized Comparative Study of Cell Transfer Therapy Using CD8+-Enriched Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Compared to High-Dose Aldesleukin in M...",
       "status": "COMPLETED",
       "last_update": "2015-10-08",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT01236573",
       "title": "Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating Lymphocytes",
       "status": "TERMINATED",
       "last_update": "2015-11-26",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT01319565",
       "title": "Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI...",
       "status": "COMPLETED",
       "last_update": "2025-12-19",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT01369875",
       "title": "Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma",
       "status": "TERMINATED",
       "last_update": "2019-12-10",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT01369888",
       "title": "Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic Melanoma",
       "status": "TERMINATED",
       "last_update": "2015-01-27",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT01468818",
       "title": "Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma",
       "status": "TERMINATED",
       "last_update": "2016-06-27",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT01585415",
       "title": "Vemurafenib and White Blood Cell Therapy for Advanced Melanoma",
       "status": "TERMINATED",
       "last_update": "2019-11-21",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT01659151",
       "title": "Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma",
       "status": "COMPLETED",
       "last_update": "2026-02-20",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT01701674",
       "title": "Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts",
       "status": "COMPLETED",
       "last_update": "2025-12-19",
       "phase": "NA",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT01740557",
       "title": "Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma",
       "status": "COMPLETED",
       "last_update": "2024-10-08",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT01807182",
       "title": "Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma",
       "status": "COMPLETED",
       "last_update": "2022-11-10",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT01814046",
       "title": "Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma",
       "status": "TERMINATED",
       "last_update": "2018-10-11",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT01883323",
       "title": "Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy Following Cyclophosphamide And Fludarabine In Patients With Melanoma",
       "status": "COMPLETED",
       "last_update": "2019-11-08",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT01955460",
       "title": "Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2026-04-15",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT01993719",
       "title": "Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma",
       "status": "COMPLETED",
       "last_update": "2023-01-18",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02111863",
       "title": "Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma",
       "status": "TERMINATED",
       "last_update": "2017-09-19",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02360579",
       "title": "Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma",
       "status": "COMPLETED",
       "last_update": "2026-03-25",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02375984",
       "title": "A Study Using Tumor-Reactive Autologous Tumor Infiltrating Lymphocytes (TIL) in Metastatic Melanomas",
       "status": "TERMINATED",
       "last_update": "2021-09-22",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02489266",
       "title": "In Vivo Persistence of Adoptively-Transferred TIL Cultured With Akti in People With Metastatic Melanoma",
       "status": "WITHDRAWN",
       "last_update": "2017-07-27",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02500576",
       "title": "Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma",
       "status": "COMPLETED",
       "last_update": "2025-01-15",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02650986",
       "title": "Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2026-07-08",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02652455",
       "title": "Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma",
       "status": "COMPLETED",
       "last_update": "2025-08-19",
       "phase": "EARLY_PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03158935",
       "title": "The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) Trial",
       "status": "COMPLETED",
       "last_update": "2020-08-14",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03374839",
       "title": "Combined Therapy of Nivolumab and Adoptive T Cell Therapy in Metastatic Melanoma Patients",
       "status": "UNKNOWN",
       "last_update": "2022-05-06",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03467516",
       "title": "Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2026-06-01",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03526185",
       "title": "A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes",
       "status": "TERMINATED",
       "last_update": "2022-07-25",
       "phase": "EARLY_PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03645928",
       "title": "Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors",
       "status": "TERMINATED",
       "last_update": "2026-05-15",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03991741",
       "title": "Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors",
       "status": "TERMINATED",
       "last_update": "2025-07-03",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04165967",
       "title": "Adoptive Tumor-infiltrating Lymphocyte Transfer With Nivolumab for Melanoma",
       "status": "COMPLETED",
       "last_update": "2024-04-10",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04223648",
       "title": "Programmed Cell Death 1 + Selected Cell Therapy With Durvalumab (MEDI4736) and Tremelimumab in Metastatic Melanoma",
       "status": "WITHDRAWN",
       "last_update": "2021-11-22",
       "phase": "EARLY_PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04812470",
       "title": "Hepatic Arterial Infusion of Autologous Tumor Infiltrating Lymphocytes in Patients With Melanoma and Liver Metastases",
       "status": "COMPLETED",
       "last_update": "2025-09-22",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05176470",
       "title": "Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2026-02-24",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05470283",
       "title": "Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2026-09-11",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05902520",
       "title": "Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2026-01-08",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06237881",
       "title": "A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2026-08-10",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06566092",
       "title": "Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2026-04-06",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06961786",
       "title": "TNF\u03b1 and IL-2 Coding Oncolytic Adenovirus TILT-123 With Lymphocyte-depleting Chemotherapy and TILs in the Treatment of Melanoma",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2026-03-05",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07028008",
       "title": "Evaluate the Safety and Efficacy of Autologous Tumor-infiltrating Lymphocyte in Patients With Refractory Melanoma Who Failed to Immune Checkpoint Inhibitors",
       "status": "NOT_YET_RECRUITING",
       "last_update": "2025-06-26",
       "phase": "NA",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07183852",
       "title": "Locoregional or Systemic Administration of Autologous Tumor Infiltrating Lymphocytes in Patients With Metastatic Melanoma",
       "status": "NOT_YET_RECRUITING",
       "last_update": "2026-09-09",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07288203",
       "title": "A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2026-04-20",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07628894",
       "title": "Circadian-Optimized Light Therapy for the Treatment of Patients With Advanced Melanoma Receiving Tumor-Infiltrating Lymphocyte Therapy",
       "status": "NOT_YET_RECRUITING",
       "last_update": "2026-06-05",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07651618",
       "title": "A Phase II Trial of Tumour Infiltrating Lymphocyte Adoptive Cell Therapy in Patients With Immune Checkpoint Inhibitor Resistant Unresectable or Metastatic Melanoma",
       "status": "NOT_YET_RECRUITING",
       "last_update": "2026-06-16",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "tumor-infiltrating lymphocytes",
     "tumour-infiltrating lymphocytes",
     "lifileucel",
     "Amtagvi"
    ]
   },
   "CSPG4": {
    "n": 1,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT07627698",
      "title": "Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-06-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 1,
     "n_observational": 0,
     "n_active": 1,
     "n_withdrawn": 0,
     "trials": [
      {
       "nct": "NCT07627698",
       "title": "Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma",
       "status": "RECRUITING",
       "last_update": "2026-06-04",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "CSPG4",
     "HMW-MAA"
    ]
   }
  },
  "by_drug": {
   "AVAPRITINIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04771520",
      "title": "Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-06-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "AVUTOMETINIB": {
    "n": 2,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT06194929",
      "title": "Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma",
      "status": "RECRUITING",
      "last_update": "2025-12-03",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04720417",
      "title": "Defactinib and VS-6766 for the Treatment of Patients With Metastatic Uveal Melanoma",
      "status": "TERMINATED",
      "last_update": "2025-07-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "BALSTILIMAB": {
    "n": 2,
    "n_observational": 1,
    "n_active": 1,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT05529316",
      "title": "A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05561491",
      "title": "A Study of ONCOS-102 in Combination With Other Novel Immune-therapies in Advanced Treatment-resistant Melanoma Patients",
      "status": "WITHDRAWN",
      "last_update": "2023-06-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "BELVARAFENIB": {
    "n": 2,
    "n_observational": 0,
    "n_active": 2,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT07449754",
      "title": "Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-03-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04835805",
      "title": "A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "BINIMETINIB": {
    "n": 53,
    "n_observational": 9,
    "n_active": 21,
    "n_withdrawn": 3,
    "trials": [
     {
      "nct": "NCT03563729",
      "title": "Melanoma Metastasized to the Brain and Steroids",
      "status": "RECRUITING",
      "last_update": "2023-07-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03947385",
      "title": "Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions",
      "status": "RECRUITING",
      "last_update": "2026-06-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04511013",
      "title": "A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases",
      "status": "RECRUITING",
      "last_update": "2025-09-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04598009",
      "title": "Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-08-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04741997",
      "title": "Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-03-02",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04903119",
      "title": "Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-02-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04913285",
      "title": "A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-09-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05026983",
      "title": "Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases",
      "status": "RECRUITING",
      "last_update": "2026-04-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06229340",
      "title": "Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations",
      "status": "RECRUITING",
      "last_update": "2024-01-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06887088",
      "title": "Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain Metastases",
      "status": "RECRUITING",
      "last_update": "2025-10-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01320085",
      "title": "A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma",
      "status": "COMPLETED",
      "last_update": "2024-01-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01562899",
      "title": "A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2020-12-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01763164",
      "title": "Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma",
      "status": "COMPLETED",
      "last_update": "2021-03-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01781572",
      "title": "A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma",
      "status": "COMPLETED",
      "last_update": "2020-12-07",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01801358",
      "title": "A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma",
      "status": "TERMINATED",
      "last_update": "2020-09-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01820364",
      "title": "LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma",
      "status": "TERMINATED",
      "last_update": "2017-01-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01909453",
      "title": "Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma",
      "status": "COMPLETED",
      "last_update": "2026-02-27",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02159066",
      "title": "LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma",
      "status": "COMPLETED",
      "last_update": "2024-03-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02263898",
      "title": "Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations",
      "status": "WITHDRAWN",
      "last_update": "2020-07-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02382549",
      "title": "A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib",
      "status": "TERMINATED",
      "last_update": "2023-12-12",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02465060",
      "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02631447",
      "title": "Sequential Combo Immuno and Target Therapy (SECOMBIT) Study",
      "status": "COMPLETED",
      "last_update": "2024-06-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02902042",
      "title": "Encorafenib + Binimetinib + Pembrolizumab in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma",
      "status": "COMPLETED",
      "last_update": "2021-02-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02910700",
      "title": "Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03026517",
      "title": "Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma",
      "status": "COMPLETED",
      "last_update": "2025-01-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03235245",
      "title": "Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-08-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03543969",
      "title": "Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-05",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03864042",
      "title": "Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2024-09-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03878719",
      "title": "Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma",
      "status": "TERMINATED",
      "last_update": "2023-04-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03898908",
      "title": "Encorafenib and Binimetinib Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Brain",
      "status": "COMPLETED",
      "last_update": "2025-05-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03911869",
      "title": "An Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-mutant Melanoma Brain Metastasis",
      "status": "TERMINATED",
      "last_update": "2023-05-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04074096",
      "title": "Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04221438",
      "title": "Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement",
      "status": "TERMINATED",
      "last_update": "2026-08-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04375527",
      "title": "Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma",
      "status": "TERMINATED",
      "last_update": "2024-12-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04439344",
      "title": "Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04543188",
      "title": "A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement",
      "status": "TERMINATED",
      "last_update": "2025-10-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04655157",
      "title": "Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimuma",
      "status": "TERMINATED",
      "last_update": "2024-05-23",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04657991",
      "title": "A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-03",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04720768",
      "title": "Encorafenib, Binimetinib and Palbociclib in BRAF-mutant Metastatic Melanoma CELEBRATE",
      "status": "UNKNOWN",
      "last_update": "2024-01-05",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04759846",
      "title": "Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma",
      "status": "WITHDRAWN",
      "last_update": "2023-02-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05097378",
      "title": "Perioperative Encobini in BRAFV600 Mutant Stage III (B/C/D) or Oligometastatic Stage IV Melanoma",
      "status": "UNKNOWN",
      "last_update": "2021-10-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05103891",
      "title": "Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations",
      "status": "UNKNOWN",
      "last_update": "2021-12-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05170334",
      "title": "Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05270044",
      "title": "Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2023-11-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05304546",
      "title": "Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2025-07-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05340621",
      "title": "NAUTILUS: OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)",
      "status": "COMPLETED",
      "last_update": "2025-03-07",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05355701",
      "title": "A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05370807",
      "title": "A Clinical Trial of Regorafenib in Patients With Pretreated Advanced Melanoma",
      "status": "UNKNOWN",
      "last_update": "2023-10-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05767879",
      "title": "(Neo)Adjuvant BRAF/MEK Inhibition in pN1c Melanoma",
      "status": "UNKNOWN",
      "last_update": "2023-03-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05810740",
      "title": "Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations",
      "status": "COMPLETED",
      "last_update": "2024-09-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05926960",
      "title": "A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma",
      "status": "TERMINATED",
      "last_update": "2026-03-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06470880",
      "title": "Circulating Tumour DNA Guided Adaptive BRAF and MEK Inhibitor Therapy",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2024-06-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07092410",
      "title": "Surgical or Radiotherapeutic Intervention Concerning Large Singular Stable to Progressive Metastases in Patients With BRAFV600-mutated Melanoma Receiving Treatment With Encorafenib + Binimetinib",
      "status": "WITHDRAWN",
      "last_update": "2026-04-21",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "BUDIGALIMAB": {
    "n": 2,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02988960",
      "title": "A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03071757",
      "title": "A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2022-04-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "CADONILIMAB": {
    "n": 5,
    "n_observational": 0,
    "n_active": 5,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT06889610",
      "title": "A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors.",
      "status": "RECRUITING",
      "last_update": "2026-07-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07586904",
      "title": "Efficacy and Safety of Neoadjuvant Cadonilimab Plus High-Dose Recombinant Human Interferon \u03b11b in Stage III/IV Melanoma.",
      "status": "RECRUITING",
      "last_update": "2026-05-14",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06327698",
      "title": "Cadonilimab in Combination With Anlotinib in the Treatment of Locally Progressive or Metastatic Melanoma With First-Line Therapy Failure",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2024-03-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06424626",
      "title": "A Trial of AK104 or AK112 in Combination With Axitinib in Patients With Metastatic Mucosal Melanoma",
      "status": "ENROLLING_BY_INVITATION",
      "last_update": "2026-07-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06553781",
      "title": "A Single-arm, Multicenter Clinical Study of Fruquintinib Combined With Cadonilimab Injection and Temozolomide in Second-line and Subsequent Treatment of Advanced Melanoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2024-08-14",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "CAMRELIZUMAB": {
    "n": 11,
    "n_observational": 0,
    "n_active": 3,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT05512481",
      "title": "Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma",
      "status": "RECRUITING",
      "last_update": "2025-03-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05789043",
      "title": "Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma",
      "status": "RECRUITING",
      "last_update": "2023-09-06",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05983237",
      "title": "Fluzoparib in Combination With Camrelizumab and Temozolomide in Advanced Melanoma",
      "status": "RECRUITING",
      "last_update": "2025-03-05",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02738489",
      "title": "A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 in Patients With Advanced Melanoma",
      "status": "COMPLETED",
      "last_update": "2023-02-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03955354",
      "title": "PD-1 Antibody SHR-1210 Combined With Apatinib of First-line Treatment of Advanced Acral Melanoma",
      "status": "UNKNOWN",
      "last_update": "2019-05-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03986515",
      "title": "Apatinib Plus SHR1210 in Advanced Mucosal Melanoma",
      "status": "UNKNOWN",
      "last_update": "2019-06-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04397770",
      "title": "Camrelizumab Plus Apatinib and Temozolomide as First Line Therapy in Advanced Acral Melanoma",
      "status": "UNKNOWN",
      "last_update": "2020-05-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04593485",
      "title": "Anti-PD-1 Antibody in the Treatment of Patients With Malignant Melanoma of the Female Genital Tract",
      "status": "UNKNOWN",
      "last_update": "2020-12-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04979585",
      "title": "Camrelizumab Plus Amlotinib and Chemotherapy in the First-line Treatment of Melanoma",
      "status": "UNKNOWN",
      "last_update": "2021-08-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05051865",
      "title": "To Explore the Efficacy and Safety of Camrelizumab Combined With SHR1020 in the Treatment of Advanced Melanoma",
      "status": "UNKNOWN",
      "last_update": "2022-11-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05664139",
      "title": "Recombinant Human Adenovirus Type 5 Injection Combined With PD-1 Monoclonal Antibody and Nab-paclitaxel in the Treatment of Patients With Liver Metastases From Malignant Melanoma",
      "status": "UNKNOWN",
      "last_update": "2023-02-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "CATEQUENTINIB": {
    "n": 5,
    "n_observational": 0,
    "n_active": 2,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT03991975",
      "title": "Study of TQB2450 Combined With Anlotinib in Subjects With Advanced Acral Malignant Melanoma",
      "status": "UNKNOWN",
      "last_update": "2019-10-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04979585",
      "title": "Camrelizumab Plus Amlotinib and Chemotherapy in the First-line Treatment of Melanoma",
      "status": "UNKNOWN",
      "last_update": "2021-08-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05087602",
      "title": "Toripalimab Combined With Anlotinib in Unresectable Locally Advanced or Metastatic Acral Malignant Melanoma",
      "status": "UNKNOWN",
      "last_update": "2021-10-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05539118",
      "title": "Interferon-\u03b11b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable Melanoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2022-09-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06327698",
      "title": "Cadonilimab in Combination With Anlotinib in the Treatment of Locally Progressive or Metastatic Melanoma With First-Line Therapy Failure",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2024-03-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "CEDIRANIB": {
    "n": 5,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT00243061",
      "title": "AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma",
      "status": "COMPLETED",
      "last_update": "2018-08-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00937482",
      "title": "Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer",
      "status": "TERMINATED",
      "last_update": "2013-03-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01131234",
      "title": "Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2014-12-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01364051",
      "title": "Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04184518",
      "title": "Durvalumab (MEDI4736) Plus Cediranib in Patients With Metastatic Uveal Melanoma",
      "status": "WITHDRAWN",
      "last_update": "2020-06-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "CEMIPLIMAB": {
    "n": 29,
    "n_observational": 1,
    "n_active": 18,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT06022029",
      "title": "A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.",
      "status": "RECRUITING",
      "last_update": "2025-12-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06090266",
      "title": "A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents",
      "status": "RECRUITING",
      "last_update": "2025-01-07",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06121180",
      "title": "Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma",
      "status": "RECRUITING",
      "last_update": "2025-12-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06246916",
      "title": "A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)",
      "status": "RECRUITING",
      "last_update": "2026-08-19",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06413680",
      "title": "A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body",
      "status": "RECRUITING",
      "last_update": "2026-04-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06585410",
      "title": "Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-08-17",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06594991",
      "title": "A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-05-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06887088",
      "title": "Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain Metastases",
      "status": "RECRUITING",
      "last_update": "2025-10-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02423863",
      "title": "In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol\u00ae",
      "status": "COMPLETED",
      "last_update": "2020-12-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03002376",
      "title": "An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Melanoma Patients Receiving REGN2810 (Anti-PD-1)",
      "status": "COMPLETED",
      "last_update": "2020-04-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03684785",
      "title": "Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2022-04-07",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04157985",
      "title": "Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2025-12-11",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04291105",
      "title": "Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04526899",
      "title": "A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of Treatment",
      "status": "COMPLETED",
      "last_update": "2026-01-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04913220",
      "title": "A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201)",
      "status": "TERMINATED",
      "last_update": "2026-02-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05094804",
      "title": "A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents",
      "status": "UNKNOWN",
      "last_update": "2023-11-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05259696",
      "title": "Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)",
      "status": "COMPLETED",
      "last_update": "2025-08-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05352672",
      "title": "Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05358938",
      "title": "Exercise to Boost Response to Checkpoint Blockade Immunotherapy",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-06",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05429866",
      "title": "Immunological Variables Associated to ICI Toxicity in Cancer Patients",
      "status": "UNKNOWN",
      "last_update": "2023-03-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05608291",
      "title": "A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-06",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05864144",
      "title": "A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2026-09-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05878288",
      "title": "Deep sequencIng in Cutaneous Squamous CEll caRciNomas",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-11-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06052852",
      "title": "Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies",
      "status": "TERMINATED",
      "last_update": "2025-11-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06190951",
      "title": "A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06848088",
      "title": "A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment",
      "status": "ENROLLING_BY_INVITATION",
      "last_update": "2026-07-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07511036",
      "title": "PROSECCO: A Phase 2, Single Arm, Neoadjuvant Study Evaluating Combination Cemiplimab, Fianlimab, And Ipilimumab In Patients With Surgically Resectable Melanoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-04-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07527325",
      "title": "Fianlimab&Cemiplimab as TotalNeoadj The (TNT) ForMelanoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07808515",
      "title": "A Study Comparing Cemiplimab-based Treatments for Adult Participants With Locally Advanced Basal Cell Skin Cancer (laBCC)",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "CM-082": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT03602547",
      "title": "Study of the Combination of CM082 With JS001 in Patients With Advanced Mucosal Melanoma.",
      "status": "UNKNOWN",
      "last_update": "2019-07-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "COBIMETINIB": {
    "n": 42,
    "n_observational": 4,
    "n_active": 7,
    "n_withdrawn": 3,
    "trials": [
     {
      "nct": "NCT05768178",
      "title": "DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.",
      "status": "RECRUITING",
      "last_update": "2025-11-24",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06229340",
      "title": "Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations",
      "status": "RECRUITING",
      "last_update": "2024-01-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07449754",
      "title": "Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-03-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01271803",
      "title": "A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2019-07-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01495988",
      "title": "Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma",
      "status": "TERMINATED",
      "last_update": "2017-10-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01656642",
      "title": "A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2020-07-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01689519",
      "title": "A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2022-05-02",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01813214",
      "title": "The Effects of Vemurafenib + Cobimetinib on Immunity in Patients With Melanoma",
      "status": "TERMINATED",
      "last_update": "2019-02-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01843738",
      "title": "Radiation Use During Vemurafenib Treatment",
      "status": "WITHDRAWN",
      "last_update": "2017-05-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01876641",
      "title": "Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib",
      "status": "TERMINATED",
      "last_update": "2018-09-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01959633",
      "title": "Vemurafenib Plus Cobimetinib Plus PEG-interferon in Advanced Melanoma Patients Harboring the V600BRAF Mutation",
      "status": "COMPLETED",
      "last_update": "2022-02-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02036086",
      "title": "Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases",
      "status": "UNKNOWN",
      "last_update": "2022-10-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02230306",
      "title": "Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases",
      "status": "TERMINATED",
      "last_update": "2017-10-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02303951",
      "title": "Neoadjuvant Vemurafenib + Cobimetinib + Atezolizumab in Melanoma: NEO-VC",
      "status": "TERMINATED",
      "last_update": "2021-02-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02382549",
      "title": "A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib",
      "status": "TERMINATED",
      "last_update": "2023-12-12",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02414750",
      "title": "Vemurafenib Plus Cobimetinib in Metastatic Melanoma",
      "status": "TERMINATED",
      "last_update": "2022-11-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02427893",
      "title": "Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma",
      "status": "WITHDRAWN",
      "last_update": "2016-11-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02457793",
      "title": "A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2018-11-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02537600",
      "title": "Vemurafenib and Cobimetinib Combination in BRAF Mutated Melanoma With Brain Metastasis",
      "status": "COMPLETED",
      "last_update": "2020-01-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02583516",
      "title": "Clinical Trial to Evaluate the Efficacy of Vemurafenib in Combination With Cobimetinib (Continuous and Intermittent) in BRAFV600-mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2020-02-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02721459",
      "title": "XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02768207",
      "title": "A Study to Detect V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) V600 Mutation on Cell-Free Deoxyribonucleic Acid (cfDNA) From Plasma in Participants With Advanced Melanoma",
      "status": "COMPLETED",
      "last_update": "2019-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02818023",
      "title": "Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced Melanoma",
      "status": "TERMINATED",
      "last_update": "2022-01-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02902029",
      "title": "Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma",
      "status": "COMPLETED",
      "last_update": "2025-04-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02908672",
      "title": "A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma",
      "status": "COMPLETED",
      "last_update": "2025-07-20",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02968303",
      "title": "Induction Therapy With Vemurafenib and Cobimetinib to Optimize Nivolumab and Ipilimumab Therapy",
      "status": "UNKNOWN",
      "last_update": "2020-06-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03005639",
      "title": "ML29255 Neoadjuvant Vemurafenib and Cobimetinib Melanoma",
      "status": "WITHDRAWN",
      "last_update": "2018-05-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03026517",
      "title": "Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma",
      "status": "COMPLETED",
      "last_update": "2025-01-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03101254",
      "title": "LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma",
      "status": "COMPLETED",
      "last_update": "2024-07-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03175432",
      "title": "Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03178851",
      "title": "Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma",
      "status": "COMPLETED",
      "last_update": "2021-11-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03224208",
      "title": "Vemurafenib Plus Cobimetinib in Advanced or Metastatic Melanoma Patients",
      "status": "TERMINATED",
      "last_update": "2021-04-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03273153",
      "title": "A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma",
      "status": "TERMINATED",
      "last_update": "2022-09-21",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03430947",
      "title": "Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain Metastases",
      "status": "TERMINATED",
      "last_update": "2023-09-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03514901",
      "title": "To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib.",
      "status": "UNKNOWN",
      "last_update": "2021-12-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03554083",
      "title": "Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma",
      "status": "COMPLETED",
      "last_update": "2026-05-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03625141",
      "title": "A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System Metastases",
      "status": "COMPLETED",
      "last_update": "2024-04-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04109456",
      "title": "IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2026-01-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04190628",
      "title": "Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2024-05-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04722575",
      "title": "Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04835805",
      "title": "A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05756556",
      "title": "T3011 in Combination With Cobimetinib in Patients With Advanced Melanoma",
      "status": "SUSPENDED",
      "last_update": "2024-02-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "DABRAFENIB": {
    "n": 80,
    "n_observational": 23,
    "n_active": 16,
    "n_withdrawn": 6,
    "trials": [
     {
      "nct": "NCT03340506",
      "title": "Dabrafenib and/or Trametinib Rollover Study",
      "status": "RECRUITING",
      "last_update": "2026-09-04",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03563729",
      "title": "Melanoma Metastasized to the Brain and Steroids",
      "status": "RECRUITING",
      "last_update": "2023-07-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04903119",
      "title": "Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-02-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07440290",
      "title": "DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.",
      "status": "RECRUITING",
      "last_update": "2026-08-17",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01072175",
      "title": "Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212",
      "status": "COMPLETED",
      "last_update": "2019-07-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01153763",
      "title": "A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2017-09-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01227889",
      "title": "A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma",
      "status": "COMPLETED",
      "last_update": "2017-10-04",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01266967",
      "title": "A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma to the Brain",
      "status": "COMPLETED",
      "last_update": "2014-05-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01512251",
      "title": "BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma",
      "status": "COMPLETED",
      "last_update": "2020-08-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01519427",
      "title": "Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib",
      "status": "TERMINATED",
      "last_update": "2014-06-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01584648",
      "title": "A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma",
      "status": "COMPLETED",
      "last_update": "2021-02-17",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01597908",
      "title": "Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma",
      "status": "COMPLETED",
      "last_update": "2021-02-24",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01619774",
      "title": "An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor",
      "status": "COMPLETED",
      "last_update": "2016-12-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01682083",
      "title": "Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD).",
      "status": "COMPLETED",
      "last_update": "2026-04-21",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01682213",
      "title": "Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation",
      "status": "COMPLETED",
      "last_update": "2020-05-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01701037",
      "title": "Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery",
      "status": "TERMINATED",
      "last_update": "2017-06-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01721603",
      "title": "Dabrafenib and Trametinib With Radiosurgery in Melanoma Brain Mets",
      "status": "TERMINATED",
      "last_update": "2018-01-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01726738",
      "title": "LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations",
      "status": "COMPLETED",
      "last_update": "2020-11-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01767454",
      "title": "Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma",
      "status": "COMPLETED",
      "last_update": "2017-11-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01902173",
      "title": "Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer",
      "status": "COMPLETED",
      "last_update": "2025-01-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01928940",
      "title": "Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part)",
      "status": "COMPLETED",
      "last_update": "2017-07-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01940809",
      "title": "Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery",
      "status": "TERMINATED",
      "last_update": "2022-03-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01954043",
      "title": "A Pharmacokinetics (PK) Study of the Effects Rabeprazole and Rifampin on Dabrafenib in Subjects With BRAF V600 Mutation Positive Tumors",
      "status": "COMPLETED",
      "last_update": "2017-11-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01972347",
      "title": "Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma",
      "status": "COMPLETED",
      "last_update": "2026-06-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01978236",
      "title": "Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites",
      "status": "TERMINATED",
      "last_update": "2018-08-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01989585",
      "title": "Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02027961",
      "title": "Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone",
      "status": "COMPLETED",
      "last_update": "2019-05-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02039947",
      "title": "Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain",
      "status": "COMPLETED",
      "last_update": "2019-05-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02052193",
      "title": "Evaluation of Photosensitivity in Dabrafenib or Vemurafenib Treated Metastatic Melanoma Patients - a Phase IIa/IIb Study",
      "status": "TERMINATED",
      "last_update": "2022-12-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02082665",
      "title": "Effects of Dabrafenib on the Single Dose Pharmacokinetics (PK) of Rosuvastatin and Midazolam",
      "status": "COMPLETED",
      "last_update": "2017-07-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02083354",
      "title": "Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma",
      "status": "COMPLETED",
      "last_update": "2022-02-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02097225",
      "title": "Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery",
      "status": "TERMINATED",
      "last_update": "2024-10-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02110355",
      "title": "A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2021-03-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02130466",
      "title": "A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022)",
      "status": "COMPLETED",
      "last_update": "2022-08-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02143050",
      "title": "Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients",
      "status": "WITHDRAWN",
      "last_update": "2023-11-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02196181",
      "title": "Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has Spread",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02200562",
      "title": "Ipilimumab and Dabrafenib in the 1st Line Tx of Unresectable Stage III/IV Melanoma",
      "status": "TERMINATED",
      "last_update": "2017-03-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02224781",
      "title": "Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02231775",
      "title": "Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02257424",
      "title": "Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma",
      "status": "COMPLETED",
      "last_update": "2022-01-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02296996",
      "title": "Dabrafenib and Trametinib for BRAF-inhibitor Pretreated Patients",
      "status": "COMPLETED",
      "last_update": "2019-01-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02314143",
      "title": "Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib",
      "status": "TERMINATED",
      "last_update": "2019-02-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02357732",
      "title": "Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib",
      "status": "WITHDRAWN",
      "last_update": "2015-12-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02382549",
      "title": "A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib",
      "status": "TERMINATED",
      "last_update": "2023-12-12",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02392871",
      "title": "Radiotherapy & Combi in Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2024-11-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02410863",
      "title": "Biopsy- and Biology-driven Optimization of Targeted Therapy in Subjects With Advanced Melanoma",
      "status": "TERMINATED",
      "last_update": "2020-10-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02447939",
      "title": "Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With Melanoma",
      "status": "WITHDRAWN",
      "last_update": "2018-09-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02465060",
      "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02625337",
      "title": "Study Comparing Pembrolizumab With Dual MAPK Pathway Inhibition Plus Pembrolizumab in Melanoma Patients",
      "status": "UNKNOWN",
      "last_update": "2017-09-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02700763",
      "title": "[18F]Dabrafenib Molecular Imaging in Melanoma Brain Metastasis",
      "status": "TERMINATED",
      "last_update": "2024-05-06",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02858921",
      "title": "Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02872259",
      "title": "BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2025-01-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02910700",
      "title": "Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02915666",
      "title": "A Clinical Trial of Patients With Melanoma",
      "status": "WITHDRAWN",
      "last_update": "2018-05-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02967692",
      "title": "A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma",
      "status": "TERMINATED",
      "last_update": "2025-09-18",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02974803",
      "title": "Concurrent Dabrafenib + Trametinib With Sterotactic Radiation in BRAF Mutation-Positive Malignant Melanoma and Brain Metastases",
      "status": "TERMINATED",
      "last_update": "2021-08-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03026517",
      "title": "Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma",
      "status": "COMPLETED",
      "last_update": "2025-01-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03088176",
      "title": "Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma",
      "status": "UNKNOWN",
      "last_update": "2020-10-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03149029",
      "title": "Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03272464",
      "title": "INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.",
      "status": "TERMINATED",
      "last_update": "2023-09-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03332589",
      "title": "E6201 Plus Dabrafenib for the Treatment of Metastatic Melanoma Central Nervous System Metastases (CNS)",
      "status": "TERMINATED",
      "last_update": "2022-05-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03352947",
      "title": "Continuous vs Intermittent Dabrafenib Plus Trametinib in BRAFV600 Mutant Stage 3 Unresectable or Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2020-12-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03391050",
      "title": "A Study of APR-246 in Combination With Dabrafenib in Resistant Patients With BRAF V600 Mutant Melanoma",
      "status": "TERMINATED",
      "last_update": "2019-07-31",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03455764",
      "title": "MCS110 With BRAF/MEK Inhibition in Patients With Melanoma",
      "status": "COMPLETED",
      "last_update": "2024-07-31",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03551626",
      "title": "Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes",
      "status": "COMPLETED",
      "last_update": "2025-04-29",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03754179",
      "title": "Dabrafenib/Trametinib/Hydroxychloroquine for Advanced Pretreated BRAF V600 Mutant Melanoma",
      "status": "UNKNOWN",
      "last_update": "2021-04-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03808441",
      "title": "CAcTUS - Circulating Tumour DNA Guided Switch",
      "status": "UNKNOWN",
      "last_update": "2023-08-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03972046",
      "title": "Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma",
      "status": "WITHDRAWN",
      "last_update": "2020-10-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04059224",
      "title": "TraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type Melanoma",
      "status": "COMPLETED",
      "last_update": "2023-09-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04310397",
      "title": "Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma",
      "status": "TERMINATED",
      "last_update": "2024-10-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04418167",
      "title": "JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations",
      "status": "SUSPENDED",
      "last_update": "2025-09-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04439292",
      "title": "Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04527549",
      "title": "Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma",
      "status": "TERMINATED",
      "last_update": "2026-08-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04557956",
      "title": "Testing the Addition of the Anti-cancer Drug, Tazemetostat, to (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04652258",
      "title": "Pyrexia Management Using an IL-6 Antibody in BRAF+ Melanoma Patients Treated with Dabrafenib/ Trametinib +/- Immunotherapy",
      "status": "TERMINATED",
      "last_update": "2024-11-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04949113",
      "title": "Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-03-08",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05299580",
      "title": "\"Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)\"",
      "status": "WITHDRAWN",
      "last_update": "2023-09-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05370807",
      "title": "A Clinical Trial of Regorafenib in Patients With Pretreated Advanced Melanoma",
      "status": "UNKNOWN",
      "last_update": "2023-10-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05388877",
      "title": "E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma",
      "status": "TERMINATED",
      "last_update": "2025-08-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05585320",
      "title": "A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "DASATINIB": {
    "n": 7,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00436605",
      "title": "Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma",
      "status": "COMPLETED",
      "last_update": "2014-05-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00597038",
      "title": "A Phase I/II Study of Dasatinib and Dacarbazine",
      "status": "COMPLETED",
      "last_update": "2013-12-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00700882",
      "title": "Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery",
      "status": "COMPLETED",
      "last_update": "2023-07-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01092728",
      "title": "Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma",
      "status": "TERMINATED",
      "last_update": "2016-09-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01876212",
      "title": "Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2019-08-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01916135",
      "title": "PET Imaging of Cancer Patients Using [18F]-SKI-249380, a Radiolabeled Dasatinib-Derivative",
      "status": "COMPLETED",
      "last_update": "2020-04-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02465060",
      "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "DOSTARLIMAB": {
    "n": 4,
    "n_observational": 0,
    "n_active": 3,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02817633",
      "title": "A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-10-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04139902",
      "title": "Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-10-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05060432",
      "title": "Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors",
      "status": "UNKNOWN",
      "last_update": "2024-06-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06521567",
      "title": "A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-11-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "DOVITINIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT01831726",
      "title": "Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib",
      "status": "COMPLETED",
      "last_update": "2017-03-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "E-6201": {
    "n": 2,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT03332589",
      "title": "E6201 Plus Dabrafenib for the Treatment of Metastatic Melanoma Central Nervous System Metastases (CNS)",
      "status": "TERMINATED",
      "last_update": "2022-05-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05388877",
      "title": "E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma",
      "status": "TERMINATED",
      "last_update": "2025-08-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "EFTILAGIMOD ALFA": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02676869",
      "title": "Phase 1 Study of IMP321 (Eftilagimod Alpha) Adjuvant to Anti-PD-1 Therapy in Unresectable or Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2019-12-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "ENCORAFENIB": {
    "n": 42,
    "n_observational": 10,
    "n_active": 14,
    "n_withdrawn": 3,
    "trials": [
     {
      "nct": "NCT03563729",
      "title": "Melanoma Metastasized to the Brain and Steroids",
      "status": "RECRUITING",
      "last_update": "2023-07-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04511013",
      "title": "A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases",
      "status": "RECRUITING",
      "last_update": "2025-09-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04741997",
      "title": "Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-03-02",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04903119",
      "title": "Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-02-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05026983",
      "title": "Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases",
      "status": "RECRUITING",
      "last_update": "2026-04-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06194929",
      "title": "Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma",
      "status": "RECRUITING",
      "last_update": "2025-12-03",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06887088",
      "title": "Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain Metastases",
      "status": "RECRUITING",
      "last_update": "2025-10-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01436656",
      "title": "A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma",
      "status": "COMPLETED",
      "last_update": "2024-10-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01519427",
      "title": "Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib",
      "status": "TERMINATED",
      "last_update": "2014-06-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01777776",
      "title": "Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.",
      "status": "TERMINATED",
      "last_update": "2016-09-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01820364",
      "title": "LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma",
      "status": "TERMINATED",
      "last_update": "2017-01-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01894672",
      "title": "BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation",
      "status": "COMPLETED",
      "last_update": "2024-07-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01909453",
      "title": "Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma",
      "status": "COMPLETED",
      "last_update": "2026-02-27",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02159066",
      "title": "LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma",
      "status": "COMPLETED",
      "last_update": "2024-03-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02263898",
      "title": "Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations",
      "status": "WITHDRAWN",
      "last_update": "2020-07-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02382549",
      "title": "A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib",
      "status": "TERMINATED",
      "last_update": "2023-12-12",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02631447",
      "title": "Sequential Combo Immuno and Target Therapy (SECOMBIT) Study",
      "status": "COMPLETED",
      "last_update": "2024-06-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02857270",
      "title": "A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer",
      "status": "COMPLETED",
      "last_update": "2022-11-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02902042",
      "title": "Encorafenib + Binimetinib + Pembrolizumab in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma",
      "status": "COMPLETED",
      "last_update": "2021-02-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02910700",
      "title": "Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03026517",
      "title": "Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma",
      "status": "COMPLETED",
      "last_update": "2025-01-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03235245",
      "title": "Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-08-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03543969",
      "title": "Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-05",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03864042",
      "title": "Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2024-09-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03878719",
      "title": "Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma",
      "status": "TERMINATED",
      "last_update": "2023-04-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03898908",
      "title": "Encorafenib and Binimetinib Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Brain",
      "status": "COMPLETED",
      "last_update": "2025-05-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03911869",
      "title": "An Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-mutant Melanoma Brain Metastasis",
      "status": "TERMINATED",
      "last_update": "2023-05-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04074096",
      "title": "Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04221438",
      "title": "Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement",
      "status": "TERMINATED",
      "last_update": "2026-08-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04655157",
      "title": "Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimuma",
      "status": "TERMINATED",
      "last_update": "2024-05-23",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04657991",
      "title": "A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-03",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04720768",
      "title": "Encorafenib, Binimetinib and Palbociclib in BRAF-mutant Metastatic Melanoma CELEBRATE",
      "status": "UNKNOWN",
      "last_update": "2024-01-05",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04759846",
      "title": "Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma",
      "status": "WITHDRAWN",
      "last_update": "2023-02-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05003622",
      "title": "Phase 1 Safety Study of Encorafenib in Chinese Patients With Advanced Metastatic BRAF V600E Mutant Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2024-06-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05097378",
      "title": "Perioperative Encobini in BRAFV600 Mutant Stage III (B/C/D) or Oligometastatic Stage IV Melanoma",
      "status": "UNKNOWN",
      "last_update": "2021-10-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05270044",
      "title": "Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2023-11-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05304546",
      "title": "Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2025-07-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05370807",
      "title": "A Clinical Trial of Regorafenib in Patients With Pretreated Advanced Melanoma",
      "status": "UNKNOWN",
      "last_update": "2023-10-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05767879",
      "title": "(Neo)Adjuvant BRAF/MEK Inhibition in pN1c Melanoma",
      "status": "UNKNOWN",
      "last_update": "2023-03-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05926960",
      "title": "A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma",
      "status": "TERMINATED",
      "last_update": "2026-03-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06470880",
      "title": "Circulating Tumour DNA Guided Adaptive BRAF and MEK Inhibitor Therapy",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2024-06-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07092410",
      "title": "Surgical or Radiotherapeutic Intervention Concerning Large Singular Stable to Progressive Metastases in Patients With BRAFV600-mutated Melanoma Receiving Treatment With Encorafenib + Binimetinib",
      "status": "WITHDRAWN",
      "last_update": "2026-04-21",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "FAMITINIB": {
    "n": 2,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT05051865",
      "title": "To Explore the Efficacy and Safety of Camrelizumab Combined With SHR1020 in the Treatment of Advanced Melanoma",
      "status": "UNKNOWN",
      "last_update": "2022-11-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07517653",
      "title": "Neoadjuvant SHR-1701 Plus Famitinib With Response-guided Adjuvant Therapy in Resectable Mucosal Melanoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-04-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "FAVEZELIMAB": {
    "n": 2,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04303169",
      "title": "Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)",
      "status": "COMPLETED",
      "last_update": "2026-08-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04305054",
      "title": "Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)",
      "status": "COMPLETED",
      "last_update": "2026-05-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "FIANLIMAB": {
    "n": 10,
    "n_observational": 1,
    "n_active": 10,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT06246916",
      "title": "A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)",
      "status": "RECRUITING",
      "last_update": "2026-08-19",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06594991",
      "title": "A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-05-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06887088",
      "title": "Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain Metastases",
      "status": "RECRUITING",
      "last_update": "2025-10-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05352672",
      "title": "Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05608291",
      "title": "A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-06",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06190951",
      "title": "A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06848088",
      "title": "A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment",
      "status": "ENROLLING_BY_INVITATION",
      "last_update": "2026-07-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07511036",
      "title": "PROSECCO: A Phase 2, Single Arm, Neoadjuvant Study Evaluating Combination Cemiplimab, Fianlimab, And Ipilimumab In Patients With Surgically Resectable Melanoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-04-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07527325",
      "title": "Fianlimab&Cemiplimab as TotalNeoadj The (TNT) ForMelanoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07808515",
      "title": "A Study Comparing Cemiplimab-based Treatments for Adult Participants With Locally Advanced Basal Cell Skin Cancer (laBCC)",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "IERAMILIMAB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT03484923",
      "title": "Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2024-06-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "IMATINIB": {
    "n": 16,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT04598009",
      "title": "Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-08-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00027586",
      "title": "Imatinib Mesylate in Treating Patients With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2018-10-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00074308",
      "title": "Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers",
      "status": "COMPLETED",
      "last_update": "2018-06-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00154388",
      "title": "Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases",
      "status": "COMPLETED",
      "last_update": "2016-11-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00402662",
      "title": "A Study of Everolimus in Combination With Imatinib in Metastatic Melanoma",
      "status": "TERMINATED",
      "last_update": "2013-12-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00421317",
      "title": "Imatinib in Adult Patients With Metastatic Ocular Melanoma",
      "status": "TERMINATED",
      "last_update": "2026-03-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00424515",
      "title": "Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma",
      "status": "COMPLETED",
      "last_update": "2016-12-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00470470",
      "title": "Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery",
      "status": "COMPLETED",
      "last_update": "2014-12-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00667953",
      "title": "Study of Temzolomide and Gleevec in Advanced Melanoma",
      "status": "TERMINATED",
      "last_update": "2023-03-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00881049",
      "title": "Trial of Imatinib (Gleevec\u00ae) in Selected Patients With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2011-01-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01046487",
      "title": "Imatinib Mesylate And Cyclophosphamide In Metronomic Administration: Dose Escalation Study Of Imatinib Mesylate",
      "status": "COMPLETED",
      "last_update": "2026-03-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01738139",
      "title": "Ipilimumab and Imatinib Mesylate in Advanced Cancer",
      "status": "COMPLETED",
      "last_update": "2024-03-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01782508",
      "title": "A Phase II Study of Imatinib Versus Interferon as Adjuvant Therapy in KIT-mutated Melanoma",
      "status": "UNKNOWN",
      "last_update": "2013-02-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02812693",
      "title": "Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplification",
      "status": "WITHDRAWN",
      "last_update": "2018-04-05",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04546074",
      "title": "Imatinib Mesylate in Combination With Pembrolizumab in Patients With Melanoma",
      "status": "UNKNOWN",
      "last_update": "2023-10-03",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05274438",
      "title": "Imatinib and Toripalimab in Patients With Locally Advanced/Metastatic Melanoma Harbored With CKIT Mut",
      "status": "UNKNOWN",
      "last_update": "2022-03-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "IPILIMUMAB": {
    "n": 176,
    "n_observational": 24,
    "n_active": 40,
    "n_withdrawn": 6,
    "trials": [
     {
      "nct": "NCT03340129",
      "title": "Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)",
      "status": "RECRUITING",
      "last_update": "2026-02-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03563729",
      "title": "Melanoma Metastasized to the Brain and Steroids",
      "status": "RECRUITING",
      "last_update": "2023-07-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04511013",
      "title": "A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases",
      "status": "RECRUITING",
      "last_update": "2025-09-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04605146",
      "title": "Impact of Telemonitoring for the Management of Side Effects in Patients with Melanoma, Lung or Renal Cancer, Treated with Immunotherapy Combination of Nivolumab and Ipilimumab or Adjuvant Nivolumab Monotherapy",
      "status": "RECRUITING",
      "last_update": "2024-10-16",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04697576",
      "title": "Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-07-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05384496",
      "title": "Axitinib and Nivolumab for the Treatment of Mucosal Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-02-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05498792",
      "title": "Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-05-22",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05968690",
      "title": "Naltrexone and Propranolol Combined With Immunotherapy",
      "status": "RECRUITING",
      "last_update": "2025-09-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06047379",
      "title": "Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis",
      "status": "RECRUITING",
      "last_update": "2026-07-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06163820",
      "title": "Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain Metastases",
      "status": "RECRUITING",
      "last_update": "2025-05-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06240143",
      "title": "Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma",
      "status": "RECRUITING",
      "last_update": "2024-11-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06594991",
      "title": "A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-05-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06624644",
      "title": "A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-04-22",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06683755",
      "title": "Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)",
      "status": "RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06743126",
      "title": "SUPRAME-ACTengine\u00ae IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-08-18",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06880198",
      "title": "Study to Evaluate Impact\u00ae as Support to Anti PD1 or Anti PD1 Based Regimen Treatment in Patients With Inoperable Locally Advanced or Metastatic Melanoma",
      "status": "RECRUITING",
      "last_update": "2025-09-17",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07155317",
      "title": "Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial",
      "status": "RECRUITING",
      "last_update": "2025-11-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07230613",
      "title": "Neo-adjuvant Immunotherapy in Patients With Localized Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-07-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07422779",
      "title": "Immunotherapy Efficacy and PD-L1 as a Predictive Biomarker in Metastatic Melanoma in Slovenia",
      "status": "RECRUITING",
      "last_update": "2026-02-20",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07504796",
      "title": "ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab",
      "status": "RECRUITING",
      "last_update": "2026-08-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07564570",
      "title": "Physical Activity Directly Before Immunotherapy (Nivolumab and Ipilimumab) in Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-05-04",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00032045",
      "title": "Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma",
      "status": "COMPLETED",
      "last_update": "2013-06-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00039091",
      "title": "Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer",
      "status": "TERMINATED",
      "last_update": "2018-09-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00050102",
      "title": "Comparison Study of MDX-010 (CTLA-4) Alone and Combined With DTIC in the Treatment of Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2011-01-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00058279",
      "title": "Monoclonal Antibody Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2013-06-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00084656",
      "title": "Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma",
      "status": "COMPLETED",
      "last_update": "2022-04-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00135408",
      "title": "A Study of MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral Budesonide",
      "status": "COMPLETED",
      "last_update": "2016-09-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00162123",
      "title": "A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies",
      "status": "COMPLETED",
      "last_update": "2016-07-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00261365",
      "title": "Phase II Study to Determine Predictive Markers of Response to BMS-734016 (MDX-010)",
      "status": "COMPLETED",
      "last_update": "2016-09-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00289640",
      "title": "Study of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma",
      "status": "COMPLETED",
      "last_update": "2010-03-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00324155",
      "title": "Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma",
      "status": "COMPLETED",
      "last_update": "2014-11-03",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00623766",
      "title": "Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases",
      "status": "COMPLETED",
      "last_update": "2014-06-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00636168",
      "title": "Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma",
      "status": "COMPLETED",
      "last_update": "2019-12-17",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00685750",
      "title": "Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma",
      "status": "TERMINATED",
      "last_update": "2019-06-20",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00729950",
      "title": "Study of MDX-010 in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma",
      "status": "COMPLETED",
      "last_update": "2010-04-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00790010",
      "title": "Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma",
      "status": "COMPLETED",
      "last_update": "2023-05-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00803374",
      "title": "Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma",
      "status": "WITHDRAWN",
      "last_update": "2011-11-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01024231",
      "title": "Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma",
      "status": "COMPLETED",
      "last_update": "2026-08-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01119508",
      "title": "Ipilimumab + Temozolomide in Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2024-06-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01134614",
      "title": "Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01176474",
      "title": "Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma",
      "status": "COMPLETED",
      "last_update": "2023-07-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01216696",
      "title": "Ipilimumab in Patients With Advanced Melanoma and Spontaneous Preexisting Immune Response to NY-ESO-1",
      "status": "COMPLETED",
      "last_update": "2016-08-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01245556",
      "title": "Safety and Efficacy Study of BMS-908662 in Combination With Ipilimumab in Subjects With Advanced Melanoma",
      "status": "COMPLETED",
      "last_update": "2013-06-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01323517",
      "title": "Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity",
      "status": "COMPLETED",
      "last_update": "2018-05-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01363206",
      "title": "Granulocyte Macrophage-Colony Stimulating Factor and Ipilimumab as Therapy in Melanoma",
      "status": "COMPLETED",
      "last_update": "2020-03-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01449279",
      "title": "Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation Therapy",
      "status": "COMPLETED",
      "last_update": "2020-03-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01480323",
      "title": "A Phase II Study to Evaluate Safety and Efficacy of Combined Treatment With Ipilimumab and Intratumoral Interleukin-2",
      "status": "COMPLETED",
      "last_update": "2015-07-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01496807",
      "title": "Yervoy With Sylatron Unresectable Stage 3 or 4 Melanoma",
      "status": "COMPLETED",
      "last_update": "2017-04-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01515189",
      "title": "Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab",
      "status": "COMPLETED",
      "last_update": "2019-07-31",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01557114",
      "title": "Study of Radiotherapy Administered in Combination With Ipilimumab in Patients With Unresectable Stage III or Stage IV Advanced Malignant Melanoma",
      "status": "TERMINATED",
      "last_update": "2016-06-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01565837",
      "title": "Concurrent Ipilimumab and Stereotactic Ablative Radiation Therapy (SART) for Oligometastatic But Unresectable Melanoma",
      "status": "UNKNOWN",
      "last_update": "2016-02-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01585194",
      "title": "Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma",
      "status": "COMPLETED",
      "last_update": "2024-07-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01590082",
      "title": "Doxycycline, Temozolomide and Ipilimumab in Melanoma",
      "status": "TERMINATED",
      "last_update": "2020-09-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01604889",
      "title": "A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma",
      "status": "TERMINATED",
      "last_update": "2026-04-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01608594",
      "title": "Neoadjuvant Combination Therapy With Ipilimumab and HighDose IFN-\u03b12b for Melanoma",
      "status": "COMPLETED",
      "last_update": "2018-08-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01673854",
      "title": "Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma",
      "status": "COMPLETED",
      "last_update": "2018-07-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01676649",
      "title": "Ipilimumab With Carboplatin and Paclitaxel in Patients With Unresectable Stage III and Stage IV Melanoma",
      "status": "UNKNOWN",
      "last_update": "2021-02-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01681212",
      "title": "Phase 2 Study of Ipilimumab Plus Dacarbazine in Japanese Patients With Advanced Melanoma",
      "status": "COMPLETED",
      "last_update": "2015-06-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01696045",
      "title": "Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma",
      "status": "TERMINATED",
      "last_update": "2017-08-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01701674",
      "title": "Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts",
      "status": "COMPLETED",
      "last_update": "2025-12-19",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01703507",
      "title": "Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma",
      "status": "COMPLETED",
      "last_update": "2025-05-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01709162",
      "title": "Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma",
      "status": "TERMINATED",
      "last_update": "2015-11-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01715077",
      "title": "Study of Ipilimumab in the Immune System",
      "status": "COMPLETED",
      "last_update": "2018-08-13",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01740297",
      "title": "Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma",
      "status": "COMPLETED",
      "last_update": "2024-05-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01740401",
      "title": "CTLA-4 Blockade and Low Dose Cyclophosphamide in Patients With Advanced Malignant Melanoma",
      "status": "TERMINATED",
      "last_update": "2017-12-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01767454",
      "title": "Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma",
      "status": "COMPLETED",
      "last_update": "2017-11-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01789827",
      "title": "Aldesleukin Imaging in Viewing Tumor Growth in Patients With Stage IV Melanoma Receiving Ipilimumab or Pembrolizumab Therapy",
      "status": "COMPLETED",
      "last_update": "2019-08-05",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01810016",
      "title": "NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma",
      "status": "TERMINATED",
      "last_update": "2022-10-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01827111",
      "title": "Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2022-02-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01856023",
      "title": "HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma",
      "status": "TERMINATED",
      "last_update": "2023-12-05",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01927419",
      "title": "Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2022-03-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01970527",
      "title": "Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma",
      "status": "TERMINATED",
      "last_update": "2020-02-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01973608",
      "title": "MSB0010445 and Stereotactic Body Radiation Therapy in Advanced Melanoma",
      "status": "TERMINATED",
      "last_update": "2016-10-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01984255",
      "title": "A Two-arm, Single Center Phase 1b Trial of Bavituximab Plus Ipilimumab in Advanced Melanoma Patients",
      "status": "TERMINATED",
      "last_update": "2016-12-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01988077",
      "title": "Clinical Evaluation of Yervoy in Combination With Adoptive T Cell Transfer for Metastatic Melanoma Patients",
      "status": "TERMINATED",
      "last_update": "2019-04-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01990859",
      "title": "Phase 2 Study of Ipilimumab in Japanese Advanced Melanoma Patients",
      "status": "COMPLETED",
      "last_update": "2016-03-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02009384",
      "title": "Ipilimumab Administered to Stage IIIC Stage IV Melanoma After Reg. T Cell Depletion With Denileukin Diftitox",
      "status": "TERMINATED",
      "last_update": "2021-10-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02027935",
      "title": "CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2024-10-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02032810",
      "title": "Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma",
      "status": "COMPLETED",
      "last_update": "2023-01-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02054520",
      "title": "Immunotherapy Study for Patients With Stage IV Melanoma",
      "status": "TERMINATED",
      "last_update": "2023-04-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02068196",
      "title": "A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma.",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2023-03-24",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02073123",
      "title": "Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2026-05-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02077114",
      "title": "Vaccination With Peptides in Combination With Either Ipilimumab or Vemurafenib for the Treatment of Unresectable Stage III or IV Malignant Melanoma",
      "status": "COMPLETED",
      "last_update": "2014-09-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02089685",
      "title": "Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29)",
      "status": "COMPLETED",
      "last_update": "2022-09-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02107755",
      "title": "Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2024-05-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02115139",
      "title": "GEM STUDY: Radiation And Yervoy in Patients With Melanoma and Brain Metastases",
      "status": "COMPLETED",
      "last_update": "2022-11-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02115243",
      "title": "Trial of Neoadjuvant Ipilimumab Followed by Melphalan Via Isolated Limb Infusion for Patients With Unresectable In-transit Extremity Melanoma",
      "status": "COMPLETED",
      "last_update": "2018-10-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02200562",
      "title": "Ipilimumab and Dabrafenib in the 1st Line Tx of Unresectable Stage III/IV Melanoma",
      "status": "TERMINATED",
      "last_update": "2017-03-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02203604",
      "title": "High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery",
      "status": "TERMINATED",
      "last_update": "2023-07-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02259231",
      "title": "RTA 408 Capsules in Patients With Melanoma - REVEAL",
      "status": "COMPLETED",
      "last_update": "2025-06-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02304458",
      "title": "Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas",
      "status": "COMPLETED",
      "last_update": "2023-10-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02307149",
      "title": "Intratumoral CAVATAK (CVA21) and Ipilimumab in Patients With Advanced Melanoma (VLA-013 MITCI)",
      "status": "COMPLETED",
      "last_update": "2023-01-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02320058",
      "title": "An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by Itself",
      "status": "COMPLETED",
      "last_update": "2021-10-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02381314",
      "title": "Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer",
      "status": "COMPLETED",
      "last_update": "2022-02-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02388906",
      "title": "Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma",
      "status": "COMPLETED",
      "last_update": "2025-04-24",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02403778",
      "title": "Ipilimumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma",
      "status": "COMPLETED",
      "last_update": "2023-09-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02406183",
      "title": "Trial of SBRT With Concurrent Ipilimumab in Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2017-01-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02460068",
      "title": "A Study of Fotemustine(FTM) Vs FTM and Ipilimumab (IPI) or IPI and Nivolumab in Melanoma Brain Metastasis",
      "status": "UNKNOWN",
      "last_update": "2015-06-02",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02506153",
      "title": "Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02516527",
      "title": "A Phase 1 Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Ipilimumab in Chinese Subjects With Select Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2020-05-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02519322",
      "title": "Neoadjuvant and Adjuvant Checkpoint Blockade",
      "status": "COMPLETED",
      "last_update": "2024-04-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02523313",
      "title": "Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab vs. Double Placebo for Stage IV Melanoma w. NED",
      "status": "COMPLETED",
      "last_update": "2025-04-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02545075",
      "title": "A Comparative Study in Chinese Subjects With Chemotherapy Na\u00efve Stage IV Melanoma Receiving Ipilimumab (3 mg/kg) vs. Dacarbazine",
      "status": "COMPLETED",
      "last_update": "2020-05-19",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02608437",
      "title": "A Study Investigating SGI-110 in Combination With Ipilimumab in Unresectable or Metastatic Melanoma Patients",
      "status": "UNKNOWN",
      "last_update": "2015-11-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02621515",
      "title": "Nivo/Ipi Combination Therapy in Symptomatic Brain Metastases",
      "status": "TERMINATED",
      "last_update": "2024-05-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02626962",
      "title": "Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melanoma",
      "status": "COMPLETED",
      "last_update": "2022-03-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02631447",
      "title": "Sequential Combo Immuno and Target Therapy (SECOMBIT) Study",
      "status": "COMPLETED",
      "last_update": "2024-06-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02644967",
      "title": "A Phase 2 Study to Assess the Safety and Efficacy of IMO-2125 With 8 mg Ipilimumab in Patients With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2022-08-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02658890",
      "title": "An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread",
      "status": "COMPLETED",
      "last_update": "2023-08-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02659540",
      "title": "Pilot Study of the Safety/Efficacy of Combination Checkpoint Blockade + External Beam Radiotherapy in Stage IV Melanoma",
      "status": "COMPLETED",
      "last_update": "2022-10-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02700971",
      "title": "RATIO: Rational Approach To Immuno-Oncology",
      "status": "COMPLETED",
      "last_update": "2024-06-14",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02763761",
      "title": "An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo",
      "status": "WITHDRAWN",
      "last_update": "2018-10-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02857569",
      "title": "A Trial Evaluating the Safety & Efficacy of Intra-Tumoral Ipilimumab in Combination With Intra-venous Nivolumab in Patients With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2023-02-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02905266",
      "title": "A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Melanoma",
      "status": "COMPLETED",
      "last_update": "2020-12-17",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02913417",
      "title": "Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases",
      "status": "UNKNOWN",
      "last_update": "2021-04-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02941744",
      "title": "A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma Macrometastases",
      "status": "COMPLETED",
      "last_update": "2019-01-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02970981",
      "title": "Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma",
      "status": "COMPLETED",
      "last_update": "2024-04-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02977052",
      "title": "Optimal Neo-adjuvant Combination Scheme of Ipilimumab and Nivolumab",
      "status": "UNKNOWN",
      "last_update": "2023-11-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02978443",
      "title": "A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab",
      "status": "TERMINATED",
      "last_update": "2024-04-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02983045",
      "title": "A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2023-03-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03033576",
      "title": "Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma",
      "status": "COMPLETED",
      "last_update": "2025-01-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03068455",
      "title": "An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma",
      "status": "COMPLETED",
      "last_update": "2021-09-20",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03068624",
      "title": "Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma",
      "status": "UNKNOWN",
      "last_update": "2024-01-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03122522",
      "title": "A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03161756",
      "title": "Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma",
      "status": "UNKNOWN",
      "last_update": "2022-04-07",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03166397",
      "title": "Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients",
      "status": "UNKNOWN",
      "last_update": "2023-01-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03225365",
      "title": "Nivolumab +/- Ipilimumab Immunomonitoring in Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2026-07-20",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03241173",
      "title": "A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies",
      "status": "COMPLETED",
      "last_update": "2022-09-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03297463",
      "title": "Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma",
      "status": "WITHDRAWN",
      "last_update": "2018-08-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03347123",
      "title": "A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)",
      "status": "TERMINATED",
      "last_update": "2022-02-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03354962",
      "title": "Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors (BOOSTER MELANOMA)",
      "status": "TERMINATED",
      "last_update": "2020-12-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03400332",
      "title": "A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers",
      "status": "COMPLETED",
      "last_update": "2026-02-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03408587",
      "title": "CAVATAK\u00ae and Ipilimumab in Uveal Melanoma Metastatic to the Liver (VLA-024 CLEVER)",
      "status": "COMPLETED",
      "last_update": "2023-05-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03425461",
      "title": "Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma",
      "status": "TERMINATED",
      "last_update": "2021-04-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03597282",
      "title": "A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma",
      "status": "TERMINATED",
      "last_update": "2020-09-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03618641",
      "title": "CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease",
      "status": "COMPLETED",
      "last_update": "2025-05-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03645928",
      "title": "Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2026-05-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03646617",
      "title": "Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03719131",
      "title": "Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-04-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03724968",
      "title": "Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression",
      "status": "TERMINATED",
      "last_update": "2021-04-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03728465",
      "title": "Evaluation of Safety and Efficacy of Patients With Four and More Symptomatic Brain Metastases of Melanoma",
      "status": "TERMINATED",
      "last_update": "2021-02-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03769155",
      "title": "VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03903640",
      "title": "Optune Device - TT Field Plus Nivolumab and Ipilimumab for Melanoma With Brain Metastasis",
      "status": "TERMINATED",
      "last_update": "2022-06-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03922880",
      "title": "Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma",
      "status": "COMPLETED",
      "last_update": "2025-05-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03949153",
      "title": "Cryotherapy With in Situ Immunotherapy in Melanoma Metastasis",
      "status": "COMPLETED",
      "last_update": "2026-06-05",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03978611",
      "title": "A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment",
      "status": "TERMINATED",
      "last_update": "2024-07-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04007588",
      "title": "A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma",
      "status": "WITHDRAWN",
      "last_update": "2020-02-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04021420",
      "title": "Safety and Efficacy of Sonocloud Device Combined With Nivolumab in Brain Metastases From Patients With Melanoma",
      "status": "UNKNOWN",
      "last_update": "2020-08-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04060407",
      "title": "CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI)",
      "status": "WITHDRAWN",
      "last_update": "2021-06-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04074967",
      "title": "Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-11-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04079166",
      "title": "SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-12-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04091750",
      "title": "Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04157985",
      "title": "Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2025-12-11",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04250246",
      "title": "A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1",
      "status": "UNKNOWN",
      "last_update": "2020-01-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04283890",
      "title": "PHP and Immunotherapy in Metastasized UM",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04382664",
      "title": "UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma",
      "status": "COMPLETED",
      "last_update": "2025-01-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04464759",
      "title": "A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04495010",
      "title": "Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants",
      "status": "WITHDRAWN",
      "last_update": "2021-03-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04562129",
      "title": "IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04866810",
      "title": "The Effect of Diet and Exercise on ImmuNotherapy and the Microbiome (EDEN)",
      "status": "SUSPENDED",
      "last_update": "2026-09-11",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04899921",
      "title": "Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets",
      "status": "TERMINATED",
      "last_update": "2024-03-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04940299",
      "title": "Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04951583",
      "title": "Fecal Microbial Transplantation Non-Small Cell Lung Cancer and Melanoma",
      "status": "UNKNOWN",
      "last_update": "2024-08-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04967196",
      "title": "Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma",
      "status": "TERMINATED",
      "last_update": "2024-12-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04988841",
      "title": "Assessing the Tolerance and Clinical Benefit of feCAl tranSplantation in patientS With melanOma",
      "status": "COMPLETED",
      "last_update": "2025-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05004025",
      "title": "Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma",
      "status": "COMPLETED",
      "last_update": "2025-08-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05200143",
      "title": "Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma",
      "status": "TERMINATED",
      "last_update": "2024-09-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05302921",
      "title": "Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2025-01-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05909995",
      "title": "Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-02-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05926960",
      "title": "A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma",
      "status": "TERMINATED",
      "last_update": "2026-03-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05987332",
      "title": "IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-17",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06250335",
      "title": "Impact of a Prebiotic Food-enriched Diet (PreFED) in Combination With Ipilimumab/Nivolumab Combination Immune Checkpoint Blockade (ICB) in ICB-refractory Melanoma Patients",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06377111",
      "title": "A Study to Test the Benefit of Vitamin B5 in Patients With Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06784648",
      "title": "Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-11-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07436390",
      "title": "IFN-Gamma Expression as a Predictor of Response to Immune Checkpoint Inhibitors in First-Line Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2026-03-02",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07574047",
      "title": "MELCHRONO: A Prospective Randomized Study Investigating Chrono-immunotherapy for Advanced Melanoma.",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "LOMVASTOMIG": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT03708328",
      "title": "A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2025-08-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "LY-3009120": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02014116",
      "title": "A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to Other Parts of Their Body",
      "status": "TERMINATED",
      "last_update": "2019-12-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "MASITINIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT01280565",
      "title": "Masitinib in Non-Resectable or Metastatic Stage 3/4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of c-Kit",
      "status": "TERMINATED",
      "last_update": "2020-11-05",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "MIRDAMETINIB": {
    "n": 2,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT07237100",
      "title": "Mirdametinib in Patients With Advanced NF1-mutant Melanoma",
      "status": "RECRUITING",
      "last_update": "2025-11-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00147550",
      "title": "MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma.",
      "status": "TERMINATED",
      "last_update": "2013-09-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "NAPORAFENIB": {
    "n": 5,
    "n_observational": 0,
    "n_active": 3,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02607813",
      "title": "Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations",
      "status": "TERMINATED",
      "last_update": "2022-12-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02974725",
      "title": "A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma",
      "status": "TERMINATED",
      "last_update": "2025-04-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04417621",
      "title": "Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05907304",
      "title": "A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06346067",
      "title": "A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-27",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "NIVOLUMAB": {
    "n": 179,
    "n_observational": 21,
    "n_active": 75,
    "n_withdrawn": 9,
    "trials": [
     {
      "nct": "NCT03340129",
      "title": "Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)",
      "status": "RECRUITING",
      "last_update": "2026-02-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03563729",
      "title": "Melanoma Metastasized to the Brain and Steroids",
      "status": "RECRUITING",
      "last_update": "2023-07-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03685890",
      "title": "Evaluating the Effect of Nivolumab for Patients With In-transit Metastases Treated With Isolated Limb Perfusion",
      "status": "RECRUITING",
      "last_update": "2024-04-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04114136",
      "title": "Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-06-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04511013",
      "title": "A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases",
      "status": "RECRUITING",
      "last_update": "2025-09-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04594187",
      "title": "Nodal Radiation Therapy for Sentinel Lymph Node Positive Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-08-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04605146",
      "title": "Impact of Telemonitoring for the Management of Side Effects in Patients with Melanoma, Lung or Renal Cancer, Treated with Immunotherapy Combination of Nivolumab and Ipilimumab or Adjuvant Nivolumab Monotherapy",
      "status": "RECRUITING",
      "last_update": "2024-10-16",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04697576",
      "title": "Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-07-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04741997",
      "title": "Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-03-02",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04895709",
      "title": "A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-08-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05076760",
      "title": "MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-06-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05136196",
      "title": "BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study",
      "status": "RECRUITING",
      "last_update": "2026-09-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05267626",
      "title": "Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2R\u03b1 Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer",
      "status": "RECRUITING",
      "last_update": "2026-07-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05384496",
      "title": "Axitinib and Nivolumab for the Treatment of Mucosal Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-02-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05498792",
      "title": "Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-05-22",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05629546",
      "title": "Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors",
      "status": "RECRUITING",
      "last_update": "2026-07-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05704647",
      "title": "Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases",
      "status": "RECRUITING",
      "last_update": "2026-07-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05968690",
      "title": "Naltrexone and Propranolol Combined With Immunotherapy",
      "status": "RECRUITING",
      "last_update": "2025-09-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06047379",
      "title": "Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis",
      "status": "RECRUITING",
      "last_update": "2026-07-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06112314",
      "title": "IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)",
      "status": "RECRUITING",
      "last_update": "2026-02-25",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06163820",
      "title": "Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain Metastases",
      "status": "RECRUITING",
      "last_update": "2025-05-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06240143",
      "title": "Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma",
      "status": "RECRUITING",
      "last_update": "2024-11-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06246916",
      "title": "A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)",
      "status": "RECRUITING",
      "last_update": "2026-08-19",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06264180",
      "title": "VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]",
      "status": "RECRUITING",
      "last_update": "2026-07-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06319196",
      "title": "Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-06-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06488482",
      "title": "Assessment of Short Immunotherapy After Radical Surgery of High-risk Malignant Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-03-09",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06624644",
      "title": "A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-04-22",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06683755",
      "title": "Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)",
      "status": "RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06743126",
      "title": "SUPRAME-ACTengine\u00ae IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-08-18",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06880198",
      "title": "Study to Evaluate Impact\u00ae as Support to Anti PD1 or Anti PD1 Based Regimen Treatment in Patients With Inoperable Locally Advanced or Metastatic Melanoma",
      "status": "RECRUITING",
      "last_update": "2025-09-17",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07130032",
      "title": "Efficacy And Safety Of Anti-PD-1/PD-L1 Antibodies In Combination With Bevacizumab And Metronomic Cyclophosphamide In Patients With Non-Small Cell Lung Cancer And Cutaneous Melanoma Previously Treated With Immune Checkpoint Blockade",
      "status": "RECRUITING",
      "last_update": "2025-08-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07221734",
      "title": "Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo\u00ae in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-01-21",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07223424",
      "title": "Patient Preference for Subcutaneous vs. Intravenous Immune Therapy",
      "status": "RECRUITING",
      "last_update": "2026-04-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07376707",
      "title": "A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-01-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07422779",
      "title": "Immunotherapy Efficacy and PD-L1 as a Predictive Biomarker in Metastatic Melanoma in Slovenia",
      "status": "RECRUITING",
      "last_update": "2026-02-20",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07492680",
      "title": "A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)",
      "status": "RECRUITING",
      "last_update": "2026-08-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07504796",
      "title": "ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab",
      "status": "RECRUITING",
      "last_update": "2026-08-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07518043",
      "title": "A Study of HLX18 vs. OPDIVO\u00ae in Multiple Resected Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-07-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07564570",
      "title": "Physical Activity Directly Before Immunotherapy (Nivolumab and Ipilimumab) in Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-05-04",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07718243",
      "title": "Investigating the Combination of Bexmarilimab and Nivolumab in Solid Tumours, Melanoma and NSCLC",
      "status": "RECRUITING",
      "last_update": "2026-09-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01176474",
      "title": "Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma",
      "status": "COMPLETED",
      "last_update": "2023-07-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01585194",
      "title": "Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma",
      "status": "COMPLETED",
      "last_update": "2024-07-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01721746",
      "title": "A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)",
      "status": "COMPLETED",
      "last_update": "2022-04-19",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02009449",
      "title": "A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2026-07-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02054520",
      "title": "Immunotherapy Study for Patients With Stage IV Melanoma",
      "status": "TERMINATED",
      "last_update": "2023-04-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02073123",
      "title": "Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2026-05-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02259231",
      "title": "RTA 408 Capsules in Patients With Melanoma - REVEAL",
      "status": "COMPLETED",
      "last_update": "2025-06-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02304458",
      "title": "Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas",
      "status": "COMPLETED",
      "last_update": "2023-10-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02320058",
      "title": "An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by Itself",
      "status": "COMPLETED",
      "last_update": "2021-10-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02388906",
      "title": "Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma",
      "status": "COMPLETED",
      "last_update": "2025-04-24",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02460068",
      "title": "A Study of Fotemustine(FTM) Vs FTM and Ipilimumab (IPI) or IPI and Nivolumab in Melanoma Brain Metastasis",
      "status": "UNKNOWN",
      "last_update": "2015-06-02",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02465060",
      "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02519322",
      "title": "Neoadjuvant and Adjuvant Checkpoint Blockade",
      "status": "COMPLETED",
      "last_update": "2024-04-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02523313",
      "title": "Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab vs. Double Placebo for Stage IV Melanoma w. NED",
      "status": "COMPLETED",
      "last_update": "2025-04-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02621515",
      "title": "Nivo/Ipi Combination Therapy in Symptomatic Brain Metastases",
      "status": "TERMINATED",
      "last_update": "2024-05-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02626962",
      "title": "Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melanoma",
      "status": "COMPLETED",
      "last_update": "2022-03-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02631447",
      "title": "Sequential Combo Immuno and Target Therapy (SECOMBIT) Study",
      "status": "COMPLETED",
      "last_update": "2024-06-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02637531",
      "title": "A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549",
      "status": "UNKNOWN",
      "last_update": "2022-04-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02652455",
      "title": "Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2025-08-19",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02658890",
      "title": "An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread",
      "status": "COMPLETED",
      "last_update": "2023-08-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02659540",
      "title": "Pilot Study of the Safety/Efficacy of Combination Checkpoint Blockade + External Beam Radiotherapy in Stage IV Melanoma",
      "status": "COMPLETED",
      "last_update": "2022-10-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02702492",
      "title": "PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)",
      "status": "TERMINATED",
      "last_update": "2024-11-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02718066",
      "title": "Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer",
      "status": "COMPLETED",
      "last_update": "2026-07-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02763761",
      "title": "An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo",
      "status": "WITHDRAWN",
      "last_update": "2018-10-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02771626",
      "title": "Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)",
      "status": "TERMINATED",
      "last_update": "2023-03-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02799901",
      "title": "Nivolumab Plus Radiotherapy in Advanced Melanoma",
      "status": "COMPLETED",
      "last_update": "2023-11-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02857569",
      "title": "A Trial Evaluating the Safety & Efficacy of Intra-Tumoral Ipilimumab in Combination With Intra-venous Nivolumab in Patients With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2023-02-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02897765",
      "title": "A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer",
      "status": "COMPLETED",
      "last_update": "2021-02-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02905266",
      "title": "A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Melanoma",
      "status": "COMPLETED",
      "last_update": "2020-12-17",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02910700",
      "title": "Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02913417",
      "title": "Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases",
      "status": "UNKNOWN",
      "last_update": "2021-04-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02941744",
      "title": "A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma Macrometastases",
      "status": "COMPLETED",
      "last_update": "2019-01-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02970981",
      "title": "Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma",
      "status": "COMPLETED",
      "last_update": "2024-04-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02977052",
      "title": "Optimal Neo-adjuvant Combination Scheme of Ipilimumab and Nivolumab",
      "status": "UNKNOWN",
      "last_update": "2023-11-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02978443",
      "title": "A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab",
      "status": "TERMINATED",
      "last_update": "2024-04-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02978625",
      "title": "Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02983045",
      "title": "A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2023-03-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03025256",
      "title": "Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03047928",
      "title": "Combination Therapy With Nivolumab and PD-L1/IDO Peptide Vaccine to Patients With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2025-02-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03050060",
      "title": "Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer",
      "status": "TERMINATED",
      "last_update": "2022-06-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03068455",
      "title": "An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma",
      "status": "COMPLETED",
      "last_update": "2021-09-20",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03122522",
      "title": "A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03132675",
      "title": "Tavo and Pembrolizumab in Patients With Stage III/IV Melanoma Progressing on Either Pembrolizumab or Nivolumab Treatment",
      "status": "UNKNOWN",
      "last_update": "2023-03-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03161756",
      "title": "Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma",
      "status": "UNKNOWN",
      "last_update": "2022-04-07",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03166397",
      "title": "Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients",
      "status": "UNKNOWN",
      "last_update": "2023-01-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03190174",
      "title": "Nivolumab (Opdivo\u00ae) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers",
      "status": "COMPLETED",
      "last_update": "2025-02-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03225365",
      "title": "Nivolumab +/- Ipilimumab Immunomonitoring in Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2026-07-20",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03241173",
      "title": "A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies",
      "status": "COMPLETED",
      "last_update": "2022-09-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03301636",
      "title": "A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects With Unresectable or Metastatic Melanoma",
      "status": "TERMINATED",
      "last_update": "2022-09-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03347123",
      "title": "A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)",
      "status": "TERMINATED",
      "last_update": "2022-02-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03400332",
      "title": "A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers",
      "status": "COMPLETED",
      "last_update": "2026-02-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03435640",
      "title": "REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies",
      "status": "TERMINATED",
      "last_update": "2023-03-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03475134",
      "title": "TIL-ACT After NMA Chemo with IL-2 and Nivo Rescue in Metastatic Melanoma (mMEL)",
      "status": "COMPLETED",
      "last_update": "2025-02-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03511391",
      "title": "CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2024-01-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03514901",
      "title": "To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib.",
      "status": "UNKNOWN",
      "last_update": "2021-12-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03520634",
      "title": "PD-L1 PET Imaging in Melanoma Patients",
      "status": "COMPLETED",
      "last_update": "2024-05-06",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03543969",
      "title": "Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-05",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03544723",
      "title": "Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.",
      "status": "UNKNOWN",
      "last_update": "2020-06-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03597282",
      "title": "A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma",
      "status": "TERMINATED",
      "last_update": "2020-09-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03618641",
      "title": "CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease",
      "status": "COMPLETED",
      "last_update": "2025-05-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03620019",
      "title": "Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma",
      "status": "COMPLETED",
      "last_update": "2026-03-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03633110",
      "title": "Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine",
      "status": "COMPLETED",
      "last_update": "2022-04-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03645928",
      "title": "Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2026-05-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03646617",
      "title": "Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03719131",
      "title": "Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-04-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03724968",
      "title": "Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression",
      "status": "TERMINATED",
      "last_update": "2021-04-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03728465",
      "title": "Evaluation of Safety and Efficacy of Patients With Four and More Symptomatic Brain Metastases of Melanoma",
      "status": "TERMINATED",
      "last_update": "2021-02-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03769155",
      "title": "VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03834623",
      "title": "Avadomide (CC-122) in Combination With Nivolumab in Advanced Melanoma",
      "status": "COMPLETED",
      "last_update": "2022-10-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03872947",
      "title": "A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03903640",
      "title": "Optune Device - TT Field Plus Nivolumab and Ipilimumab for Melanoma With Brain Metastasis",
      "status": "TERMINATED",
      "last_update": "2022-06-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03922880",
      "title": "Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma",
      "status": "COMPLETED",
      "last_update": "2025-05-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03949153",
      "title": "Cryotherapy With in Situ Immunotherapy in Melanoma Metastasis",
      "status": "COMPLETED",
      "last_update": "2026-06-05",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03970382",
      "title": "A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors",
      "status": "SUSPENDED",
      "last_update": "2022-08-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04007588",
      "title": "A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma",
      "status": "WITHDRAWN",
      "last_update": "2020-02-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04017897",
      "title": "The Combination of Anti-PD-1 With Radiotherapy in Previously Untreated Metastatic Melanoma",
      "status": "UNKNOWN",
      "last_update": "2019-07-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04044859",
      "title": "ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04060407",
      "title": "CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI)",
      "status": "WITHDRAWN",
      "last_update": "2021-06-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04074967",
      "title": "Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-11-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04079166",
      "title": "SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-12-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04091750",
      "title": "Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04125719",
      "title": "PVSRIPO in Combination With Nivolumab in Melanoma",
      "status": "WITHDRAWN",
      "last_update": "2020-02-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04142931",
      "title": "Sequentional Immuno Apheresis Plasma Volume Escalation Cohort Study of Reduction of Soluble Tumor Necrosis Factor Receptors 1 and 2 (sTNFR1/2) With or Without Nivolumab in Patients With Inoperable or Metastatic Solid Tumors",
      "status": "UNKNOWN",
      "last_update": "2021-03-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04157985",
      "title": "Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2025-12-11",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04250246",
      "title": "A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1",
      "status": "UNKNOWN",
      "last_update": "2020-01-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04283890",
      "title": "PHP and Immunotherapy in Metastasized UM",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04309409",
      "title": "Adjuvant Nivolumab Treatment in Stage II (IIA, IIB, IIC) High-risk Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-05-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04382664",
      "title": "UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma",
      "status": "COMPLETED",
      "last_update": "2025-01-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04423029",
      "title": "A Study of DF6002 Alone and in Combination With Nivolumab",
      "status": "COMPLETED",
      "last_update": "2026-03-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04455503",
      "title": "Study of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1",
      "status": "TERMINATED",
      "last_update": "2024-02-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04464759",
      "title": "A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04493203",
      "title": "Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma",
      "status": "COMPLETED",
      "last_update": "2025-07-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04495010",
      "title": "Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants",
      "status": "WITHDRAWN",
      "last_update": "2021-03-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04521075",
      "title": "A Phase Ib Trial to Evaluate the Safety and Efficacy of FMT and Nivolumab in Subjects With Metastatic or Inoperable Melanoma, MSI-H, dMMR or NSCLC",
      "status": "UNKNOWN",
      "last_update": "2021-08-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04562129",
      "title": "IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04581382",
      "title": "Radiation Therapy, Plasma Exchange, and Immunotherapy (Pembrolizumab or Nivolumab) for the Treatment of Melanoma",
      "status": "COMPLETED",
      "last_update": "2025-07-10",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04695977",
      "title": "CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma",
      "status": "TERMINATED",
      "last_update": "2026-06-15",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04866810",
      "title": "The Effect of Diet and Exercise on ImmuNotherapy and the Microbiome (EDEN)",
      "status": "SUSPENDED",
      "last_update": "2026-09-11",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04891718",
      "title": "CIVO Intratumoural Microdosing of Anti-Cancer Therapies in Australia",
      "status": "WITHDRAWN",
      "last_update": "2022-07-08",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04899921",
      "title": "Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets",
      "status": "TERMINATED",
      "last_update": "2024-03-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04901988",
      "title": "Circulating Tumour DNA guidEd Therapy for Stage IIB/C mElanoma After surgiCal resecTION",
      "status": "TERMINATED",
      "last_update": "2025-02-27",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04902040",
      "title": "Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies",
      "status": "TERMINATED",
      "last_update": "2026-04-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04913025",
      "title": "REduced Frequency ImmuNE Checkpoint Inhibition in Cancers",
      "status": "UNKNOWN",
      "last_update": "2022-09-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04930783",
      "title": "NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04940299",
      "title": "Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04951583",
      "title": "Fecal Microbial Transplantation Non-Small Cell Lung Cancer and Melanoma",
      "status": "UNKNOWN",
      "last_update": "2024-08-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04955262",
      "title": "A CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Using \u2078\u2079Zr Df-IAB22M2C in Patients With Metastatic Melanoma Receiving Bempegaldesleukin (NKTR-214) and Nivolumab",
      "status": "WITHDRAWN",
      "last_update": "2021-07-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04967196",
      "title": "Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma",
      "status": "TERMINATED",
      "last_update": "2024-12-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04988841",
      "title": "Assessing the Tolerance and Clinical Benefit of feCAl tranSplantation in patientS With melanOma",
      "status": "COMPLETED",
      "last_update": "2025-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05002569",
      "title": "A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma",
      "status": "TERMINATED",
      "last_update": "2026-01-08",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05004025",
      "title": "Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma",
      "status": "COMPLETED",
      "last_update": "2025-08-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05034536",
      "title": "PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05061017",
      "title": "Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)",
      "status": "COMPLETED",
      "last_update": "2026-09-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05063058",
      "title": "Biomarker-driven Therapy for Melanoma",
      "status": "COMPLETED",
      "last_update": "2021-09-30",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05069935",
      "title": "FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2023-09-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05077280",
      "title": "A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma",
      "status": "UNKNOWN",
      "last_update": "2022-12-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05089370",
      "title": "Oral Decitabine/Cedazuridine (DEC-C) in Combination With Nivolumab for Patients With Mucosal Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05200143",
      "title": "Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma",
      "status": "TERMINATED",
      "last_update": "2024-09-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05302921",
      "title": "Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2025-01-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05303493",
      "title": "Camu-Camu Prebiotic and Immune Checkpoint Inhibition in Patients With Non-small Cell Lung Cancer and Melanoma",
      "status": "COMPLETED",
      "last_update": "2025-07-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05354102",
      "title": "A First-in-human (FIH) Combination Treatment Study With a Single Dose Level of BMC128",
      "status": "UNKNOWN",
      "last_update": "2024-05-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05418972",
      "title": "A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05496192",
      "title": "A Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma and Bladder Cancer",
      "status": "WITHDRAWN",
      "last_update": "2023-04-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05625399",
      "title": "A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-26",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05717140",
      "title": "Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung",
      "status": "WITHDRAWN",
      "last_update": "2025-08-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05926960",
      "title": "A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma",
      "status": "TERMINATED",
      "last_update": "2026-03-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05987332",
      "title": "IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-17",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06034860",
      "title": "Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types",
      "status": "TERMINATED",
      "last_update": "2024-11-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06054555",
      "title": "A Study to Evaluate ABP 206 Compared With OPDIVO\u00ae (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-12",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06101134",
      "title": "A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06112808",
      "title": "A Clinical Study of the Pharmacokinetics and Safety of BCD-263 and Opdivo\u00ae as Monotherapy in Subjects With Advanced Melanoma of the Skin",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-07-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06250335",
      "title": "Impact of a Prebiotic Food-enriched Diet (PreFED) in Combination With Ipilimumab/Nivolumab Combination Immune Checkpoint Blockade (ICB) in ICB-refractory Melanoma Patients",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06377111",
      "title": "A Study to Test the Benefit of Vitamin B5 in Patients With Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06640530",
      "title": "Clinical Study of the Efficacy and Safety of BCD-263 and Opdivo\u00ae as Monotherapy in Subjects With Advanced Melanoma of the Skin",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-07-08",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07436390",
      "title": "IFN-Gamma Expression as a Predictor of Response to Immune Checkpoint Inhibitors in First-Line Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2026-03-02",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07459543",
      "title": "A Study to Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Unresectable or Metastatic Melanoma Participants In India",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-12",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07476326",
      "title": "Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo\u00ae as Adjuvant Monotherapy in Participants With Melanoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07574047",
      "title": "MELCHRONO: A Prospective Randomized Study Investigating Chrono-immunotherapy for Advanced Melanoma.",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07576725",
      "title": "Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-05-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "PAZOPANIB": {
    "n": 7,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00861913",
      "title": "Pazopanib Hydrochloride in Treating Patients With Metastatic Melanoma That Cannot be Removed by Surgery",
      "status": "COMPLETED",
      "last_update": "2018-10-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01107665",
      "title": "Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma",
      "status": "COMPLETED",
      "last_update": "2019-08-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01392352",
      "title": "HYPAZ: Hypertension Induced by Pazopanib",
      "status": "TERMINATED",
      "last_update": "2020-02-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01639911",
      "title": "Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2019-07-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01666418",
      "title": "Pilot Study Investigating the Metabolic Activity and Transcriptional Profiling in Vivo in Tumor Biopsies in Melanoma Patients During Treatment With Pazopanib Alone and in Combination With Paclitaxel",
      "status": "COMPLETED",
      "last_update": "2018-10-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02009449",
      "title": "A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2026-07-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02645149",
      "title": "Molecular Profiling and Matched Targeted Therapy for Patients With Unresectable Advanced or Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2026-05-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "PEMBROLIZUMAB": {
    "n": 188,
    "n_observational": 12,
    "n_active": 73,
    "n_withdrawn": 4,
    "trials": [
     {
      "nct": "NCT03563729",
      "title": "Melanoma Metastasized to the Brain and Steroids",
      "status": "RECRUITING",
      "last_update": "2023-07-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04198766",
      "title": "Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda\u00ae) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)",
      "status": "RECRUITING",
      "last_update": "2026-07-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04318717",
      "title": "Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-08-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04370587",
      "title": "A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2025-10-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04513028",
      "title": "Beta Glucan's Effect on Pembrolizumab Immunologic Response in Stage III-IV Melanoma",
      "status": "RECRUITING",
      "last_update": "2025-10-30",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04594187",
      "title": "Nodal Radiation Therapy for Sentinel Lymph Node Positive Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-08-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04697576",
      "title": "Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-07-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04787042",
      "title": "Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067",
      "status": "RECRUITING",
      "last_update": "2024-11-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05086692",
      "title": "A Beta-only IL-2 ImmunoTherapY Study",
      "status": "RECRUITING",
      "last_update": "2025-07-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05155033",
      "title": "Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-09-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05492682",
      "title": "START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer",
      "status": "RECRUITING",
      "last_update": "2026-05-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05669430",
      "title": "A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies",
      "status": "RECRUITING",
      "last_update": "2025-02-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05746897",
      "title": "A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2024-01-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05824975",
      "title": "A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)",
      "status": "RECRUITING",
      "last_update": "2024-11-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05859074",
      "title": "A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer",
      "status": "RECRUITING",
      "last_update": "2026-08-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06047379",
      "title": "Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis",
      "status": "RECRUITING",
      "last_update": "2026-07-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06264180",
      "title": "VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]",
      "status": "RECRUITING",
      "last_update": "2026-07-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06270706",
      "title": "A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-08-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06284590",
      "title": "Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients",
      "status": "RECRUITING",
      "last_update": "2026-09-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06488482",
      "title": "Assessment of Short Immunotherapy After Radical Surgery of High-risk Malignant Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-03-09",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06624644",
      "title": "A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-04-22",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06697301",
      "title": "Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.",
      "status": "RECRUITING",
      "last_update": "2026-05-08",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06743126",
      "title": "SUPRAME-ACTengine\u00ae IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-08-18",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06771544",
      "title": "Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-03-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06797297",
      "title": "A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic Therapy",
      "status": "RECRUITING",
      "last_update": "2025-04-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06880549",
      "title": "A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-08-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06906822",
      "title": "PLUG-IN: Pembrolizumab Combined With Enfortumab Vedotin for Advanced Melanoma Patients",
      "status": "RECRUITING",
      "last_update": "2025-09-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06961006",
      "title": "A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)",
      "status": "RECRUITING",
      "last_update": "2026-07-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07130032",
      "title": "Efficacy And Safety Of Anti-PD-1/PD-L1 Antibodies In Combination With Bevacizumab And Metronomic Cyclophosphamide In Patients With Non-Small Cell Lung Cancer And Cutaneous Melanoma Previously Treated With Immune Checkpoint Blockade",
      "status": "RECRUITING",
      "last_update": "2025-08-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07223424",
      "title": "Patient Preference for Subcutaneous vs. Intravenous Immune Therapy",
      "status": "RECRUITING",
      "last_update": "2026-04-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07349303",
      "title": "Neoadjuvant Pembrolizumab in Patients With Stage IIb/c Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-08-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07410676",
      "title": "EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 \u00b1 Pembrolizumab in Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-02-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07422779",
      "title": "Immunotherapy Efficacy and PD-L1 as a Predictive Biomarker in Metastatic Melanoma in Slovenia",
      "status": "RECRUITING",
      "last_update": "2026-02-20",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07634380",
      "title": "Sitagliptin With Pembro in RCC and Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-07-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01295827",
      "title": "Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001)",
      "status": "COMPLETED",
      "last_update": "2019-12-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02009449",
      "title": "A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2026-07-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02054520",
      "title": "Immunotherapy Study for Patients With Stage IV Melanoma",
      "status": "TERMINATED",
      "last_update": "2023-04-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02073123",
      "title": "Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2026-05-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02085070",
      "title": "MK-3475 in Melanoma and NSCLC Patients With Brain Metastases",
      "status": "COMPLETED",
      "last_update": "2021-03-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02089685",
      "title": "Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29)",
      "status": "COMPLETED",
      "last_update": "2022-09-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02122861",
      "title": "Phase 1 Study of Intradermal LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1",
      "status": "COMPLETED",
      "last_update": "2019-03-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02263508",
      "title": "Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma",
      "status": "TERMINATED",
      "last_update": "2022-11-14",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02298959",
      "title": "Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02346955",
      "title": "Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001)",
      "status": "TERMINATED",
      "last_update": "2020-08-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02359851",
      "title": "Pembrolizumab in Treating Patients With Advanced Uveal Melanoma",
      "status": "TERMINATED",
      "last_update": "2019-09-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02376699",
      "title": "Safety Study of SEA-CD40 in Cancer Patients",
      "status": "TERMINATED",
      "last_update": "2023-05-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02407171",
      "title": "Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLC",
      "status": "COMPLETED",
      "last_update": "2023-10-31",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02434354",
      "title": "A Tissue Collection Study of Pembrolizumab (MK-3475) in Subjects With Resectable Advanced Melanoma",
      "status": "COMPLETED",
      "last_update": "2022-06-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02475213",
      "title": "Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer",
      "status": "COMPLETED",
      "last_update": "2025-08-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02500576",
      "title": "Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2025-01-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02565992",
      "title": "Intratumoral CAVATAK (CVA21) and Pembrolizumab in Patients With Advanced Melanoma (VLA-011 CAPRA)",
      "status": "COMPLETED",
      "last_update": "2023-01-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02574533",
      "title": "Pilot Study of Vigil\u2122 + Pembrolizumab for Advanced Melanoma",
      "status": "COMPLETED",
      "last_update": "2017-09-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02575404",
      "title": "GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients",
      "status": "COMPLETED",
      "last_update": "2023-06-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02595866",
      "title": "Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer",
      "status": "COMPLETED",
      "last_update": "2024-08-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02644967",
      "title": "A Phase 2 Study to Assess the Safety and Efficacy of IMO-2125 With 8 mg Ipilimumab in Patients With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2022-08-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02680184",
      "title": "Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy",
      "status": "COMPLETED",
      "last_update": "2025-07-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02681549",
      "title": "Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC)",
      "status": "COMPLETED",
      "last_update": "2025-08-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02740920",
      "title": "Response to Pembrolizumab in Metastatic Melanoma: Computed Tomography Texture Analysis as a Predictive Biomarker",
      "status": "TERMINATED",
      "last_update": "2023-08-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02760225",
      "title": "Pembrolizumab-PET Imaging",
      "status": "COMPLETED",
      "last_update": "2024-05-03",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02783300",
      "title": "An Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-03-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02799095",
      "title": "A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2025-05-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02812693",
      "title": "Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplification",
      "status": "WITHDRAWN",
      "last_update": "2018-04-05",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02816021",
      "title": "Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2026-04-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02818023",
      "title": "Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced Melanoma",
      "status": "TERMINATED",
      "last_update": "2022-01-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02823405",
      "title": "X4P-001 and Pembrolizumab in Patients With Advanced Melanoma",
      "status": "COMPLETED",
      "last_update": "2020-07-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02872259",
      "title": "BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2025-01-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02875132",
      "title": "Pembrolizumab in Advanced/Metastatic Acral Lentiginous Melanoma",
      "status": "COMPLETED",
      "last_update": "2025-04-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02981303",
      "title": "Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer",
      "status": "COMPLETED",
      "last_update": "2024-07-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03003676",
      "title": "A Pilot Study of Sequential ONCOS-102, an Engineered Oncolytic Adenovirus Expressing GMCSF, and Pembrolizumab in Patients With Advanced or Unresectable Melanoma Progressing After Programmed Cell Death Protein 1 (PD1) Blockade",
      "status": "COMPLETED",
      "last_update": "2021-11-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03006887",
      "title": "Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2021-05-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03021460",
      "title": "Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery",
      "status": "COMPLETED",
      "last_update": "2026-09-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03050060",
      "title": "Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer",
      "status": "TERMINATED",
      "last_update": "2022-06-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03092453",
      "title": "Dendritic Cell Vaccination in Patients With Advanced Melanoma",
      "status": "COMPLETED",
      "last_update": "2024-12-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03131908",
      "title": "Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss",
      "status": "COMPLETED",
      "last_update": "2026-08-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03132675",
      "title": "Tavo and Pembrolizumab in Patients With Stage III/IV Melanoma Progressing on Either Pembrolizumab or Nivolumab Treatment",
      "status": "UNKNOWN",
      "last_update": "2023-03-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03158935",
      "title": "The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) Trial",
      "status": "COMPLETED",
      "last_update": "2020-08-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03161431",
      "title": "SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-12-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03236935",
      "title": "Phase Ib of L-NMMA and Pembrolizumab",
      "status": "COMPLETED",
      "last_update": "2026-04-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03239145",
      "title": "Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor",
      "status": "COMPLETED",
      "last_update": "2026-07-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03273153",
      "title": "A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma",
      "status": "TERMINATED",
      "last_update": "2022-09-21",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03276832",
      "title": "Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma",
      "status": "COMPLETED",
      "last_update": "2026-03-19",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03301636",
      "title": "A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects With Unresectable or Metastatic Melanoma",
      "status": "TERMINATED",
      "last_update": "2022-09-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03329950",
      "title": "A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies",
      "status": "COMPLETED",
      "last_update": "2024-03-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03407170",
      "title": "Immunologic Determinants of Response to Pembrolizumab (MK-3475) in Advanced Melanoma (MK-3475-161/KEYNOTE-161)",
      "status": "TERMINATED",
      "last_update": "2020-07-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03448666",
      "title": "ECT-Pembrolizumab in Patients With Unresectable Melanoma With Superficial or Superficial and Visceral Metastases",
      "status": "WITHDRAWN",
      "last_update": "2024-09-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03474497",
      "title": "UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03511391",
      "title": "CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2024-01-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03514901",
      "title": "To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib.",
      "status": "UNKNOWN",
      "last_update": "2021-12-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03534635",
      "title": "Analysis of the Modulation of the Tumor Microenvironment by MK-3475 (Pembrolizumab) Using a Systems Biology Approach (PEMSYS)",
      "status": "UNKNOWN",
      "last_update": "2023-02-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03538314",
      "title": "UV1 Vaccine With Pembrolizumab for Patients With Unresectable or Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2024-08-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03544723",
      "title": "Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.",
      "status": "UNKNOWN",
      "last_update": "2020-06-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03611868",
      "title": "A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-08-07",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03620019",
      "title": "Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma",
      "status": "COMPLETED",
      "last_update": "2026-03-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03621982",
      "title": "Study of ADCT-301 in Patients With Selected Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2024-06-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03633110",
      "title": "Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine",
      "status": "COMPLETED",
      "last_update": "2022-04-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03637803",
      "title": "Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2023-06-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03645928",
      "title": "Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2026-05-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03684785",
      "title": "Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2022-04-07",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03698019",
      "title": "A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03715205",
      "title": "Study to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non-small Cell Lung Cancer in India (MK-3475-593/KEYNOTE-593)",
      "status": "COMPLETED",
      "last_update": "2025-08-29",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03765229",
      "title": "An Exploratory Study of Pembrolizumab Plus Entinostat in Non-Inflamed Stage III/IV Melanoma",
      "status": "COMPLETED",
      "last_update": "2024-01-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03773744",
      "title": "MG1-MAGEA3 With Ad-MAGEA3 and Pembrolizumab in Patients With Previously Treated Metastatic Melanoma or Cutaneous Squamous Cell Carcinoma",
      "status": "WITHDRAWN",
      "last_update": "2021-04-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03776136",
      "title": "Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants (MK-7902-004/E7080-G000-225/LEAP-004)",
      "status": "COMPLETED",
      "last_update": "2024-10-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03799003",
      "title": "A Study of ASP1951 in Subjects With Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2024-11-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03809624",
      "title": "Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer",
      "status": "TERMINATED",
      "last_update": "2024-10-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03815682",
      "title": "RPTR-147 in Patients With Selected Solid Tumors and Lymphomas",
      "status": "TERMINATED",
      "last_update": "2022-12-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03818893",
      "title": "Combination Therapy With GEN0101 and Pembrolizmub in Advanced Melanoma Patients PIb/PII",
      "status": "UNKNOWN",
      "last_update": "2019-01-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03820986",
      "title": "Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)",
      "status": "COMPLETED",
      "last_update": "2026-02-09",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03872947",
      "title": "A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03875079",
      "title": "A Study to Evaluate Safety and Therapeutic Activity of RO6874281 in Combination with Pembrolizumab, in Participants with Advanced or Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2024-10-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03897881",
      "title": "An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03957551",
      "title": "Cabozantinib and Pembrolizumab for Advanced Metastatic Melanoma",
      "status": "TERMINATED",
      "last_update": "2026-01-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04007744",
      "title": "Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04017897",
      "title": "The Combination of Anti-PD-1 With Radiotherapy in Previously Untreated Metastatic Melanoma",
      "status": "UNKNOWN",
      "last_update": "2019-07-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04032704",
      "title": "A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-03-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04044859",
      "title": "ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04074096",
      "title": "Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04079166",
      "title": "SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-12-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04083599",
      "title": "GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04116320",
      "title": "Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-07-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04140526",
      "title": "Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-05-23",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04148937",
      "title": "A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer",
      "status": "COMPLETED",
      "last_update": "2024-04-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04152863",
      "title": "Efficacy, Safety, and Tolerability of Gebasaxturev (V937) Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011)",
      "status": "TERMINATED",
      "last_update": "2024-08-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04157985",
      "title": "Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2025-12-11",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04187872",
      "title": "LITT and Pembrolizumab in Recurrent Brain Metastasis",
      "status": "TERMINATED",
      "last_update": "2023-12-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04205227",
      "title": "ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-09-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04386967",
      "title": "OH2 Injection in Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2026-08-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04452214",
      "title": "A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2023-07-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04483778",
      "title": "B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04485013",
      "title": "TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04541108",
      "title": "Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-22",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04546074",
      "title": "Imatinib Mesylate in Combination With Pembrolizumab in Patients With Melanoma",
      "status": "UNKNOWN",
      "last_update": "2023-10-03",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04581382",
      "title": "Radiation Therapy, Plasma Exchange, and Immunotherapy (Pembrolizumab or Nivolumab) for the Treatment of Melanoma",
      "status": "COMPLETED",
      "last_update": "2025-07-10",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04609566",
      "title": "Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2026-07-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04633902",
      "title": "Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation",
      "status": "UNKNOWN",
      "last_update": "2022-12-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04700072",
      "title": "Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02)",
      "status": "COMPLETED",
      "last_update": "2025-10-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04703426",
      "title": "Sargramostim (GM-CSF) + PD-1",
      "status": "WITHDRAWN",
      "last_update": "2023-05-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04708418",
      "title": "A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04725331",
      "title": "A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-11-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04830124",
      "title": "Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6",
      "status": "TERMINATED",
      "last_update": "2025-06-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04866810",
      "title": "The Effect of Diet and Exercise on ImmuNotherapy and the Microbiome (EDEN)",
      "status": "SUSPENDED",
      "last_update": "2026-09-11",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04889118",
      "title": "Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advanced Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)-China Extension Study",
      "status": "COMPLETED",
      "last_update": "2025-12-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04902040",
      "title": "Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies",
      "status": "TERMINATED",
      "last_update": "2026-04-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04913025",
      "title": "REduced Frequency ImmuNE Checkpoint Inhibition in Cancers",
      "status": "UNKNOWN",
      "last_update": "2022-09-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04913337",
      "title": "Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies",
      "status": "UNKNOWN",
      "last_update": "2024-10-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04930783",
      "title": "NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04951583",
      "title": "Fecal Microbial Transplantation Non-Small Cell Lung Cancer and Melanoma",
      "status": "UNKNOWN",
      "last_update": "2024-08-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04955743",
      "title": "Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2026-06-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04971499",
      "title": "A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05034536",
      "title": "PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05060432",
      "title": "Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors",
      "status": "UNKNOWN",
      "last_update": "2024-06-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05061017",
      "title": "Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)",
      "status": "COMPLETED",
      "last_update": "2026-09-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05069935",
      "title": "FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2023-09-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05081609",
      "title": "A Study to Investigate Safety and Tolerability of TransCon IL-2 \u03b2/\u03b3 Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05155254",
      "title": "IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-08-28",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05176470",
      "title": "Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05215574",
      "title": "Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-10-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05229614",
      "title": "Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease",
      "status": "UNKNOWN",
      "last_update": "2024-08-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05303493",
      "title": "Camu-Camu Prebiotic and Immune Checkpoint Inhibition in Patients With Non-small Cell Lung Cancer and Melanoma",
      "status": "COMPLETED",
      "last_update": "2025-07-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05304546",
      "title": "Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2025-07-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05308901",
      "title": "Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Na\u00efve Metastatic Uveal Melanoma",
      "status": "TERMINATED",
      "last_update": "2026-08-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05309421",
      "title": "A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05311618",
      "title": "Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors",
      "status": "UNKNOWN",
      "last_update": "2024-04-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05420324",
      "title": "A Study to Assess YH003 in Combination with Pebolizumab and Albumin Paclitaxel Injection in Subjects with Unresectable/metastatic Mucosal Melanoma",
      "status": "COMPLETED",
      "last_update": "2025-01-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05479812",
      "title": "Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2026-08-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05524935",
      "title": "Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05537740",
      "title": "A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05576077",
      "title": "A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-03-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05581004",
      "title": "A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05585034",
      "title": "Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb\u00ae808 in Combination With Pembrolizumab in Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2025-08-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05585320",
      "title": "A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05614102",
      "title": "A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05620134",
      "title": "Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-10-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05647954",
      "title": "A Study of HX008 Plus Transcatheter Arterial Chemoembolization (TACE) in the First-Line Treatment of Subjects With Stage IV (M1c) Melanoma That is Metastatic to the Liver",
      "status": "UNKNOWN",
      "last_update": "2022-12-13",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05708950",
      "title": "A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)",
      "status": "COMPLETED",
      "last_update": "2026-06-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05709821",
      "title": "IMM60 and Pembrolizumab in Melanoma and NSCLC",
      "status": "TERMINATED",
      "last_update": "2024-04-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05926960",
      "title": "A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma",
      "status": "TERMINATED",
      "last_update": "2026-03-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05987332",
      "title": "IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-17",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06171178",
      "title": "A Study of ASP1012 in Adults With Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2026-08-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06212388",
      "title": "Allogeneic Gammadelta T Cells Combined With Interferon-\u03b11b or PD-1 Monoclonal Antibody in Stage III-IV Amenable to Surgical Resection Melanoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2024-01-25",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06320353",
      "title": "Study \u0441omparing the Efficacy and Safety of RPH-075 and Keytruda\u00ae in Patients With Unresectable or Metastatic Skin Melanoma",
      "status": "COMPLETED",
      "last_update": "2026-07-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06540391",
      "title": "A Phase 1b Trial to Evaluate Safety of MB097 in Combination With Pembrolizumab in Melanoma Patients",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06784648",
      "title": "Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-11-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06894771",
      "title": "A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001)",
      "status": "COMPLETED",
      "last_update": "2026-03-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07040436",
      "title": "Assessment of Safety and Efficacy of OPM-101 Combined With Anti-PD-1 in Patients With Advanced Melanoma Showing Resistance to Anti-PD-1",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-06-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07376317",
      "title": "Optimization of Immunotherapy Treatment for Advanced Melanoma in the Context of the Public Brazilian Health System (OTIMAS)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07436390",
      "title": "IFN-Gamma Expression as a Predictor of Response to Immune Checkpoint Inhibitors in First-Line Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2026-03-02",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07581509",
      "title": "Pharmacokinetics, Safety, and Immunogenicity of Bmab1800 and Keytruda\u00ae as Adjuvant Monotherapy in Patients With Melanoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-05-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "PENPULIMAB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT06500091",
      "title": "TQB2916 Injection Combined With Chemotherapy or Penpulimab Injection in the Treatment of Solid Tumors",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2024-07-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "PEXIDARTINIB": {
    "n": 5,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT01826448",
      "title": "A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma",
      "status": "TERMINATED",
      "last_update": "2020-05-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02071940",
      "title": "PLX3397 KIT in Acral aNd mucOsal Melanoma",
      "status": "COMPLETED",
      "last_update": "2021-08-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02452424",
      "title": "A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2020-03-05",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02975700",
      "title": "A Study of PLX3397 in Patients With Unresectable or Metastatic KIT-mutated Melanoma",
      "status": "COMPLETED",
      "last_update": "2026-01-13",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03291288",
      "title": "Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)",
      "status": "COMPLETED",
      "last_update": "2021-05-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "PIDILIZUMAB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT01435369",
      "title": "Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2016-01-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "PIMASERTIB": {
    "n": 4,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT01390818",
      "title": "Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2017-03-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01693068",
      "title": "Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma",
      "status": "COMPLETED",
      "last_update": "2018-01-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04789668",
      "title": "Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases",
      "status": "TERMINATED",
      "last_update": "2026-03-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07121829",
      "title": "Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-08-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "PUCOTENLIMAB": {
    "n": 4,
    "n_observational": 0,
    "n_active": 4,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT06889610",
      "title": "A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors.",
      "status": "RECRUITING",
      "last_update": "2026-07-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07750067",
      "title": "Tunlametinib in Combination With Pucotenlimab and Hydroxychloroquine in NRAS Mutant Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-08-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07353073",
      "title": "A Prospective, Single-Arm, Phase II Clinical Study of Neoadjuvant Therapy With Pucotenlimab, Lenvatinib, and Temozolomide for Resectable Head and Neck Mucosal Melanoma (PLT-NAT-HNMM-II)",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-01-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07501104",
      "title": "Neoadjuvant Pucotenlimab Combined With Lenvatinib and Temozolomide in Resectable Stage IIB/III Acral Melanoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-03-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "QUAVONLIMAB": {
    "n": 3,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04305041",
      "title": "Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)",
      "status": "COMPLETED",
      "last_update": "2026-09-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04305054",
      "title": "Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)",
      "status": "COMPLETED",
      "last_update": "2026-05-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04700072",
      "title": "Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02)",
      "status": "COMPLETED",
      "last_update": "2025-10-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "RAF-265": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00304525",
      "title": "A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2020-12-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "REGORAFENIB": {
    "n": 5,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT06047379",
      "title": "Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis",
      "status": "RECRUITING",
      "last_update": "2026-07-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02307500",
      "title": "Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy",
      "status": "COMPLETED",
      "last_update": "2022-09-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02501551",
      "title": "Regorafenib, C-kit Mutated Malignant Melanoma, 2nd Line Therapy",
      "status": "UNKNOWN",
      "last_update": "2021-04-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02587650",
      "title": "Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma",
      "status": "TERMINATED",
      "last_update": "2020-01-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05370807",
      "title": "A Clinical Trial of Regorafenib in Patients With Pretreated Advanced Melanoma",
      "status": "UNKNOWN",
      "last_update": "2023-10-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "RELATLIMAB": {
    "n": 39,
    "n_observational": 3,
    "n_active": 28,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04697576",
      "title": "Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-07-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05428007",
      "title": "Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-01-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05629546",
      "title": "Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors",
      "status": "RECRUITING",
      "last_update": "2026-07-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05704647",
      "title": "Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases",
      "status": "RECRUITING",
      "last_update": "2026-07-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06112314",
      "title": "IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)",
      "status": "RECRUITING",
      "last_update": "2026-02-25",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06246916",
      "title": "A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)",
      "status": "RECRUITING",
      "last_update": "2026-08-19",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06264180",
      "title": "VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]",
      "status": "RECRUITING",
      "last_update": "2026-07-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06295159",
      "title": "Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-04-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06624644",
      "title": "A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-04-22",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06683755",
      "title": "Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)",
      "status": "RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06712927",
      "title": "Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases",
      "status": "RECRUITING",
      "last_update": "2026-05-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06743126",
      "title": "SUPRAME-ACTengine\u00ae IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-08-18",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06880198",
      "title": "Study to Evaluate Impact\u00ae as Support to Anti PD1 or Anti PD1 Based Regimen Treatment in Patients With Inoperable Locally Advanced or Metastatic Melanoma",
      "status": "RECRUITING",
      "last_update": "2025-09-17",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06999980",
      "title": "Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation)",
      "status": "RECRUITING",
      "last_update": "2026-02-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07237594",
      "title": "IL-17 Blockade to Decrease irAEs (REPLAY)",
      "status": "RECRUITING",
      "last_update": "2026-06-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07281924",
      "title": "Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis",
      "status": "RECRUITING",
      "last_update": "2026-09-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07492680",
      "title": "A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)",
      "status": "RECRUITING",
      "last_update": "2026-08-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07504796",
      "title": "ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab",
      "status": "RECRUITING",
      "last_update": "2026-08-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02465060",
      "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02519322",
      "title": "Neoadjuvant and Adjuvant Checkpoint Blockade",
      "status": "COMPLETED",
      "last_update": "2024-04-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03470922",
      "title": "A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-09",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03645928",
      "title": "Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2026-05-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03724968",
      "title": "Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression",
      "status": "TERMINATED",
      "last_update": "2021-04-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03743766",
      "title": "Nivolumab, BMS-936558 in Combination With Relatlimab, BMS-986016 in Patients With Metastatic Melanoma Na\u00efve to Prior Immunotherapy in the Metastatic Setting",
      "status": "COMPLETED",
      "last_update": "2026-08-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03978611",
      "title": "A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment",
      "status": "TERMINATED",
      "last_update": "2024-07-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04552223",
      "title": "Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma",
      "status": "COMPLETED",
      "last_update": "2026-02-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04866810",
      "title": "The Effect of Diet and Exercise on ImmuNotherapy and the Microbiome (EDEN)",
      "status": "SUSPENDED",
      "last_update": "2026-09-11",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04935229",
      "title": "Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma",
      "status": "TERMINATED",
      "last_update": "2025-10-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05002569",
      "title": "A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma",
      "status": "TERMINATED",
      "last_update": "2026-01-08",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05034536",
      "title": "PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05077280",
      "title": "A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma",
      "status": "UNKNOWN",
      "last_update": "2022-12-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05358938",
      "title": "Exercise to Boost Response to Checkpoint Blockade Immunotherapy",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-06",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05418972",
      "title": "A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05625399",
      "title": "A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-26",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05704933",
      "title": "Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases",
      "status": "COMPLETED",
      "last_update": "2026-04-06",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05912244",
      "title": "A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06101134",
      "title": "A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07459543",
      "title": "A Study to Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Unresectable or Metastatic Melanoma Participants In India",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-12",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07574047",
      "title": "MELCHRONO: A Prospective Randomized Study Investigating Chrono-immunotherapy for Advanced Melanoma.",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "RETIFANLIMAB": {
    "n": 3,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02475213",
      "title": "Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer",
      "status": "COMPLETED",
      "last_update": "2025-08-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03679767",
      "title": "A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)",
      "status": "COMPLETED",
      "last_update": "2023-07-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04370704",
      "title": "Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies",
      "status": "COMPLETED",
      "last_update": "2026-08-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "RIPRETINIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02571036",
      "title": "A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies",
      "status": "COMPLETED",
      "last_update": "2023-12-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "SASANLIMAB": {
    "n": 9,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04254107",
      "title": "A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer",
      "status": "TERMINATED",
      "last_update": "2025-02-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04458259",
      "title": "Study of PF-07265807 in Participants With Metastatic Solid Tumors.",
      "status": "TERMINATED",
      "last_update": "2026-06-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05061537",
      "title": "Study of PF-07263689 in Participants With Selected Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2024-04-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06285097",
      "title": "A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-09-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06448364",
      "title": "A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination",
      "status": "TERMINATED",
      "last_update": "2024-11-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06546553",
      "title": "A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.",
      "status": "TERMINATED",
      "last_update": "2026-02-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06580938",
      "title": "A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer",
      "status": "TERMINATED",
      "last_update": "2026-03-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06870487",
      "title": "A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers",
      "status": "TERMINATED",
      "last_update": "2026-05-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06974734",
      "title": "A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies",
      "status": "TERMINATED",
      "last_update": "2026-04-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "SELUMETINIB": {
    "n": 14,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00338130",
      "title": "Randomised Study to Compare the Efficacy of AZD6244 vs TMZ",
      "status": "COMPLETED",
      "last_update": "2014-08-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00600496",
      "title": "A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)",
      "status": "COMPLETED",
      "last_update": "2026-05-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00710515",
      "title": "Study to Assess the Effect of Dosing AZD6244 HydSulfate in the Presence and Absence of Food in Patients With Advanced Solid Malignancies",
      "status": "COMPLETED",
      "last_update": "2014-08-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00866177",
      "title": "MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma",
      "status": "COMPLETED",
      "last_update": "2015-08-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00936221",
      "title": "Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients",
      "status": "COMPLETED",
      "last_update": "2016-03-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01143402",
      "title": "Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye",
      "status": "COMPLETED",
      "last_update": "2017-07-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01166126",
      "title": "Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV",
      "status": "TERMINATED",
      "last_update": "2014-05-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01256359",
      "title": "Docetaxel With or Without AZD6244 in Melanoma",
      "status": "COMPLETED",
      "last_update": "2024-08-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01364051",
      "title": "Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01519427",
      "title": "Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib",
      "status": "TERMINATED",
      "last_update": "2014-06-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01974752",
      "title": "Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)",
      "status": "COMPLETED",
      "last_update": "2017-01-05",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02586987",
      "title": "A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours",
      "status": "COMPLETED",
      "last_update": "2019-11-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02768766",
      "title": "Intermittent Selumetinib for Uveal Melanoma",
      "status": "COMPLETED",
      "last_update": "2023-08-31",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05063058",
      "title": "Biomarker-driven Therapy for Melanoma",
      "status": "COMPLETED",
      "last_update": "2021-09-30",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "SEMAXANIB": {
    "n": 2,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00006003",
      "title": "SU5416 in Treating Patients With Metastatic Melanoma That Has Been Previously Treated",
      "status": "TERMINATED",
      "last_update": "2013-01-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00017316",
      "title": "Thalidomide and SU5416 in Treating Patients With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2013-02-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "SINTILIMAB": {
    "n": 4,
    "n_observational": 1,
    "n_active": 2,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT06703398",
      "title": "A Study of GC101 TIL in Advanced Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-08-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07400302",
      "title": "Sintilimab Combined With Chemotherapy for Adjuvant Treatment of Mucosal Melanoma After Surgery",
      "status": "RECRUITING",
      "last_update": "2026-09-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04277663",
      "title": "The Study of IBI310 in Combination With IBI308 Compared to High-Dose Interferon In Patients With Acral Melanoma That Has Been Removed by Surgery",
      "status": "TERMINATED",
      "last_update": "2023-03-09",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05572463",
      "title": "A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma",
      "status": "WITHDRAWN",
      "last_update": "2022-11-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "SORAFENIB": {
    "n": 30,
    "n_observational": 1,
    "n_active": 1,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT00110019",
      "title": "Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery",
      "status": "COMPLETED",
      "last_update": "2015-10-19",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00110994",
      "title": "Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma",
      "status": "COMPLETED",
      "last_update": "2015-06-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00111007",
      "title": "A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma",
      "status": "COMPLETED",
      "last_update": "2014-10-31",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00119249",
      "title": "Sorafenib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery",
      "status": "COMPLETED",
      "last_update": "2013-01-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00281957",
      "title": "Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery",
      "status": "COMPLETED",
      "last_update": "2014-05-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00329641",
      "title": "Sorafenib, Carboplatin, and Paclitaxel in Treating Patients With Stage IV Melanoma of the Eye",
      "status": "COMPLETED",
      "last_update": "2014-07-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00349206",
      "title": "Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma",
      "status": "COMPLETED",
      "last_update": "2014-04-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00387751",
      "title": "Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma",
      "status": "COMPLETED",
      "last_update": "2017-11-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00418496",
      "title": "Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2017-02-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00483301",
      "title": "A Phase II Trial OF Carboplatin, ABI-007 (Abraxane) And Sorafenib (BAY 43-9006) in Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2012-05-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00492297",
      "title": "A Phase II, Multi-Center, Open-Label, Uncontrolled Study to Evaluate the Efficacy and Safety of Sorafenib Given Daily in Combination With Repeated 21-Day Cycles of Dacarbazine (DTIC) Chemotherapy in Subjects With Advanced Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2014-10-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00492505",
      "title": "Sorafenib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Stage III Melanoma",
      "status": "UNKNOWN",
      "last_update": "2014-01-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00498836",
      "title": "Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant Melanoma",
      "status": "COMPLETED",
      "last_update": "2013-09-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00538005",
      "title": "Sorafenib, Bevacizumab, and Oxaliplatin in Treating Patients With Metastatic Malignant Melanoma",
      "status": "UNKNOWN",
      "last_update": "2014-01-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00565968",
      "title": "Sorafenib and Isolated Limb Infusion of Melphalan in Treating Patients With Stage III Melanoma of the Arm or Leg",
      "status": "COMPLETED",
      "last_update": "2015-03-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00602576",
      "title": "Temozolomide and Sorafenib in Treating Patients With Metastatic or Unresectable Melanoma",
      "status": "COMPLETED",
      "last_update": "2022-06-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00623402",
      "title": "Combined Treatment of Sorafenib and Pegylated Interferon \u03b12b in Stage IV Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2011-01-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00673361",
      "title": "Pilot Trial of \"Chemo-Switch\" Regimen to Treat Advanced Melanoma",
      "status": "TERMINATED",
      "last_update": "2016-01-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00794235",
      "title": "Monocentric Pilot Study Investigating the Metabolic Activity of Melanoma in Vivo During Sorafenib and Dacarbazine",
      "status": "COMPLETED",
      "last_update": "2010-01-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00811759",
      "title": "Sorafenib and Temozolomide in Treating Patients With Stage III or Stage IV Melanoma",
      "status": "UNKNOWN",
      "last_update": "2010-10-07",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00827177",
      "title": "Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2014-01-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01078961",
      "title": "An Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma",
      "status": "COMPLETED",
      "last_update": "2016-06-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01178411",
      "title": "An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) Protocols",
      "status": "COMPLETED",
      "last_update": "2021-03-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01183663",
      "title": "Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)",
      "status": "COMPLETED",
      "last_update": "2016-06-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01303341",
      "title": "Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01377025",
      "title": "A Study of Sorafenib in Patients With Chemonaive Metastatic Uveal Melanoma",
      "status": "UNKNOWN",
      "last_update": "2014-12-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01851408",
      "title": "Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma",
      "status": "WITHDRAWN",
      "last_update": "2015-04-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01893099",
      "title": "Sorafenib and Radioembolization With Sir-Spheres\u00ae for the Treatment of Metastatic Ocular Melanoma",
      "status": "COMPLETED",
      "last_update": "2018-04-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02517736",
      "title": "Study Multicentre Evaluating the Effectiveness and Toxicity Sorafenib (Nexavar\u00ae) in Adult Patients With Uveal Melanoma and Metastatic Dissemination",
      "status": "COMPLETED",
      "last_update": "2026-02-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05063058",
      "title": "Biomarker-driven Therapy for Melanoma",
      "status": "COMPLETED",
      "last_update": "2021-09-30",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "SPARTALIZUMAB": {
    "n": 29,
    "n_observational": 0,
    "n_active": 6,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT06425926",
      "title": "Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-08-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01176461",
      "title": "Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558",
      "status": "COMPLETED",
      "last_update": "2023-01-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01176474",
      "title": "Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma",
      "status": "COMPLETED",
      "last_update": "2023-07-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01351103",
      "title": "A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands",
      "status": "COMPLETED",
      "last_update": "2025-06-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02112032",
      "title": "Treatment of Advanced Melanoma With MK-3475 and Peginterferon",
      "status": "COMPLETED",
      "last_update": "2021-05-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02404441",
      "title": "Phase I/II Study of PDR001 in Patients With Advanced Malignancies",
      "status": "COMPLETED",
      "last_update": "2022-08-03",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02460224",
      "title": "Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.",
      "status": "COMPLETED",
      "last_update": "2022-02-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02607813",
      "title": "Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations",
      "status": "TERMINATED",
      "last_update": "2022-12-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02608268",
      "title": "Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies",
      "status": "TERMINATED",
      "last_update": "2023-12-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02658890",
      "title": "An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread",
      "status": "COMPLETED",
      "last_update": "2023-08-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02807844",
      "title": "Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies",
      "status": "COMPLETED",
      "last_update": "2021-08-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02967692",
      "title": "A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma",
      "status": "TERMINATED",
      "last_update": "2025-09-18",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03009058",
      "title": "Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer",
      "status": "TERMINATED",
      "last_update": "2024-11-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03207867",
      "title": "A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma",
      "status": "TERMINATED",
      "last_update": "2024-10-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03301896",
      "title": "Study of the Safety and Efficacy of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies",
      "status": "TERMINATED",
      "last_update": "2024-06-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03484923",
      "title": "Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2024-06-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03891953",
      "title": "Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03958383",
      "title": "IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma",
      "status": "TERMINATED",
      "last_update": "2026-06-03",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03982134",
      "title": "PDR001 + Panobinostat for Melanoma and NSCLC",
      "status": "WITHDRAWN",
      "last_update": "2019-10-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03991130",
      "title": "High Dose IL-2 in Combination With Anti-PD-1",
      "status": "TERMINATED",
      "last_update": "2026-08-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04072900",
      "title": "A Personalized NeoAntigen Cancer Vaccine Combined With Anti-PD-1 in Melanoma",
      "status": "UNKNOWN",
      "last_update": "2020-04-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04152018",
      "title": "Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.",
      "status": "TERMINATED",
      "last_update": "2025-05-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04261439",
      "title": "A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab",
      "status": "TERMINATED",
      "last_update": "2025-05-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04310397",
      "title": "Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma",
      "status": "TERMINATED",
      "last_update": "2024-10-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04572451",
      "title": "Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04802876",
      "title": "Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-03-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04928365",
      "title": "Evaluation of Cytokine Biomarkers in Melanoma Patients During Immunotherapy",
      "status": "UNKNOWN",
      "last_update": "2021-06-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05751928",
      "title": "A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-07-08",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06377111",
      "title": "A Study to Test the Benefit of Vitamin B5 in Patients With Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "SUNITINIB": {
    "n": 13,
    "n_observational": 0,
    "n_active": 2,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT00304200",
      "title": "Temodar and Sutent as Therapy for Melanoma",
      "status": "TERMINATED",
      "last_update": "2009-02-05",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00462982",
      "title": "Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or Melanoma",
      "status": "COMPLETED",
      "last_update": "2015-12-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00482911",
      "title": "Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye Melanoma",
      "status": "TERMINATED",
      "last_update": "2017-03-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00489944",
      "title": "Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma",
      "status": "UNKNOWN",
      "last_update": "2014-01-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00496223",
      "title": "A Phase I/II Study of Sunitinib and Dacarbazine",
      "status": "TERMINATED",
      "last_update": "2011-02-23",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00577382",
      "title": "SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma",
      "status": "COMPLETED",
      "last_update": "2016-12-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00631618",
      "title": "Clinical Trial of Sutent to Treat Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2014-02-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01005472",
      "title": "Temozolomide and Sunitinib Malate in Treating Patients With Stage III or Stage IV Malignant Melanoma",
      "status": "COMPLETED",
      "last_update": "2020-08-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01216657",
      "title": "Trial of Single Agent Sunitinib for Patients With Chemo-refractory Metastatic Melanoma",
      "status": "TERMINATED",
      "last_update": "2013-06-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01551459",
      "title": "A Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal Melanoma",
      "status": "COMPLETED",
      "last_update": "2019-10-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02068586",
      "title": "Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02400385",
      "title": "A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma",
      "status": "WITHDRAWN",
      "last_update": "2017-02-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02465060",
      "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "SUNITINIB MALATE": {
    "n": 13,
    "n_observational": 0,
    "n_active": 2,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT00304200",
      "title": "Temodar and Sutent as Therapy for Melanoma",
      "status": "TERMINATED",
      "last_update": "2009-02-05",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00462982",
      "title": "Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or Melanoma",
      "status": "COMPLETED",
      "last_update": "2015-12-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00482911",
      "title": "Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye Melanoma",
      "status": "TERMINATED",
      "last_update": "2017-03-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00489944",
      "title": "Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma",
      "status": "UNKNOWN",
      "last_update": "2014-01-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00496223",
      "title": "A Phase I/II Study of Sunitinib and Dacarbazine",
      "status": "TERMINATED",
      "last_update": "2011-02-23",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00577382",
      "title": "SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma",
      "status": "COMPLETED",
      "last_update": "2016-12-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00631618",
      "title": "Clinical Trial of Sutent to Treat Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2014-02-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01005472",
      "title": "Temozolomide and Sunitinib Malate in Treating Patients With Stage III or Stage IV Malignant Melanoma",
      "status": "COMPLETED",
      "last_update": "2020-08-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01216657",
      "title": "Trial of Single Agent Sunitinib for Patients With Chemo-refractory Metastatic Melanoma",
      "status": "TERMINATED",
      "last_update": "2013-06-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01551459",
      "title": "A Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal Melanoma",
      "status": "COMPLETED",
      "last_update": "2019-10-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02068586",
      "title": "Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02400385",
      "title": "A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma",
      "status": "WITHDRAWN",
      "last_update": "2017-02-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02465060",
      "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "TAK-733": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00948467",
      "title": "Study of TAK-733 in Adult Patients With Advanced Nonhematologic Malignancies",
      "status": "COMPLETED",
      "last_update": "2013-07-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "TEBENTAFUSP": {
    "n": 16,
    "n_observational": 1,
    "n_active": 13,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT05549297",
      "title": "Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)",
      "status": "RECRUITING",
      "last_update": "2026-02-25",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06070012",
      "title": "Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06246149",
      "title": "Adjuvant Tebentafusp in High Risk Ocular Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-06-30",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06414590",
      "title": "Neoadjuvant Tebentafusp for Uveal Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-06-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06626516",
      "title": "Tebentafusp-tebn With LDT in Metastatic UM",
      "status": "RECRUITING",
      "last_update": "2026-07-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06627244",
      "title": "Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-02-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07057596",
      "title": "Neoadjuvant Tebentafusp in Patients With Metastatic Uveal Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-03-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07063875",
      "title": "Adding IL-2 to Tebentafusp to Eradicate Cancer Progression",
      "status": "RECRUITING",
      "last_update": "2025-07-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07203391",
      "title": "Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell Homeostasis",
      "status": "RECRUITING",
      "last_update": "2026-04-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07276386",
      "title": "Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-03-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02535078",
      "title": "Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma",
      "status": "WITHDRAWN",
      "last_update": "2024-07-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02570308",
      "title": "A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma",
      "status": "COMPLETED",
      "last_update": "2023-03-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03070392",
      "title": "Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma",
      "status": "COMPLETED",
      "last_update": "2026-03-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05315258",
      "title": "Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-07-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05415072",
      "title": "A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07803562",
      "title": "Low Dose Dexamethasone for the Prevention of Cytokine Release Syndrome Associated With Tebentafusp",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-09-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "TISLELIZUMAB": {
    "n": 12,
    "n_observational": 0,
    "n_active": 4,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04261439",
      "title": "A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab",
      "status": "TERMINATED",
      "last_update": "2025-05-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04631731",
      "title": "Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity",
      "status": "UNKNOWN",
      "last_update": "2023-06-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04802876",
      "title": "Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-03-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04924413",
      "title": "L-TIL Plus Tislelizumab as First-line Treatment in Advanced Malignant Melanoma",
      "status": "TERMINATED",
      "last_update": "2024-07-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05104801",
      "title": "Sitravatinib With or Without Tislelizumab in Patients With Unresectable or Metastatic Melanoma",
      "status": "UNKNOWN",
      "last_update": "2021-11-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05238883",
      "title": "A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-11-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05406466",
      "title": "Cryoablation Combined With Tislelizumab Plus Lenvatinib in Patients With Melanoma Liver Metastasis",
      "status": "UNKNOWN",
      "last_update": "2022-11-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05466474",
      "title": "PD-1 Antibody Tislelizumab Combined With Dacarbazine in the Treatment of Advanced Melanoma",
      "status": "UNKNOWN",
      "last_update": "2023-10-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05542342",
      "title": "Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases.",
      "status": "COMPLETED",
      "last_update": "2026-06-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05661955",
      "title": "A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05789069",
      "title": "A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05798533",
      "title": "Neo-T in Treating Patients With Advanced Solid Tumors(GI-NeoT-03)",
      "status": "UNKNOWN",
      "last_update": "2023-07-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "TORIPALIMAB": {
    "n": 34,
    "n_observational": 2,
    "n_active": 6,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT06889610",
      "title": "A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors.",
      "status": "RECRUITING",
      "last_update": "2026-07-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06965231",
      "title": "Perioperative Toripalimab and Endostatin for Stage II Melanoma: A Phase II Trial",
      "status": "RECRUITING",
      "last_update": "2025-05-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07099430",
      "title": "A Trial of LBL-024 Monotherapy, LBL-024 Combined With LBL-007 or Toripalimab in Patients With Advanced Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-05-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07562841",
      "title": "Au-TMP and Radiotherapy for Advanced Melanoma With Anti-PD-1 Therapy",
      "status": "RECRUITING",
      "last_update": "2026-05-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07644897",
      "title": "Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients With Advanced Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-06-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02836795",
      "title": "Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal Antibody Toripalimab for Patients With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2025-06-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03013101",
      "title": "Safety and Efficacy of Recombinant Humanized Anti-PD-1 mAb for Patients With Locally Advanced or Metastatic Melanoma",
      "status": "UNKNOWN",
      "last_update": "2020-09-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03086174",
      "title": "Tolerability and Pharmacokinetics of Toripalimab in Combination With Axitinib in Patients With Kidney Cancer and Melanoma",
      "status": "UNKNOWN",
      "last_update": "2020-09-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03178123",
      "title": "The Study of JS001 Compared to High-Dose Interferon In Patients With Mucosal Melanoma That Has Been Removed by Surgery",
      "status": "TERMINATED",
      "last_update": "2026-07-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03941795",
      "title": "Phase II Study in the Treatment of Patients With Advanced Mucinous Melanoma",
      "status": "UNKNOWN",
      "last_update": "2019-12-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04072900",
      "title": "A Personalized NeoAntigen Cancer Vaccine Combined With Anti-PD-1 in Melanoma",
      "status": "UNKNOWN",
      "last_update": "2020-04-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04137900",
      "title": "Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies",
      "status": "UNKNOWN",
      "last_update": "2024-02-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04180995",
      "title": "Toripalimab in Combination With Axitinib in Patients With Localized Mucosal Melanoma",
      "status": "UNKNOWN",
      "last_update": "2022-01-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04197882",
      "title": "Clinical Study to Evaluate OrienX010 in Combination With Toripalimab as Neoadjuvant Treatment in Advanced Melanoma",
      "status": "UNKNOWN",
      "last_update": "2021-02-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04248387",
      "title": "Toripalimab in the Neoadjuvant Treatment of BRAF V600 Wild Type Melanoma",
      "status": "UNKNOWN",
      "last_update": "2020-01-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04462965",
      "title": "Postoperative Adjuvant Treatment of Completely Resected Mucosal Melanoma Phase II Study",
      "status": "UNKNOWN",
      "last_update": "2022-01-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04472806",
      "title": "Maintenance Treatment of Toripalimab(JS001) in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma",
      "status": "UNKNOWN",
      "last_update": "2020-07-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04640545",
      "title": "A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma",
      "status": "COMPLETED",
      "last_update": "2026-05-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04727164",
      "title": "Study Investigating Safety,Tolerability,Pharmacokinetics and Antitumor Activities of HBM4003 Combine With Toripalimab",
      "status": "UNKNOWN",
      "last_update": "2021-01-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04773951",
      "title": "A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of JS004 in Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2026-07-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04879654",
      "title": "Toripalimab Combined With Radiotherapy and Chemotherapy in the Treatment of SNMM After Endoscopic Surgery",
      "status": "UNKNOWN",
      "last_update": "2024-03-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04884997",
      "title": "A Study of Toripalimab or Combining With Temozolomide\uff08iv\uff09 in the Treatment of Advanced/Metastatic Malignant Melanoma",
      "status": "UNKNOWN",
      "last_update": "2021-05-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05031494",
      "title": "A Study to Assess YH003 in Combination with Toripalimab(anti-PD-1 MAb) Injection in Patients with Cancers",
      "status": "COMPLETED",
      "last_update": "2025-01-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05087602",
      "title": "Toripalimab Combined With Anlotinib in Unresectable Locally Advanced or Metastatic Acral Malignant Melanoma",
      "status": "UNKNOWN",
      "last_update": "2021-10-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05274438",
      "title": "Imatinib and Toripalimab in Patients With Locally Advanced/Metastatic Melanoma Harbored With CKIT Mut",
      "status": "UNKNOWN",
      "last_update": "2022-03-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05451407",
      "title": "Efficacy and Safety of TQB2618 Injection Combined With Toripalimab Injection in Patients With Advanced Melanoma",
      "status": "UNKNOWN",
      "last_update": "2023-07-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05478473",
      "title": "Clinical Study of Chidamide Combined With Toripalimab in the Treatment of Advanced Melanoma",
      "status": "UNKNOWN",
      "last_update": "2023-06-18",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05539118",
      "title": "Interferon-\u03b11b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable Melanoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2022-09-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05723432",
      "title": "KD6001 in Combination With Anti-PD-1 Antibody in Patients With Advanced Melanoma",
      "status": "UNKNOWN",
      "last_update": "2023-04-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05798533",
      "title": "Neo-T in Treating Patients With Advanced Solid Tumors(GI-NeoT-03)",
      "status": "UNKNOWN",
      "last_update": "2023-07-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05827770",
      "title": "The Efficacy and Safety of Neoadjuvant Toripalimab Combined With Temozolomide in Resectable Stage III Melanoma",
      "status": "UNKNOWN",
      "last_update": "2023-04-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05907512",
      "title": "Endostar Plus Toripalimab as Adjuvant Therapy for Resectable Stage III-Oligometastatic Stage IV Cutaneous Melanoma",
      "status": "UNKNOWN",
      "last_update": "2023-06-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05955105",
      "title": "A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies",
      "status": "UNKNOWN",
      "last_update": "2024-05-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07614828",
      "title": "Exploratory Clinical Study of Neoadjuvant Immunotherapy Combined With Chemotherapy in Malignant Melanoma of Nasal and Paranasal Mucosa",
      "status": "WITHDRAWN",
      "last_update": "2026-07-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "TOVORAFENIB": {
    "n": 4,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT01425008",
      "title": "Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2020-08-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02723006",
      "title": "Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma",
      "status": "TERMINATED",
      "last_update": "2024-03-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04985604",
      "title": "Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-10-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07121829",
      "title": "Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-08-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "TRAMETINIB": {
    "n": 89,
    "n_observational": 23,
    "n_active": 21,
    "n_withdrawn": 9,
    "trials": [
     {
      "nct": "NCT03340506",
      "title": "Dabrafenib and/or Trametinib Rollover Study",
      "status": "RECRUITING",
      "last_update": "2026-09-04",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03563729",
      "title": "Melanoma Metastasized to the Brain and Steroids",
      "status": "RECRUITING",
      "last_update": "2023-07-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04903119",
      "title": "Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-02-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06229340",
      "title": "Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations",
      "status": "RECRUITING",
      "last_update": "2024-01-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07440290",
      "title": "DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.",
      "status": "RECRUITING",
      "last_update": "2026-08-17",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00687622",
      "title": "Open-label Study to Investigate the Safety, PK, and Pharmacodynamics of GSK1120212 in Subjects With Solid Tumors or Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-11-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01037127",
      "title": "Study to Determine the Effectiveness of GSK1120212 in BRAF Mutation-positive Melanoma Previously Treated With or Without a BRAF Inhibitor",
      "status": "COMPLETED",
      "last_update": "2014-03-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01072175",
      "title": "Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212",
      "status": "COMPLETED",
      "last_update": "2019-07-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01138085",
      "title": "Safety, Pharmacokinetics (PK) of AKT and MEK Combination",
      "status": "COMPLETED",
      "last_update": "2017-11-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01245062",
      "title": "GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma",
      "status": "COMPLETED",
      "last_update": "2018-04-05",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01328106",
      "title": "Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma",
      "status": "WITHDRAWN",
      "last_update": "2017-12-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01584648",
      "title": "A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma",
      "status": "COMPLETED",
      "last_update": "2021-02-17",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01597908",
      "title": "Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma",
      "status": "COMPLETED",
      "last_update": "2021-02-24",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01619774",
      "title": "An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor",
      "status": "COMPLETED",
      "last_update": "2016-12-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01682083",
      "title": "Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD).",
      "status": "COMPLETED",
      "last_update": "2026-04-21",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01701037",
      "title": "Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery",
      "status": "TERMINATED",
      "last_update": "2017-06-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01721603",
      "title": "Dabrafenib and Trametinib With Radiosurgery in Melanoma Brain Mets",
      "status": "TERMINATED",
      "last_update": "2018-01-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01726738",
      "title": "LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations",
      "status": "COMPLETED",
      "last_update": "2020-11-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01767454",
      "title": "Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma",
      "status": "COMPLETED",
      "last_update": "2017-11-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01902173",
      "title": "Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer",
      "status": "COMPLETED",
      "last_update": "2025-01-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01928940",
      "title": "Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part)",
      "status": "COMPLETED",
      "last_update": "2017-07-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01940809",
      "title": "Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery",
      "status": "TERMINATED",
      "last_update": "2022-03-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01941927",
      "title": "Trametinib With GSK2141795 in BRAF Wild-type Melanoma",
      "status": "COMPLETED",
      "last_update": "2020-02-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01972347",
      "title": "Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma",
      "status": "COMPLETED",
      "last_update": "2026-06-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01978236",
      "title": "Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites",
      "status": "TERMINATED",
      "last_update": "2018-08-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01979523",
      "title": "Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01989585",
      "title": "Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02027961",
      "title": "Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone",
      "status": "COMPLETED",
      "last_update": "2019-05-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02039947",
      "title": "Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain",
      "status": "COMPLETED",
      "last_update": "2019-05-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02065063",
      "title": "A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2018-06-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02083354",
      "title": "Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma",
      "status": "COMPLETED",
      "last_update": "2022-02-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02097225",
      "title": "Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery",
      "status": "TERMINATED",
      "last_update": "2024-10-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02110355",
      "title": "A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2021-03-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02130466",
      "title": "A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022)",
      "status": "COMPLETED",
      "last_update": "2022-08-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02138292",
      "title": "A Phase 1B Clinical Trial of Trametinib Plus Digoxin in Patients With Unresectable or Metastatic BRAF Wild-type Melanoma",
      "status": "COMPLETED",
      "last_update": "2018-05-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02143050",
      "title": "Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients",
      "status": "WITHDRAWN",
      "last_update": "2023-11-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02196181",
      "title": "Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has Spread",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02224781",
      "title": "Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02231775",
      "title": "Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02257424",
      "title": "Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma",
      "status": "COMPLETED",
      "last_update": "2022-01-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02296112",
      "title": "Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations",
      "status": "COMPLETED",
      "last_update": "2021-05-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02296996",
      "title": "Dabrafenib and Trametinib for BRAF-inhibitor Pretreated Patients",
      "status": "COMPLETED",
      "last_update": "2019-01-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02300935",
      "title": "Study of Trametinib and Nab-paclitaxel in Patients With Melanoma",
      "status": "WITHDRAWN",
      "last_update": "2019-05-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02314143",
      "title": "Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib",
      "status": "TERMINATED",
      "last_update": "2019-02-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02357732",
      "title": "Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib",
      "status": "WITHDRAWN",
      "last_update": "2015-12-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02382549",
      "title": "A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib",
      "status": "TERMINATED",
      "last_update": "2023-12-12",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02392871",
      "title": "Radiotherapy & Combi in Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2024-11-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02410863",
      "title": "Biopsy- and Biology-driven Optimization of Targeted Therapy in Subjects With Advanced Melanoma",
      "status": "TERMINATED",
      "last_update": "2020-10-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02447939",
      "title": "Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With Melanoma",
      "status": "WITHDRAWN",
      "last_update": "2018-09-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02465060",
      "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02625337",
      "title": "Study Comparing Pembrolizumab With Dual MAPK Pathway Inhibition Plus Pembrolizumab in Melanoma Patients",
      "status": "UNKNOWN",
      "last_update": "2017-09-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02645149",
      "title": "Molecular Profiling and Matched Targeted Therapy for Patients With Unresectable Advanced or Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2026-05-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02858921",
      "title": "Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02872259",
      "title": "BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2025-01-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02910700",
      "title": "Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02915666",
      "title": "A Clinical Trial of Patients With Melanoma",
      "status": "WITHDRAWN",
      "last_update": "2018-05-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02967692",
      "title": "A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma",
      "status": "TERMINATED",
      "last_update": "2025-09-18",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02974725",
      "title": "A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma",
      "status": "TERMINATED",
      "last_update": "2025-04-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02974803",
      "title": "Concurrent Dabrafenib + Trametinib With Sterotactic Radiation in BRAF Mutation-Positive Malignant Melanoma and Brain Metastases",
      "status": "TERMINATED",
      "last_update": "2021-08-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03026517",
      "title": "Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma",
      "status": "COMPLETED",
      "last_update": "2025-01-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03088176",
      "title": "Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma",
      "status": "UNKNOWN",
      "last_update": "2020-10-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03149029",
      "title": "Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03272464",
      "title": "INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.",
      "status": "TERMINATED",
      "last_update": "2023-09-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03352947",
      "title": "Continuous vs Intermittent Dabrafenib Plus Trametinib in BRAFV600 Mutant Stage 3 Unresectable or Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2020-12-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03391050",
      "title": "A Study of APR-246 in Combination With Dabrafenib in Resistant Patients With BRAF V600 Mutant Melanoma",
      "status": "TERMINATED",
      "last_update": "2019-07-31",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03455764",
      "title": "MCS110 With BRAF/MEK Inhibition in Patients With Melanoma",
      "status": "COMPLETED",
      "last_update": "2024-07-31",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03501368",
      "title": "Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma",
      "status": "COMPLETED",
      "last_update": "2026-02-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03551626",
      "title": "Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes",
      "status": "COMPLETED",
      "last_update": "2025-04-29",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03580382",
      "title": "Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma",
      "status": "TERMINATED",
      "last_update": "2020-05-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03754179",
      "title": "Dabrafenib/Trametinib/Hydroxychloroquine for Advanced Pretreated BRAF V600 Mutant Melanoma",
      "status": "UNKNOWN",
      "last_update": "2021-04-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03808441",
      "title": "CAcTUS - Circulating Tumour DNA Guided Switch",
      "status": "UNKNOWN",
      "last_update": "2023-08-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03972046",
      "title": "Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma",
      "status": "WITHDRAWN",
      "last_update": "2020-10-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03979651",
      "title": "MEK and Autophagy Inhibition in Metastatic/Locally Advanced, Unresectable Neuroblastoma RAS (NRAS) Melanoma",
      "status": "COMPLETED",
      "last_update": "2025-05-22",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04059224",
      "title": "TraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type Melanoma",
      "status": "COMPLETED",
      "last_update": "2023-09-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04310397",
      "title": "Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma",
      "status": "TERMINATED",
      "last_update": "2024-10-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04417621",
      "title": "Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04439292",
      "title": "Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04527549",
      "title": "Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma",
      "status": "TERMINATED",
      "last_update": "2026-08-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04557956",
      "title": "Testing the Addition of the Anti-cancer Drug, Tazemetostat, to (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04652258",
      "title": "Pyrexia Management Using an IL-6 Antibody in BRAF+ Melanoma Patients Treated with Dabrafenib/ Trametinib +/- Immunotherapy",
      "status": "TERMINATED",
      "last_update": "2024-11-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04949113",
      "title": "Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-03-08",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05063058",
      "title": "Biomarker-driven Therapy for Melanoma",
      "status": "COMPLETED",
      "last_update": "2021-09-30",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05275374",
      "title": "XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-04-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05299580",
      "title": "\"Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)\"",
      "status": "WITHDRAWN",
      "last_update": "2023-09-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05370807",
      "title": "A Clinical Trial of Regorafenib in Patients With Pretreated Advanced Melanoma",
      "status": "UNKNOWN",
      "last_update": "2023-10-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05668585",
      "title": "A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2025-11-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05677373",
      "title": "Testing the Safety and Effectiveness of Combining Two Drugs, PLX2853 and Trametinib in the Treatment of Advanced Uveal Melanoma",
      "status": "WITHDRAWN",
      "last_update": "2023-08-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05907304",
      "title": "A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06346067",
      "title": "A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-27",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "TRAMETINIB DIMETHYL SULFOXIDE": {
    "n": 6,
    "n_observational": 0,
    "n_active": 4,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT01902173",
      "title": "Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer",
      "status": "COMPLETED",
      "last_update": "2025-01-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02196181",
      "title": "Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has Spread",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02224781",
      "title": "Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04439292",
      "title": "Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04527549",
      "title": "Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma",
      "status": "TERMINATED",
      "last_update": "2026-08-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04557956",
      "title": "Testing the Addition of the Anti-cancer Drug, Tazemetostat, to (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "TREMELIMUMAB": {
    "n": 19,
    "n_observational": 3,
    "n_active": 0,
    "n_withdrawn": 2,
    "trials": [
     {
      "nct": "NCT00086489",
      "title": "CP-675,206 In Patients With Advanced Melanoma",
      "status": "COMPLETED",
      "last_update": "2012-06-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00254579",
      "title": "Study of CP-675,206 in Refractory Melanoma",
      "status": "COMPLETED",
      "last_update": "2012-06-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00257205",
      "title": "CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy",
      "status": "COMPLETED",
      "last_update": "2012-07-02",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00378482",
      "title": "A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.",
      "status": "COMPLETED",
      "last_update": "2024-08-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00431275",
      "title": "Study to Compare Two Formulations of CP-675,206 Monoclonal Antibody",
      "status": "COMPLETED",
      "last_update": "2012-06-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00471887",
      "title": "Ticilimumab (CP-675,206) in Treating Patients With Stage IIIC or Stage IV Melanoma",
      "status": "COMPLETED",
      "last_update": "2020-10-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00585000",
      "title": "A Study To Assess The Safety Of Administering CP-675,206 As A One Hour Infusion In Patients With Surgically Incurable Advanced Melanoma",
      "status": "TERMINATED",
      "last_update": "2012-06-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00610857",
      "title": "Safety and Efficacy of Combination HDI and Anti-CTLA4 for Recurrent Inoperable Stage III or Stage IV Melanoma",
      "status": "COMPLETED",
      "last_update": "2017-06-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01034787",
      "title": "Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal Melanoma",
      "status": "COMPLETED",
      "last_update": "2017-10-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01103635",
      "title": "Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2020-04-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02141542",
      "title": "Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma",
      "status": "COMPLETED",
      "last_update": "2023-05-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02535078",
      "title": "Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma",
      "status": "WITHDRAWN",
      "last_update": "2024-07-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02586987",
      "title": "A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours",
      "status": "COMPLETED",
      "last_update": "2019-11-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02639026",
      "title": "Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers",
      "status": "COMPLETED",
      "last_update": "2025-11-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02643303",
      "title": "A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers",
      "status": "COMPLETED",
      "last_update": "2022-12-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03693612",
      "title": "GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2024-08-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04223648",
      "title": "Programmed Cell Death 1 + Selected Cell Therapy With Durvalumab (MEDI4736) and Tremelimumab in Metastatic Melanoma",
      "status": "WITHDRAWN",
      "last_update": "2021-11-22",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04274816",
      "title": "Intradermal Injection of Anti-CTLA-4 in Patients With Stage I/II Melanoma",
      "status": "COMPLETED",
      "last_update": "2020-02-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05928962",
      "title": "An Exploratory Single-arm Study: PD-1 With Recombinant Human Adenovirus Type 5 Injection for Malignant Melanomas",
      "status": "UNKNOWN",
      "last_update": "2023-07-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "VATALANIB": {
    "n": 3,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00563823",
      "title": "Vatalanib in Treating Patients With Metastatic Cutaneous Melanoma That Cannot be Removed by Surgery",
      "status": "COMPLETED",
      "last_update": "2013-08-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00615160",
      "title": "PTK/ZK in Disseminated Malignant Melanoma",
      "status": "TERMINATED",
      "last_update": "2021-10-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00655655",
      "title": "Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2024-08-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "VEMURAFENIB": {
    "n": 86,
    "n_observational": 6,
    "n_active": 4,
    "n_withdrawn": 6,
    "trials": [
     {
      "nct": "NCT01638676",
      "title": "A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients",
      "status": "RECRUITING",
      "last_update": "2021-10-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05768178",
      "title": "DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.",
      "status": "RECRUITING",
      "last_update": "2025-11-24",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00405587",
      "title": "Safety Study of PLX4032 in Patients With Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2017-08-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00949702",
      "title": "A Study of Vemurafenib in Previously Treated Patients With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2017-07-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01006980",
      "title": "A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)",
      "status": "COMPLETED",
      "last_update": "2016-09-28",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01248936",
      "title": "A Study of RO5185426 in Patients With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2016-08-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01271803",
      "title": "A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2019-07-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01307397",
      "title": "A Study of Vemurafenib in Participants With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2017-12-18",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01378975",
      "title": "A Study of Vemurafenib in Metastatic Melanoma Participants With Brain Metastases",
      "status": "COMPLETED",
      "last_update": "2025-06-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01400451",
      "title": "Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF)",
      "status": "TERMINATED",
      "last_update": "2015-01-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01474551",
      "title": "Vemurafenib (R05185426) in Poor Performance Status Patients With Unresectable Locally Advanced or Metastatic Melanoma Harboring a V600E/K Mutation",
      "status": "TERMINATED",
      "last_update": "2015-11-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01495988",
      "title": "Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma",
      "status": "TERMINATED",
      "last_update": "2017-10-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01512251",
      "title": "BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma",
      "status": "COMPLETED",
      "last_update": "2020-08-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01519323",
      "title": "BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations",
      "status": "TERMINATED",
      "last_update": "2016-10-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01519427",
      "title": "Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib",
      "status": "TERMINATED",
      "last_update": "2014-06-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01585415",
      "title": "Vemurafenib and White Blood Cell Therapy for Advanced Melanoma",
      "status": "TERMINATED",
      "last_update": "2019-11-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01586195",
      "title": "Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E",
      "status": "TERMINATED",
      "last_update": "2017-05-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01596140",
      "title": "Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer",
      "status": "COMPLETED",
      "last_update": "2020-06-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01597908",
      "title": "Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma",
      "status": "COMPLETED",
      "last_update": "2021-02-24",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01603212",
      "title": "Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor",
      "status": "COMPLETED",
      "last_update": "2019-05-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01611675",
      "title": "Leflunomide+Vemurafenib in V600 Mutant Met. Melanoma",
      "status": "TERMINATED",
      "last_update": "2017-04-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01616199",
      "title": "Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma",
      "status": "TERMINATED",
      "last_update": "2018-05-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01656642",
      "title": "A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2020-07-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01657591",
      "title": "Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma",
      "status": "COMPLETED",
      "last_update": "2023-01-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01659151",
      "title": "Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2026-02-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01667419",
      "title": "A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant Melanoma",
      "status": "COMPLETED",
      "last_update": "2019-07-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01673737",
      "title": "A Phase I/Ib Trial for the Evaluation of SAR260301 in Monotherapy or in Combination With Vemurafenib in Patients With Various Advanced Cancer",
      "status": "COMPLETED",
      "last_update": "2015-04-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01673854",
      "title": "Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma",
      "status": "COMPLETED",
      "last_update": "2018-07-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01683188",
      "title": "HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma",
      "status": "TERMINATED",
      "last_update": "2021-02-01",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01689519",
      "title": "A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2022-05-02",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01754376",
      "title": "Combined BRAF-Targeted Therapy & Immunotherapy for Melanoma",
      "status": "TERMINATED",
      "last_update": "2017-04-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01765543",
      "title": "A Pharmacokinetics (PK) Study to Investigate the Effect of Rifampin on PK of Vemurafenib (Zelboraf)",
      "status": "COMPLETED",
      "last_update": "2016-12-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01765556",
      "title": "A Pharmacokinetics Study to Investigate the Effect of Ketoconazole on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma",
      "status": "WITHDRAWN",
      "last_update": "2016-11-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01765569",
      "title": "A Pharmacokinetics Study to Investigate the Effect of Vemurafenib on Digoxin in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2015-09-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01781026",
      "title": "Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases",
      "status": "COMPLETED",
      "last_update": "2017-03-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01813214",
      "title": "The Effects of Vemurafenib + Cobimetinib on Immunity in Patients With Melanoma",
      "status": "TERMINATED",
      "last_update": "2019-02-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01826448",
      "title": "A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma",
      "status": "TERMINATED",
      "last_update": "2020-05-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01835184",
      "title": "Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery",
      "status": "TERMINATED",
      "last_update": "2014-09-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01841463",
      "title": "Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation",
      "status": "SUSPENDED",
      "last_update": "2014-09-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01843738",
      "title": "Radiation Use During Vemurafenib Treatment",
      "status": "WITHDRAWN",
      "last_update": "2017-05-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01844674",
      "title": "A Study on the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine in Patients With BRAFV600 Mutation-Positive Metastatic Malignancies",
      "status": "COMPLETED",
      "last_update": "2017-03-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01849666",
      "title": "A Study of the Effect of Vemurafenib on the Pharmacokinetics of Phenprocoumon in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy",
      "status": "COMPLETED",
      "last_update": "2016-11-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01851824",
      "title": "A Study of the Effect of Vemurafenib on the Pharmacokinetics of Acenocoumarol in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy",
      "status": "COMPLETED",
      "last_update": "2016-11-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01876641",
      "title": "Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib",
      "status": "TERMINATED",
      "last_update": "2018-09-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01897116",
      "title": "A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma",
      "status": "COMPLETED",
      "last_update": "2020-05-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01898585",
      "title": "An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2020-01-07",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01909453",
      "title": "Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma",
      "status": "COMPLETED",
      "last_update": "2026-02-27",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01910181",
      "title": "A Study of Vemurafenib (Zelboraf) in Chinese Participants With BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2019-05-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01942993",
      "title": "The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma",
      "status": "TERMINATED",
      "last_update": "2020-09-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01943422",
      "title": "Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma",
      "status": "COMPLETED",
      "last_update": "2018-04-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01959633",
      "title": "Vemurafenib Plus Cobimetinib Plus PEG-interferon in Advanced Melanoma Patients Harboring the V600BRAF Mutation",
      "status": "COMPLETED",
      "last_update": "2022-02-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01983124",
      "title": "Vemurafenib + Fotemustine to Treat Advanced Melanoma Patients With V600BRAF Mutation Recurred While on Vemurafenib",
      "status": "COMPLETED",
      "last_update": "2016-01-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02036086",
      "title": "Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases",
      "status": "UNKNOWN",
      "last_update": "2022-10-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02050321",
      "title": "A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma",
      "status": "TERMINATED",
      "last_update": "2018-12-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02052193",
      "title": "Evaluation of Photosensitivity in Dabrafenib or Vemurafenib Treated Metastatic Melanoma Patients - a Phase IIa/IIb Study",
      "status": "TERMINATED",
      "last_update": "2022-12-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02068079",
      "title": "A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma",
      "status": "WITHDRAWN",
      "last_update": "2019-01-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02077114",
      "title": "Vaccination With Peptides in Combination With Either Ipilimumab or Vemurafenib for the Treatment of Unresectable Stage III or IV Malignant Melanoma",
      "status": "COMPLETED",
      "last_update": "2014-09-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02145910",
      "title": "Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain Metastases",
      "status": "WITHDRAWN",
      "last_update": "2025-05-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02202200",
      "title": "Phase I-II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation and Pharmacokinetics of PD-0332991 in Patients Suffering Metastatic Melanoma",
      "status": "UNKNOWN",
      "last_update": "2016-04-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02230306",
      "title": "Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases",
      "status": "TERMINATED",
      "last_update": "2017-10-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02303951",
      "title": "Neoadjuvant Vemurafenib + Cobimetinib + Atezolizumab in Melanoma: NEO-VC",
      "status": "TERMINATED",
      "last_update": "2021-02-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02354690",
      "title": "Vemurafenib and TIL Therapy for Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2020-03-23",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02382549",
      "title": "A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib",
      "status": "TERMINATED",
      "last_update": "2023-12-12",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02414750",
      "title": "Vemurafenib Plus Cobimetinib in Metastatic Melanoma",
      "status": "TERMINATED",
      "last_update": "2022-11-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02427893",
      "title": "Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma",
      "status": "WITHDRAWN",
      "last_update": "2016-11-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02441465",
      "title": "Bioavailability Study of Vemurafenib in Participants With BRAF^V600 Mutation-Positive Malignancies",
      "status": "COMPLETED",
      "last_update": "2017-11-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02537600",
      "title": "Vemurafenib and Cobimetinib Combination in BRAF Mutated Melanoma With Brain Metastasis",
      "status": "COMPLETED",
      "last_update": "2020-01-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02583516",
      "title": "Clinical Trial to Evaluate the Efficacy of Vemurafenib in Combination With Cobimetinib (Continuous and Intermittent) in BRAFV600-mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2020-02-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02608034",
      "title": "A Study to Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady State",
      "status": "COMPLETED",
      "last_update": "2020-02-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02721459",
      "title": "XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02768207",
      "title": "A Study to Detect V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) V600 Mutation on Cell-Free Deoxyribonucleic Acid (cfDNA) From Plasma in Participants With Advanced Melanoma",
      "status": "COMPLETED",
      "last_update": "2019-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02818023",
      "title": "Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced Melanoma",
      "status": "TERMINATED",
      "last_update": "2022-01-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02902029",
      "title": "Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma",
      "status": "COMPLETED",
      "last_update": "2025-04-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02908672",
      "title": "A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma",
      "status": "COMPLETED",
      "last_update": "2025-07-20",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02968303",
      "title": "Induction Therapy With Vemurafenib and Cobimetinib to Optimize Nivolumab and Ipilimumab Therapy",
      "status": "UNKNOWN",
      "last_update": "2020-06-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03005639",
      "title": "ML29255 Neoadjuvant Vemurafenib and Cobimetinib Melanoma",
      "status": "WITHDRAWN",
      "last_update": "2018-05-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03026517",
      "title": "Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma",
      "status": "COMPLETED",
      "last_update": "2025-01-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03101254",
      "title": "LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma",
      "status": "COMPLETED",
      "last_update": "2024-07-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03176485",
      "title": "Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors",
      "status": "COMPLETED",
      "last_update": "2019-01-04",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03224208",
      "title": "Vemurafenib Plus Cobimetinib in Advanced or Metastatic Melanoma Patients",
      "status": "TERMINATED",
      "last_update": "2021-04-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03430947",
      "title": "Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain Metastases",
      "status": "TERMINATED",
      "last_update": "2023-09-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03514901",
      "title": "To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib.",
      "status": "UNKNOWN",
      "last_update": "2021-12-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03554083",
      "title": "Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma",
      "status": "COMPLETED",
      "last_update": "2026-05-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03625141",
      "title": "A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System Metastases",
      "status": "COMPLETED",
      "last_update": "2024-04-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04722575",
      "title": "Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05263453",
      "title": "HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation",
      "status": "UNKNOWN",
      "last_update": "2023-05-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "XL-281": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00451880",
      "title": "Study of XL281 in Adults With Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2011-10-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "ZIMBERELIMAB": {
    "n": 3,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT03629756",
      "title": "A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies",
      "status": "COMPLETED",
      "last_update": "2024-05-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04772989",
      "title": "A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies",
      "status": "COMPLETED",
      "last_update": "2025-08-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05130177",
      "title": "Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   }
  }
 }
}